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Abstract 
The phenomenology of impulsive compulsive behaviours in patients with Parkinson’s 
disease (PD) treated with dopaminergic therapy has been reviewed. Neuropsychological 
studies have been conducted to explore the behavioural mechanisms responsible for these 
socially devastating disorders, which affect a substantial proportion of treated patients.  
Results demonstrated that poor information sampling and impaired working memory 
capacity, especially when mental manipulation of information was required, distinguish 
PD patients with impulsive compulsive behaviours from those without. A direct 
comparison to non PD-patients with addictions revealed that impulsive PD patients 
closely resembled illicit drug abusers, whereas non-impulsive PD patients treated with a 
dopamine agonist performed similarly to pathological gamblers. PD patients who were 
not taking dopamine agonists performed as well as healthy volunteers, even when treated 
with deep brain stimulation. Therefore, dopamine agonists are the single most important 
risk factor for impulsive choice in PD.  
Conversely, response inhibition and feedback learning were intact in medicated PD 
patients with impulsive compulsive behaviours. Furthermore, all PD patients became 
more risk prone after dopaminergic medication, but greater salivary cortisol release only 
correlated with risk taking behaviour in the PD group with behavioural addictions.  
Cortisol plays also a prominent role in stress regulation. Therefore, the literature was 
reviewed to explore links between emotional stress and PD.   
4 
 
Papers associated with this thesis  
1) Djamshidian A, Cardoso F, Grossett D, Bowden-Jones H, Lees A. “Pathological   
 Gambling in Parkinson’s disease. A review of the literature”. Mov Disord. 2011 
 Sep;26(11):1976-84. 
2) Djamshidian A, Averbeck BB, Lees A, O'Sullivan SS. “Clinical aspects of impulsive
 compulsive behaviours in Parkinson’s disease”. J Neurol Sci. 2011 Nov 15;310(1-
 2):183-88. 
3) Djamshidian A, Jha A, O'Sullivan SS, Silveira-Moriyama L, Jacobson C, Brown P,
 Lees A, Averbeck BB. “Risk and learning in impulsive and non- impulsive patients
 with Parkinson's disease”. Mov Disord. 2010 Oct 15;25(13):2203-10. 
4) Djamshidian A, O'Sullivan SS, Doherty KM, Lees A, Averbeck BB. ”Altruistic 
 punishment in patients with Parkinson’s disease with and without impulsive behaviour”.
 Neuropsychologia 2011 Jan;49(1):103-37. 
5) Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. “Stroop test performance in
 impulsive and non-impulsive patients with Parkinson’s disease”. Parkinsonism Relat 
 Disord. 2011 Mar;17(3):212-14. 
6) Djamshidian A, O'Sullivan SS, Wittmann B. Lees A, Averbeck BB. “Novelty seeking 
behaviour in Parkinson's disease”. Neuropsychologia. 2011 Jul;49(9):2483-88. 
7) Djamshidian A, O'Sullivan SS, Sanotsky Y, Sharman S, Matviyenko Y, Foltynie T,
 Michalczuk R ,Aviles-Olmos
 
I, Fedoryshyn
 
L, Doherty KM, Filts Y, Selikhova M, 
 Bowden-Jones
 
H, Joyce E, Lees A,  Averbeck BB. ” Decision making impulsivity and 
 addictions: Do Parkinson’s disease patients jump to conclusions?” Mov Disord. 2012 
 Aug;27(9):1137-45. 
5 
 
8) Djamshidian A, O'Sullivan SS, Foltynie T, Aviles-Olmos I, Limousin P, Zrinzo L, Lees 
 A, Averbeck BB. “Dopamine agonists cause reflection impulsivity in Parkinson’s 
 disease, not Deep Brain Stimulation”. Journal of Parkinson’s disease 2013 3(2):139-44. 
9) Djamshidian A, Sanotsky Y, Matviyenko Y, O;Sullivan SS, Sharman S, Selikova M, 
 Fedoryshyn L, Filts Y, Bearn J, Lees A, Averbeck BB. “Increased reflection impulsivity 
 in patients with ephedrone induced Parkinsonism”. Addiction 2012. Dec.11. 
10) Djamshidian A, O'Sullivan SS, Papadopoulos A, Bassett P, Shaw K, Averbeck BB, 
 Lees A. “Salivary cortisol levels in Parkinson's disease and its correlation to risk 
 behaviour”. J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1107-11. 
Related publications during the degree period  
1) Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. “Effects of dopamine on 
sensitivity to social bias in Parkinson's disease”. PLoS One. 2012;7(3).e32889. 
2) Averbeck BB, Djamshidian A, O'Sullivan SS, Housden CR, Roiser JP, Lees AJ. 
“Uncertainty about mapping future actions into rewards may underlie performance on 
multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's 
disease”.Behav Neurosci. 2013 Apr;127(2):245-55.  
3) O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, 
Lees AJ, Piccini P.” Cue-induced striatal dopamine release in Parkinson's disease-
associated impulsive-compulsive behaviours.” Brain. 2011 Apr;134(Pt 4):969-78. 
4) O'Sullivan SS, Djamshidian A, Ahmed Z, Evans AH, Lawrence AD, Holton JL, Revesz 
T, Lees AJ. ” Impulsive-compulsive spectrum behaviors in pathologically confirmed 
progressive supranuclear palsy”. Mov Disord. 2010 Apr 15;25(5):638-42. 
6 
 
5) O'Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD. 
“Excessive hoarding in Parkinson's disease”. Mov Disord. 2010 Jun 15;25(8):1026-33. 
 
 
 
  
7 
 
List of abbreviations  
ACC  Anterior cingulate cortex 
AM  Amygdala 
ANOVA  Analysis Of Variance  
BOLD  Blood-Oxygen-Level Dependent  
C   Congruent 
CG  Cingulate gyrus 
CO   Control 
CO-O   Elderly Controls 
CO-Y   Young Controls 
COMT  Catechol-O-Methyl Transferase  
DA   Dopamine Agonists 
DAT   Dopamine Transporter Scan 
DBS   Deep Brain Stimulation  
DDS   Dopamine Dysregulation Syndrome  
DRT   Dopamine Replacement Therapy  
DSM-IV  Diagnostic and Statistical Manual, 4th Edition  
FAB   Frontal Assessment Battery 
fMRI   functional Magnetic Resonance Imaging 
HC  Hippocampus 
HIP  Hippocampus   
HPA   Hypothalamo-Pituitary-adrenal Axis  
I   Incongruent 
IBS   Irritable Bowel Syndrome 
ICBs   Impulsive Compulsive Behaviours  
IGT   Iowa Gambling Task 
I.V.   Intravenous  
KHZ   Kilohertz 
KMNO4  Potassium Permanganate 
8 
 
L-DOPA  Levodopa 
LEU   L-dopa Equivalent Unit  
LRRK2  Leucine- Rich Repeat-Kinase type 2  
MAO-B  Monoamine Oxidase B  
MMSE  Mini Mental State Examination 
MPTP   1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine   
MRI   Magnetic Resonance Imaging  
MS   Multiple Sclerosis 
MSA   Multiple System Atrophy 
NAc  Nucleus accumbens 
NEG   Negative 
NMDA  N-Methyl D-Aspartate 
NS   Not Significant  
6-OHDA  6-Hydroxydopamine  
OCD   Obsessive Compulsive Disorder 
OFC  Orbitofrontal cortex  
PFC  Prefrontal cortex 
PPA   Phenylpropranolamine 
PANAS  Positive and Negative Affect Schedule  
PD   Parkinson’s disease  
PD+ICB PD patients with Impulsive Compulsive Behaviours  
PD-ICB PD patients without Impulsive Compulsive Behaviours 
PD+PG  PD patients with Pathological Gambling  
PET   Positron Emission Tomography  
PG   Pathological Gambling  
POS   Positive 
PSP   Progressive Supranuclear Palsy  
QUIP   Questionnaire for Impulsive Compulsive Disorders in Parkinson’s disease  
RAC   Raclopride   
RLS   Restless Legs Syndrome  
9 
 
RT   Reaction Time 
SD   Standard Deviation  
SE   Standard Error 
SEM   Standard Error of the Mean 
SPECT  Single-Photon Emission Computed Tomography   
SSRI  Selective Serotonin Reuptake Inhibitor 
STN   Subthalamic Nucleus  
UCLH  University College London Hospitals  
UK   United Kingdom  
UPDRS  Unified Parkinson’s disease Rating Scale 
VTA  Ventral tegmental area 
WM   Working memory 
YRS   Years 
 
10 
 
Table of contents  
Abstract ............................................................................................................................................................................... 3 
Papers associated with this thesis .......................................................................................................................... 4 
Related publications during the degree period ................................................................................................ 5 
List of abbreviations ...................................................................................................................................................... 7 
Table of contents ...........................................................................................................................................................10 
List of tables ....................................................................................................................................................................14 
List of figures ..................................................................................................................................................................15 
Chapter 1 - Introduction to Parkinson’s disease .......................................................... 17 
Overview and research aims....................................................................................................................................17 
Clinical features of Parkinson’s disease..............................................................................................................18 
Diagnosis of Parkinson’s disease ...........................................................................................................................19 
Environmental factors................................................................................................................................................22 
Pharmacological treatment of Parkinson’s disease and motor complications ...............................24 
Chapter 2 - Addictive behaviours in Parkinson’s disease ........................................... 26 
2.1 Pathological gambling in Parkinson’s disease ........................................................ 26 
Phenomenology of pathological gambling in Parkinson’s disease ........................................................31 
Prevalence of pathological gambling ..................................................................................................................32 
Risk factors for pathological gambling ..............................................................................................................33 
Mechanisms underlying pathological gambling in Parkinson’s disease .............................................36 
Model of brain circuits involved in addictive behaviours in the general population ....................39 
Imaging studies in patients with Parkinson’s disease with pathological gambling .....................41 
Treatment of patients with Parkinson’s disease with pathological gambling ................................43 
2.2. Other treatment related behavioural disturbances in Parkinson’s disease .......... 48 
Phenomenology and prevalence of ICBs in Parkinson’s disease .............................................................49 
‘Green flags’ for the development of ICBs in Parkinson’s disease ...........................................................55 
Personality traits, decision-making and reward processing in Parkinson’s disease .....................57 
Brain circuitry implicated in patients with Parkinson’s disease with ICBs .......................................60 
11 
 
Behavioural changes after dopamine agonist therapy...............................................................................66 
Mechanisms underlying ICBs in Parkinson’s disease ...................................................................................68 
Treatment of patients with Parkinson’s disease with ICBs .......................................................................69 
Conclusion ........................................................................................................................................................................73 
Chapter 3 - Behavioural tests in patients with Parkinson’s disease ........................... 75 
Introduction ....................................................................................................................................................................75 
3.1. Risk and learning in Parkinson’s disease ................................................................ 81 
Introduction ....................................................................................................................................................................81 
Patients and methods .................................................................................................................................................81 
Statistical analysis........................................................................................................................................................87 
Results ................................................................................................................................................................................89 
Discussion .........................................................................................................................................................................97 
Conclusion ..................................................................................................................................................................... 101 
3.2. Altruistic punishment in patients with Parkinson’s disease with and without 
impulsive behaviour ......................................................................................................103 
Introduction ................................................................................................................................................................. 103 
Patients and methods .............................................................................................................................................. 105 
Statistical analysis..................................................................................................................................................... 109 
Results ............................................................................................................................................................................. 110 
Discussion ...................................................................................................................................................................... 114 
Conclusion ..................................................................................................................................................................... 117 
3.3. Stroop test performance in impulsive and non-impulsive patients with Parkinson's 
disease............................................................................................................................118 
Introduction ................................................................................................................................................................. 118 
Patients and methods .............................................................................................................................................. 119 
Statistical analysis..................................................................................................................................................... 122 
Results ............................................................................................................................................................................. 123 
Discussion ...................................................................................................................................................................... 126 
Conclusion ..................................................................................................................................................................... 128 
3.4 Novelty seeking behaviour in Parkinson’s disease .................................................129 
12 
 
Introduction ................................................................................................................................................................. 129 
Patients and methods .............................................................................................................................................. 131 
Statistical analysis..................................................................................................................................................... 135 
Results ............................................................................................................................................................................. 138 
Discussion ...................................................................................................................................................................... 142 
Conclusion ..................................................................................................................................................................... 145 
3.5. Decision-making, impulsivity and addictions: Do Parkinson’s disease patients 
jump to conclusions?......................................................................................................147 
Introduction ................................................................................................................................................................. 147 
Patients and methods .............................................................................................................................................. 149 
Statistical analysis..................................................................................................................................................... 154 
Results ............................................................................................................................................................................. 158 
Sensitivity of the beads task versus the QUIP in detecting impulsive behaviours in PD ........... 171 
Discussion ...................................................................................................................................................................... 172 
Conclusion ..................................................................................................................................................................... 177 
3.6. Dopamine agonists cause reflection impulsivity in Parkinson’s disease, not Deep 
Brain Stimulation ..........................................................................................................179 
Introduction ................................................................................................................................................................. 179 
Patients and methods .............................................................................................................................................. 180 
Statistical analysis..................................................................................................................................................... 183 
Results ............................................................................................................................................................................. 183 
Discussion ...................................................................................................................................................................... 190 
Conclusion ..................................................................................................................................................................... 193 
3.7. Jumping to conclusions behaviour in patients with ephedrone induced 
Parkinsonism .................................................................................................................195 
Introduction ................................................................................................................................................................. 195 
Patients and methods .............................................................................................................................................. 198 
Statistical analysis..................................................................................................................................................... 202 
Results ............................................................................................................................................................................. 203 
Discussion ...................................................................................................................................................................... 210 
Conclusion ..................................................................................................................................................................... 214 
13 
 
Chapter 4 - The role of Stress in Parkinson’s disease .................................................215 
Introduction ................................................................................................................................................................. 215 
Psychogenic Parkinsonism .................................................................................................................................... 217 
Stress induced reversible Parkinsonism .......................................................................................................... 218 
Stress induced neuronal damage ....................................................................................................................... 221 
Variants of stress........................................................................................................................................................ 223 
Kinesia paradoxica in Parkinson’s disease .................................................................................................... 224 
Stress induced functional somatic syndromes ............................................................................................. 226 
Clinical overlap between functional somatic syndromes and Parkinson’s disease ..................... 229 
Striato-thalamo-cortical alterations in functional somatic syndromes .......................................... 232 
The prodrome of Parkinson’s disease ............................................................................................................... 234 
Conclusion ..................................................................................................................................................................... 237 
4.1. The role of cortisol in Parkinson’s disease ...........................................................239 
Introduction ................................................................................................................................................................. 239 
Patients and methods .............................................................................................................................................. 240 
Discussion ...................................................................................................................................................................... 250 
Conclusion ..................................................................................................................................................................... 252 
Summary and general discussion ................................................................................254 
Future work .................................................................................................................................................................. 258 
Acknowledgments ..........................................................................................................260 
Appendix ........................................................................................................................261 
Bibliography ..................................................................................................................263 
  
14 
 
List of tables  
Table 1.  Diagnostic criteria of pathological gambling DSM-IV. ................................................. 28 
Table 2.  Proposed criteria for compulsive sexual behaviour. ..................................................... 50 
Table 3.  Diagnostic criteria for DDS. ........................................................................................... 52 
Table 4.  Diagnostic criteria for compulsive shopping. ............................................................... 53 
Table 5.  Diagnostic criteria for binge eating (DSM-IV). ............................................................. 54 
Table 6.  Behavioural studies performed in PD+ICBs patients until March 2011. ..................... 59 
Table 7.  Risk and learning task: Demographic characteristics. ................................................. 90 
Table 8.  Altruistic punishment: Demographic characteristics. ................................................ 106 
Table 9.  Stroop test: Demographic characteristics. .................................................................. 121 
Table 10. Novelty task: Demographic characteristics. .............................................................. 139 
Table 11.  Beads task: Demographic characteristics. ................................................................ 159 
Table 12.  Beads task: Pairwise comparisons. ........................................................................... 164 
Table 13.  WM task: Pairwise comparisons for WM performance. ........................................... 168 
Table 14.  WM task: Pairwise comparisons for recalling the distractors. ................................ 170 
Table 15.  STN-DBS: Demographic characteristics.................................................................... 184 
Table 16.  STN-DBS: Pairwise comparisons. .............................................................................. 188 
Table 17.  Ephedrone: Demographic characteristics................................................................. 200 
Table 18.  Cortisol: Demographic characteristics. ..................................................................... 243 
 
  
15 
 
List of figures 
Figure 1.  Queen Square Brain Bank criteria of PD. .................................................................... 20 
Figure 2. Illustration of the relevant structures involved in addictive behaviours. ................... 39 
Figure 3. Increased “bottom up” mesolimbic dopamine release. ................................................ 60 
Figure 4.  11C-raclopride binding potential between PD patients with and without ICBs. ......... 62 
Figure 5.  Learning and risk task. ................................................................................................. 86 
Figure 6.  WM performance. ......................................................................................................... 92 
Figure 7.  Learning from positive and negative feedback. .......................................................... 94 
Figure 8.  Risk preference.............................................................................................................. 96 
Figure 9.  Average punishment score of participants in fair and unfair rounds. ..................... 113 
Figure 10.  Stroop test: Behavioural results. .............................................................................. 125 
Figure 11. Sequence of events in 3-armed bandit task. ............................................................. 133 
Figure 12. Novelty seeking task: Behavioural results. ............................................................... 141 
Figure 13.  Beads task. ................................................................................................................ 153 
Figure 14.  WM task. ................................................................................................................... 156 
Figure 15.  WM task: Positive and neutral distractors. ............................................................. 157 
Figure 16.  Beads task: Average number of draws per condition by group. ............................. 162 
Figure 17.  Beads task: Number of times participants chose the opposite colour. ................... 165 
Figure 18.  WM performance. ..................................................................................................... 167 
Figure 19.  WM task: Remembering distractors (positive, neutral, negative). ......................... 169 
Figure 20.  STN-DBS:  Average drawing behaviour per condition of different groups. ........... 187 
Figure 21.  STN-DBS: Number of times participants chose the opposite colour. ...................... 189 
Figure 22.  Ephedrone: WM performance. ................................................................................. 204 
Figure 23.  Ephedrone: Effects of memoranda on WM performance. ....................................... 206 
16 
 
Figure 24.  Ephedrone: Average drawing behaviour per condition of different groups. ......... 207 
Figure 25.  Ephedrone: Number of times participants chose the opposite colour. ................... 208 
Figure 26.  Ephedrone: Risk and learning behaviour. ............................................................... 209 
Figure 27.  Stress induced micrographia. .................................................................................. 219 
Figure 28.  Schematic outline of the time course of saliva samples. ......................................... 242 
Figure 29.  Cortisol levels of participants. .................................................................................. 246 
Figure 30.  Log scores of diurnal salivary cortisol levels. .......................................................... 248 
17 
 
-
 
Overview and research aims 
In this thesis behavioural addictions such as pathological gambling, compulsive sexual 
behaviour, compulsive shopping, punding and binge eating, collectively termed as 
impulsive compulsive behaviours (ICBs) in treated Parkinson’s disease (PD) have been 
assessed on a variety of different neuropsychological tasks. PD patients were tested once 
prior to and once after their usual dopaminergic medication. Healthy volunteers were 
tested in the same way but without taking any medication. In a follow up study PD 
patients were directly compared to patients with pathological gambling and to substance 
abusers on opioid replacement therapy who both did not have PD.  
To assess the role of dopamine agonists in decision making, non-impulsive PD patients 
with dopamine agonist medication in combination with Levodopa (L-dopa) treatment 
were compared to PD patients who were taking L-dopa but not dopamine agonists. 
Further, these two patient groups were compared to PD patients who were treated with 
deep brain stimulation of the subthalamic nucleus and were taking either L-dopa or L-
dopa in combination with a dopamine agonist.   
Patients with ephedrone induced extrapyramidal disorders due to chronic manganism 
have been also compared to substance abusers on opioid replacement therapy to assess 
the role of the accumbens-pallidum connection in decision making.  
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In the final chapter the role of stress as a potential trigger factor of PD has been 
reviewed. Further, salivary cortisol samples of PD patients with and without ICBs were 
obtained and correlated to risk taking behaviour.  
Clinical features of Parkinson’s disease 
Idiopathic PD, originally described by James Parkinson in 1817 (Parkinson 1817), is a 
chronic progressive neurodegenerative disorder characterized by dopaminergic cell loss 
in the substantia nigra (Kish, Shannak et al. 1988, Fearnley and Lees 1991). It is the 
second most common neurodegenerative disease after Alzheimer’s disease (de Lau and 
Breteler 2006). The median age of disease onset is 60 years and the incidence increases 
with age and affects about 1% of people over 60 and 2-3% over 65. It is unclear whether 
the disease plateaus or even declines after the age of 80 (Hirtz, Thurman et al. 2007) or 
whether this decline is artificial since PD is less likely to be diagnosed in geriatric 
patients (Lees, Hardy et al. 2009). The mean survival after the diagnosis is 15 years, 
with the most common cause of death being aspiration pneumonia (Lees, Hardy et al. 
2009). 
The cardinal features of PD, bradykinesia, tremor, rigidity and postural instability, only 
emerge when more than 30% of the dopaminergic neurons in the ventrolateral tier of the  
pars compacta have been destroyed (Cheng, Ulane et al. 2010). Over the last decade 
depression, apathy, fatigue, pain and cognitive problems have been increasingly studied 
(Chaudhuri, Healy et al. 2006). In some patients these can be more disabling than the 
motor handicap.  
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Diagnosis of Parkinson’s disease 
PD is a clinical diagnosis relying on bradykinesia, defined as a progressive reduction in 
the speed and amplitude of sequential  movements (sequence effect), a rhythmical pill 
rolling rest tremor (4-6 Hz), rigidity and postural instability (Lees, Hardy et al. 2009). A 
unilateral onset and persistent asymmetry is present in about two thirds of cases (Gelb, 
Oliver et al. 1999). However, the diagnosis of PD can be difficult and error rates even 
amongst movement disorder specialists as high as 24 per cent, may occur in the earliest 
stages of the disease (Tolosa, Wenning et al. 2006). The commonest sources of error in 
neurological practice are in distinguishing the disorder from multiple system atrophy 
(MSA) - parkinsonism and progressive supranuclear palsy (PSP) - parkinsonism. Rare 
secondary causes such as atypical and dystonic tremor, drug induced or toxic 
parkinsonism, normal pressure hydrocephalus, dopa-responsive dystonia and 
psychogenic parkinsonism may masquerade as PD but can be distinguished by 
dopamine transporter (DAT) scan. Most patients experience a greater than 30% 
improvement in motor handicap with L-dopa therapy which is sustained over many 
years. Scales most commonly used to assess the response to L-dopa and disease severity 
are the Unified Parkinson’s Disease Rating Scale (UPDRS part 3) and the Hoehn and 
Yahr rating scale (Hoehn and Yahr 1967). The Queen Square Brain Bank criteria of PD 
(Gibb and Lees 1988) have improved diagnostic accuracy and only slight changes to 
these accepted criteria of PD have been made over the last years, replacing in step two 
CT scan with an MRI scan and not ruling out PD if other family members are affected 
(Figure 1).   
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Figure 1.  Queen Square Brain Bank criteria of PD.  
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Pathology of Parkinson’s disease 
The basal ganglia are made up of the caudate, the putamen (together referred to as the 
corpus striatum), the nucleus accumbens (referred to as the ventral striatum), the globus 
pallidus, the subthalamic nucleus and the substantia nigra. 
For the neuropathological diagnosis of PD Lewy body pathology and dopaminergic cell 
loss, particularly in the ventrolateral tier of the substantia nigra, a region that projects 
mainly to the putamen is necessary (Fearnley and Lees 1991, Daniel and Lees 1993). 
Lewy bodies are neuronal intracytoplasmatic inclusions, which are particularly rich in 
aggregated α-synuclein, but also contain other proteins, including components of the 
ubiqiuitin-proteasome system (Brundin, Li et al. 2008). In PD Lewy bodies occur in the 
brain stem but can also be found in the cerebral cortex. However, the diagnostic value of 
Lewy bodies is unclear. Lewy bodies are present in 10%-40% in patients with 
Alzheimer’s disease and in various other neurodegenerative diseases such as ataxia 
teleangiectasia or pantothenate kinase 2. Further, Lewy bodies occur in about 12% of 
octogenarians dying without recorded PD or dementia (Gibb and Lees 1988), which has 
led to a debate of whether Lewy bodies are damaging or are actually a compensatory 
survival mechanism of the neuron and thus are beneficial (Dickson, Braak et al. 2009). 
In some autosomal recessive forms of PD (such as parkin mutations), Lewy bodies are 
usually absent and the pathological lesion may be more restricted (Dickson, Braak et al. 
2009). 
It has been estimated that nigral cell loss begins about seven years before the first motor 
symptoms appear but some suggested that the disease may begin much earlier than this 
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in the enteric nervous system, sympathetic ganglia, olfactory bulb and medulla 
oblongata (Braak, Del Tredici et al. 2003). 
Environmental factors 
In 1973 a 23 year old addict injected 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) and developed severe parkinsonism which was partially responsive to L-dopa. 
In the early 1980s another cluster of identical young cases were reported in San 
Francisco, who injected the same substance, which was sold to them as “synthetic 
heroin”. Those patients developed severe parkinsonism, which responded well to L-dopa 
but resulted in severe early motor fluctuations and hallucinations. Around 100 other 
addicts exposed to the same dosage remained unaffected, indicating individual 
susceptibility as a factor. MPTP is an inhibitor of a mitochondrial enzyme complex 1, 
causes selective damage to the substantia nigra (Langston, Ballard et al. 1983) and has 
proved to be a useful non-human primate model of PD for preclinical drug testing.  
Another mitochondrial respiratory chain inhibitor is 6-Hydroxydopamine (6-OHDA), 
which is often used to create rodent models of PD. 6-OHDA has to be stereotactically 
targeted into the substantia nigra as it fails to cross the blood brain barrier. 6-OHDA, 
similarly to MPTP rapidly destroys the catecholaminergic systems, causing degeneration 
of the nigrostrital system (Schober 2004).  
Manganese neurotoxicity was first described in 1837 by James Couper in five Scottish 
workers employed grinding manganese dioxide ore. Since then a large number of cases 
have been reported with a constellation of extrapyramidal symptoms labelled “chronic 
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manganism”. Patients develop dystonia, a typical cock gait, a vacant facial expression, 
sometimes termed as “masque manganique”, bradykinesia, and dysarthria. They may 
also develop neuropsychiatric symptoms known as “locura manganica” or “manganese 
madness” (Lucchini, Martin et al. 2009). In contrast to idiopathic PD a typical resting 
tremor is less prominent and patients develop early postural instability with a tendency 
to fall backwards (Lucchini, Martin et al. 2009). Further, imaging studies show severe 
damage of the globus pallidus and the substantia nigra pars reticularis. DAT scans, 
however, have been reported as normal (Olanow 2004). As a consequence these patients 
do not benefit from L-dopa (Olanow 2004) but may improve with chelation therapy. 
Manganism can be found in welders, in those with chronic liver failure, in patients 
receiving long term parental nutrition and in methcathinone abusers, who use potassium 
permanganese as an oxidant (Lucchini, Martin et al. 2009).  
Other toxins such as agricultural chemicals, rotenone, maneb and paraquat, when 
administered systemically, can also resemble PD. Weak associations between PD and 
other environmental factors such as well water ingestion, middle age obesity, lack of 
exercise and rural living have been reported. Smoking and coffee consumptions have 
been inversely associated with PD (Lees, Hardy et al. 2009). 
Although several genes responsible for PD have been discovered, these account 
currently for a small proportion of cases and 95% of the cases are considered to be 
sporadic. In these cases non-genetic factors probably in combination with genetic 
susceptibility are thought to trigger the disease (de Lau and Breteler 2006).  
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Pharmacological treatment of Parkinson’s disease and motor 
complications  
L-dopa although reported in the early 1960s by Hornykiewicz and collaborators and 
later introduced by Cotzias (Cotzias, Papavasiliou et al. 1969), still remains the most 
efficacious treatment for PD (Lees, Hardy et al. 2009). Non ergoline dopamine agonists 
such as pramipexole, ropinirole and rotigotine are other albeit less effective drugs 
targeting mainly the dopamine D2 and D3 receptors. The only dopamine agonist, which 
has been found to be as effective as L-dopa is apomorphine, which both have the highest 
affinity to the dopamine D1 receptor. Dopamine agonists have been claimed to be 
particularly useful in younger onset PD patients because when used as monotherapy 
they rarely induce drug induced dyskinesias. However, increasing reports of devastating 
behavioural side effects directly triggered by dopamine agonists have limited its use. 
Further, motor deterioration requires the introduction of L-dopa therapy usually within 3 
years after diagnosis (Lees, Hardy et al. 2009). Other therapies include selective type B 
monoamine oxidase inhibitors (MAO) selegeline and rasagiline, catechol-O-methyl 
transferase inhibitors (entacapone and tolcapone) or amantadine.  
After about 3-5 years of treatment with L-dopa patients start to notice some wearing off 
of individual doses and attempts to overcome this by increasing dosage or frequency of 
L-dopa may lead to the emergence of inter-dose chorea or less commonly onset and end 
of dose dyskinesias. Nocturnal difficulties also increase with difficulties turning in bed 
and getting out of bed. As treatment continues capricious motor fluctuations likened to 
the switching on and off of a light switch may develop despite treatment modification. 
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Gait freezing, start hesitation, poor balance and falls are other causes of morbidity in the 
later stages. Dementia is one of the most debilitating consequences of PD with 
frequencies ranging between 30-80% of patients (Obeso, Rodriguez-Oroz et al. 2010).  
Indeed four milestones of advanced PD have been described as markers for severe 
motor impairment: Frequent falls, visual hallucinations, dementia and need for 
residential care (Kempster, O'Sullivan et al. 2010). For those patients who have severe 
refractory motor fluctuations deep brain stimulation (DBS) of the subthalamic nucleus 
(STN) is an option. However, STN-DBS has its limitations as it fails to improve some 
parkinsonian features such as freezing of gait, postural instability and can worsen 
dysphagia, cognitive function and speech (Weaver, Follett et al. 2009). Suicide and 
severe abulia are recognised rare risks of operated patients (Piasecki and Jefferson 
2004). Although STN-DBS alleviates motor handicaps in both older and younger PD 
patients, postoperative quality of life only improves in patients who are younger than 65 
years (Derost, Ouchchane et al. 2007). Pallidal DBS for dyskinesias and stimulation of 
the ventral intermediate nucleus of the thalamus for tremor are other commonly used 
targets in PD (Walter and Vitek 2004). 
Alternative therapies, such as continuous subcutaneous apomorphine administration via 
a pump system and the enteral administration of an L-dopa formulation (duo-dopa), may 
have to be considered in suitable patients (Lees, Hardy et al. 2009).  
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Gambling was first described more than 6000 years ago in ancient Egypt and was also 
popular in the ancient civilisations of China, Babylon and India. In Greek mythology the 
gods Zeus, Poseidon and Hades divided the universe by casting dice and descriptions of 
gaming can also be found in the Old Testament and the Koran (Arnold 1977). The first 
private lottery was founded in Florence in 1530, and gambling subsequently became a 
lucrative business in Europe. In England the first law prohibiting gambling was enacted 
in 1661 to prevent members of the lower classes from ruining their lives (Arnold 1977).  
It is also claimed that the devastating fire of Chicago in 1871 was caused by a 
preoccupied gambler accidentally knocking over a lantern while shooting dice in a barn 
(Flemming 1978). 
The word ‘risk’ derives from the Latin word ‘risicare’ and means ‘to dare’. It 
necessitates an element of danger and uncertainty about outcome but can bring 
opportunity, and without an element of risk taking there can be no innovation or social 
progress, quoting a common saying: “The biggest risk of life is not taking one”. A 
degree of novelty seeking with its implicit risk taking is part of normal adolescence and 
contributes to independence from ones parents control (Kelley, Schochet et al. 2004).  
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Gambling involves risk taking on the outcome of an event determined by chance (Korn 
and Shaffer 1999) and in the market place has been considered an evolutionary response 
to risk management. Successful entrepreneurs balance risks and returns to ensure that 
profits compensate for their level of risk taking and often adopt one of the most common 
sayings on Wall Street "cut your losses short and let your winners run" in their everyday 
dealings. Risk managers also frequently take chances in order to make higher profits, 
but these decisions are logical and based on experience and knowledge rather than 
emotion. However, the path between Scylla and Charybdis is narrow, and 
overconfidence and misjudgement can easily occur, as seen in the ‘Great crash’ of 1929 
and the credit crunch of 2008. 
In professional gambling for large sums of money, discipline is crucial, risks are 
measured and calculated, and emotions and passion are concealed. Casinos employ risk 
management strategies to keep their financial risks as low as possible and may ban 
consistently successful gamblers from their tables. Recreational gamblers minimise their 
loss by playing with friends for relatively short periods of time and for manageable 
losses, but occasionally in susceptible individuals this innocent pastime can lead on to 
problem gambling.  Problem gamblers start to overestimate their chances of winning 
and start developing an “illusion of control” in games in which the probabilities of 
winning is at chance level (Langer 1975). 
 In recent years the popularity of all forms of gambling has increased in many countries, 
partly as a result of internet betting. According to the British Gambling Prevalence 
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Study 2007, approximately 32 million adults had participated in some form of gambling 
during the previous year (Wardle, Sproston et al. 2007).   
Pathological gambling (PG) is defined as inappropriate, persistent, and maladaptive 
gaming behaviour, which has been included by psychiatrists within the broader category 
of impulse control disorders (American Psychiatric Association 2000). (See Table 1).  
Persistent and recurrent maladaptive gambling behaviour as indicated by five (or more) of         
the following: 
o is preoccupied with gambling (e.g. preoccupied with reliving past gambling 
 experiences, handicapping or planning the next venture, or thinking of ways to get 
 money with which to gamble)  
o needs to gamble with increasing amounts of money in order to achieve the desired              
 excitement 
o has repeated unsuccessful efforts to control, cut back, or stop gambling 
o is restless or irritable when attempting to cut down or stop gambling 
o gambles as a way of escaping from problems or of relieving a dysphoric mood (e.g. 
 feelings of helplessness, guilt, anxiety, depression)  
o after losing money gambling, often returns another day to get even (“chasing” 
 one’s losses) 
o lies to family members, therapist, or others to conceal the extent of involvement 
 with gambling 
o has committed illegal acts such as forgery, fraud, theft, or embezzlement to finance 
 gambling 
o has jeopardized or lost a significant relationship, job, or educational or career 
 opportunity because of gambling 
o relies on others to provide money to relieve a desperate financial situation caused 
 by gambling 
B. The gambling behaviour is not better accounted for by a Manic Episode. 
 
Table 1.  Diagnostic criteria of pathological gambling DSM-IV. 
 (American Psychiatric Association 2000). 
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Vivid descriptions of the personality of the gambler appear in the world’s great literature 
including Dostoevsky’s autobiographical account of his own addiction in ‘The 
Gambler’. Pushkin’s novel ‘The Queen of Spades’ written in 1833, deals with human 
avarice, a superstitious belief of an invincible sequence of winning cards, and eventual 
madness of the protagonist, Hermann.  
Pathological gamblers ruminate and become preoccupied with gambling to the detriment 
of everyday responsibilities; they lose self-control of their finances and become 
manipulative and deceitful, particularly where money is concerned. They gamble to 
relieve stress and escape into a make-believe world, which at first is exciting and 
rewarding. They withdraw socially and avoid former friends and contacts, lie and steal 
from family, friends and acquaintances. Personal relationships deteriorate, and they may 
lose their job due to increasing unreliability and absenteeism. They feel guilt and 
remorse but become irritable and hostile when deprived of the opportunity to gamble. 
Eventually they experience little or no pleasure on winning even large sums of money. 
Patients continue gambling to recover their losses, often known as “loss chasing 
behaviour” (Lesieur 1984). Loss chasing contributes significantly to pathological 
gambling as patients lose control over the amount of money spent (Lesieur 1979). This 
behaviour is driven mainly by anxiety over the already acquired debt and losses but on 
the other hand loss chasing is also driven by hope to win the jackpot (Campbell-
Meiklejohn, Woolrich et al. 2008). “It’s one crisis after another and you gamble to get 
even…one big hit, make that one big hit, and pay off the bets and never gamble again“ 
(Lesieur 1984). 
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Patients also start feeling guilty, pessimistic and depressed. “Then came the feeling of 
uneasiness within myself; a feeling of, probably you might call it of impending doom or 
disaster, that I had never had before. There was no way I wasn’t going to blow 
everything” (Lesieur 1984). 
The clinical diagnosis of PG requires the presence of least five out of ten ‘green flags’ 
on a structured interview whereas “problem gambling” is often used in the presence of 
only two or three of these warning signs (Shaffer, Hall et al. 1999, American Psychiatric 
Association 2000).  
The British Gambling Prevalence Study 2007 have estimated a prevalence of problem 
gambling in the UK population of 0.6% (Wardle, Sproston et al. 2007). Higher figures 
have been reported in the United States of America where the lifetime prevalence of PG 
is considered to be 1.6% (Shaffer, Hall et al. 1999). A subgroup of patients with PD 
develops a constellation of socially disruptive behavioural addictions during long-term 
dopamine replacement. These include pathological gambling, hyperlibidinous behaviour 
and paraphilias, compulsive shopping, binge eating, hoarding and reckless generosity. 
One fourth of these patients exhibit more than one addictive behaviour at the same time 
(Weintraub, Koester et al. 2010).  
PG in Parkinson’s disease was first described 13 years ago in a South African patient 
prescribed pergolide (Seedat, Kesler et al. 2000) and is now generally accepted as a 
complication of dopaminergic therapy.  
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Illustrative case   
A 52-year-old male with PD was initially treated with L-dopa. He took medication only 
on weekdays because he had a natural dislike of tablets. Four years after diagnosis L-
dopa was stopped altogether on the patient’s request, but deteriorating mobility led to 
the need for replacement with the dopamine agonist drug pramipexole, the dose of 
which was increased steadily to 3mg salt daily. Within a few months his wife reported 
that he had started to gamble uncontrollably and was spending £170-£200 per week on 
scratch cards and at bookmakers. He obsessively studied the form of jockeys and used 
lucky stones in the belief they would improve his chances of winning.  He became 
devious and manipulative and hid scratch cards from his wife. In just over a year he lost 
£10,000 on gambling. At the same time he developed a craving for sweets and started 
binge eating. Once this behaviour came to medical attention, pramipexole was reduced 
and then stopped altogether, and L-dopa was reintroduced. Within a few weeks his 
behaviour returned to normal, and he lost all further interest in gambling.   
Phenomenology of pathological gambling in Parkinson’s disease 
In the UK, the British Gambling Prevalence Study 2007 showed that online roulette and 
spread betting were the commonest gambling activities leading to PG (Wardle, Sproston 
et al. 2007).  In the United States, pull tabs, a paper version of an electronic slot machine 
game where the player has to open tabs for winning symbol combinations, was most 
frequently reported, followed in descending order by casino games, bingo, lottery cards 
and betting on sporting events (Welte, Barnes et al. 2004). Several studies have reported 
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that PD patients with PG have a particular predilection for slot machines (Gallagher, 
O'Sullivan et al. 2007, Cilia, Siri et al. 2008). Slot machines offer rapid pay out intervals 
equally brief loss periods, giving patients little time to reflect and providing the 
opportunity for winnings to be re-gambled almost instantly (Griffiths 1999). Arousing 
lights and enticing coin chimes are powerful associated reinforcing sensory reward cues. 
Playing slot machines is mechanical, ritualistic and involves repetitive stereotyped 
movements similar to those seen in some types of punding (Voon, Hassan et al. 2006). 
Near misses and immediate rewards render these games highly addictive, especially for 
individuals who seek instant self-gratification (Voon, Reynolds et al. 2010). Scratch 
cards and lottery are other popular pursuits for PD gamblers whereas, poker, spread 
betting, and speculating on the stock exchange occur but seem to be less popular 
(Gallagher, O'Sullivan et al. 2007).  
Prevalence of pathological gambling 
Cross sectional studies have shown a lifetime prevalence of PG in treated PD between 
3.4% and 6% (Avanzi, Baratti et al. 2006, Grosset, Macphee et al. 2006, Voon, Hassan 
et al. 2006, Weintraub, Koester et al. 2010). Higher prevalence rates have been reported 
in patients treated with a dopamine agonist (6-8%) (Grosset, Macphee et al. 2006, 
Singh, Kandimala et al. 2007). In a questionnaire survey of 3000 North American PD 
patients, PG was found to be more prevalent in the United States (5.5%) than in Canada 
(3.6%), possibly because of easier casino access and more explicit and overt advertising 
in the United States (Weintraub, Koester et al. 2010). Even these high figures of PG in 
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PD may be a significant underestimate, as many patients have a reduced insight into the 
social consequences of their behaviour or conceal it from their families because of 
shame or denial (Singh, Kandimala et al. 2007). An online survey has claimed a figure 
of 13%, but possible selection bias (online survey that requires registration focussing on 
gambling) and the lack of confirmation of the diagnosis of PD by neurological 
examination are important limitations of this study (Wicks and MacPhee 2009). Much 
lower prevalence rates between 0.32% and 1.3% for PG in PD have been reported in 
China and Korea where the opportunity to gamble is restricted (Fan, Ding et al. 2009, 
Lee, Kim et al. 2009). 
Risk factors for pathological gambling 
Comparison studies between patients with amyotrophic lateral sclerosis and treated PD 
patients showed that PG was significantly more common in PD, supporting the notion 
that aberrant pathways involving risk taking rather than a chronic neurological handicap 
are responsible for gambling (Wicks and MacPhee 2009). Pathological gambling was 
not reported in association with Parkinson’s disease until the modern era of 
pharmacotherapy (Molina, Sainz-Artiga et al. 2000, Avanzi, Baratti et al. 2006).  
However, in 1822 Théodore Géricault painted the Madwoman Obsessed With Gambling, 
illustrating a woman with hypomimia, stooped shoulders, and a walking aid, who might 
be the first documented PD patient with PG (Healy 2007). 
The large majority of PD patients with PG never gambled regularly before the onset of 
dopamine agonist therapy, and it is this single factor that contributes by far the greatest 
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risk. PG and other behavioural addictions have been described in atypical parkinsonism 
(O'Sullivan, Djamshidian et al. 2010) and also in patients with no evidence of striatal 
damage such as patients with restless legs syndrome (Ondo and Lai 2008), pituitary 
adenomas (Falhammar and Yarker 2009) and fibromyalgia when they have been treated 
with dopamine agonists (Holman 2009).  
While the vast majority of PD patients develop PG on dopamine agonist medication 
(Gallagher, O'Sullivan et al. 2007), less than ten patients have been treated with L-dopa 
monotherapy (Ardouin, Voon et al. 2006, Avanzi, Baratti et al. 2006, Solla, Cannas et 
al. 2011) and one patient was taking a combination of selegiline and L-dopa (Drapier, 
Drapier et al. 2006). It is therefore likely that PG on L-dopa monotherapy corresponds 
roughly with the prevalence of PG in the general population. There is no convincing 
proof that non ergolene dopamine agonists (e.g. pramipexole and ropinirole) are more 
likely to induce PG than ergolene agonists such as bromocriptine and cabergoline 
(Gallagher, O'Sullivan et al. 2007). Less information is available yet for the more 
recently introduced transdermal rotigotine, a non ergolene dopamine receptor agonist, 
(Wingo, Evatt et al. 2009) which in common with pramipexole and ropinirole has a high 
affinity to dopamine D3 receptors (Gerlach, Double et al. 2003, Jenner 2005).  
Animal studies have shown a potential benefit of dopamine D3 antagonists on craving 
behaviour in rats (Higley, Spiller et al. 2011),however, studies in humans have yet to be 
performed.  
PG usually develops after a few months of drug therapy, suggesting either duration of 
treatment or cumulative dosage is an independent risk factor (Evans, Strafella et al. 
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2009). Although PG may occur at low doses of dopamine agonist medication, higher 
doses further increase the risk in susceptible individuals (Hassan, Bower et al. 2011) and 
the combination of lower doses of an agonist with L-dopa also seems to increase risk 
(Gallagher, O'Sullivan et al. 2007, Evans, Strafella et al. 2009, Bharmal, Lu et al. 2010, 
Weintraub, Koester et al. 2010, Hassan, Bower et al. 2011). 
In common with pathological gambling in the general population (Petry, Stinson et al. 
2005, Slutske, Caspi et al. 2005, Blanco, Hasin et al. 2006) male gender, a previous 
history of alcohol or substance abuse, a history of depression, and high novelty seeking 
personality traits have all been identified as risk factors in PD (Gallagher, O'Sullivan et 
al. 2007, Singh, Kandimala et al. 2007, Voon, Thomsen et al. 2007, Siri, Cilia et al. 
2010). Young onset PD patients who are unmarried and smoke are also more vulnerable, 
particularly if there is a positive family history for addictive behaviours or pathological 
gambling (Weintraub, Koester et al. 2010). This is in sharp contrast to non-impulsive 
PD patients who have lower nicotine, alcohol and caffeine intake than the general 
population (Evans, Lawrence et al. 2006).  
Apathy is linked with anxiety, depression and impulsivity and is more frequent in PD 
patients with PG compared to PD controls (Gallagher, O'Sullivan et al. 2007, Shapiro, 
Chang et al. 2007, Leroi, Andrews et al. 2009). It is often a prominent feature of the 
“off” state in patients who gamble when “on”. In these cases apathy may become a 
significant problem after dopamine agonist withdrawal (Czernecki, Schupbach et al. 
2008, Thobois, Ardouin et al. 2010). Craving for sweets in PD patients is associated 
with dopamine agonist use, suggesting dopamine mediated alterations in reward 
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processing (Nirenberg and Waters 2006, Shahed, Davidson et al. 2006) and has been 
linked to novelty seeking and addictive behaviour in non PD patients (Lange, Kampov-
Polevoy et al. 2010). Although approximately 20% of individuals with PG in the general 
population have a first degree relative who also has a gambling addiction (Ibanez, 
Blanco et al. 2003), no reliable genetic marker has yet been identified. Candidate gene 
studies on the TaqIA polymorphism, dopamine 1 and 4 receptor and the dopamine 
catechol-O-methyl transferase (COMT) gene have given conflicting results, and further 
work will be required to confirm these suggested associations (Comings, Gade et al. 
1996, Vandenbergh, Rodriguez et al. 1997, Comings, Gonzalez et al. 1999, Eisen, 
Slutske et al. 2001, Foltynie, Lewis et al. 2005, da Silva Lobo, Vallada et al. 2007, 
Lobo, Souza et al. 2010).  
Mechanisms underlying pathological gambling in Parkinson’s 
disease 
There are several similarities between PG and substance abuse, including an overriding 
desire to satisfy a craving, intrusive recurrent thoughts relating to the deleterious 
behaviour, and a loss of self-control (World Health Organization Geneva, 1992). It has 
been claimed that PG patients have more problems resisting the urge to gamble than 
drug abusers have in resisting their craving for ‘a fix’ (Castellani and Rugle 1995). PG is 
more prevalent amongst cocaine addicts (Hall, Carriero et al. 2000), and amphetamine 
can induce the desire to game in problem gamblers (Zack and Poulos 2004), suggesting 
that drugs that increase presynaptic dopaminergic terminal release increase the risk of 
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PG. Previous studies have proposed that slot machines and other electronic gaming 
machines are the “crack cocaine” of gambling with the highest addictive potential 
(Dowling, Smith et al. 2005). Pathological gamblers need to progressively increase the 
amount of money they risk over time in order to achieve equivalent levels of excitement, 
a behavioural response that resembles the dependence and tolerance observed in drug 
addicts. Withdrawal symptoms from PG similarly include depression, irritability and 
restlessness (Wray and Dickerson 1981). PD patients who gamble often report drug 
induced hypomania or euphoria on dopamine agonists (Voon, Thomsen et al. 2007). 
There is also a significant overlap between other addictions such as alcohol dependency, 
personality disorder and PG (Eisen, Slutske et al. 2001, Petry, Stinson et al. 2005).   
In PD there is an uneven distribution of dopaminergic cell loss, with the dorsal striatum 
being much more severely damaged than the ventral striatum (Kish, Shannak et al. 
1988). This has led to the hypothesis that exogenous dopaminergic medication, 
necessary to correct the depleted dopamine levels in the putamen, might over-stimulate 
the ventral circuitry (“cognitive overdose hypothesis”) leading to adverse behavioural 
and cognitive consequences (Gotham, Brown et al. 1988, Swainson, Rogers et al. 2000). 
Those PD patients with the most intact ventral striatum may therefore be at highest risk 
of developing PG. An opposing hypothesis is that the severity of the lesion in the A10 
ventral tegmental area dictates the likelihood of treatment related behavioural 
disturbances, in the same way as the severity of the pars compacta nigral lesion 
predisposes to dyskinesias under pulsatile exogenous D2 stimulation (Jenner 2008). 
38 
 
Dopamine agonists increase activity in the ventral striatum during the anticipation of 
reward, but at the same time reduce interaction with the prefrontal cortex (Ye, Hammer 
et al. 2011). They also reduce reward processing in the lateral orbito frontal cortex and 
impair the negative reinforcing effect of losing (van Eimeren, Ballanger et al. 2009). 
Dopaminergic medication might also prevent dopamine dips that normally happen 
during negative feedback learning (Frank and O'Reilly R 2006). “Cool” or rational 
decision making is mediated via the dorsolateral prefrontal cortex and is necessary for 
risk/benefit evaluations and working memory, whilst “hot” decision making involves 
affective responses (Seguin, Arseneault et al. 2007). Modulation of this “hot” limbic 
versus “cool” executive balance caused by dopamine agonists is likely to lead to risky 
behaviour with impairment of long term negative feedback learning.  
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Model of brain circuits involved in addictive behaviours in the 
general population 
 
Figure 2. Illustration of the relevant structures involved in addictive behaviours.  
A: In healthy controls inhibitory control from the PFC is sufficient to refrain stop an 
addictive behaviour. This regulatory mechanism is impaired in patients with 
addictions (B). Increased mesolimbic dopamine levels are responsible for an 
overvalue of an immediate action, causing pathological motivation. PFC=prefrontal 
cortex, CG=cingulate gyrus, ACC=anterior cingulate cortex, OFC=orbitofrontal cortex, 
Am=Amygdala, Hip=Hippocampus, NAc=nucleus accumbens.  Permission to 
reproduce this figure was granted by the Nature publishing group. Figure adapted 
from Lee et al. (Lee, Carter et al. 2012). 
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The prefrontal cortex is necessary for inhibitory control (Aron, Robbins et al. 2004) and 
the orbitofrontal cortex is crucial for determining the value of a potential reward (Rolls 
2000) (Figure 2). In healthy volunteers these brain areas prevent a behaviour to become 
addictive. In patients with addictions poor self-control impaired inhibitory control of the 
prefrontal cortex together with an overvalue of an outcome because of impaired 
orbitofrontal cortex function and an up regulation of mesolimbic dopamine release cause 
aberrant motivation (Figure 2) (Lee, Carter et al. 2012). Mesolimbic dopamine, 
originating from the ventral tegmental area and projecting to the prefrontal cortex via 
the ventral striatum and the amygdala, is known to reduce the reward threshold (Koob 
and Volkow 2010), causing the feeling of pleasure, which is necessary to reinforce an 
addictive behaviour. As the addiction continues, withdrawal symptoms  and anxiety 
mediated via the amygdala occur (Koob and Volkow 2010). Projections from the 
amygdala to the ventral striatum reinforce pathological motivation to reverse the 
negative affect causing incentive salience (“wanting”). This model has been established 
for drug addiction and behavioural addiction in the general population (Koob and 
Volkow 2010, Lee, Carter et al. 2012), but can also explain addictive behaviours seen in 
PD. In fact, there are several studies strengthening the link between addictive behaviours 
seen in PD and drug addiction seen in the general population (Dagher and Robbins 
2009, Koob and Volkow 2010). 
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Imaging studies in patients with Parkinson’s disease with 
pathological gambling 
Resting
 
cerebral perfusion measured via single-photon emission
 
computed tomography 
(SPECT) showed enhanced activation in the orbitofrontal
 
cortex, the hippocampus, the 
amygdala, the insula, and the ventral
 
pallidum in PD patients with PG. These alterations 
in the reward centres of the brain suggest possible drug induced overstimulation of an 
intact mesolimbic dopamine system (Cilia, Siri et al. 2008). A [
11
C] raclopride positron 
emission tomography (PET) study measured striatal dopamine D2/D3 receptor binding 
and release of dopamine in seven PD patients with PG patients and seven patients 
without PG during the performance of a gambling task. PD patients with PG had a 
significant reduction of [
11
C] raclopride bilaterally in the ventral striatum (Steeves, 
Miyasaki et al. 2009). Another recent PET study showed extra-striatal dopaminergic 
dysfunction in PD patients with PG, compared to non-impulsive PD patients. Increased 
midbrain dopamine release and a reduction of dopamine in the anterior cingulate were 
seen after 1 mg of pramipexole during gambling in PD patients with PG but not in PD 
controls. These dopaminergic changes correlated with impulsivity measured with the 
Barrat impulsivity scale (Ray, Miyasaki et al. 2012). 
Some (Steeves, Miyasaki et al. 2009) but not all PET studies (Evans, Pavese et al. 2006, 
O'Sullivan, Wu et al. 2011) have also found lower D2/D3 receptor levels in PD patients 
with behavioural addictions posing an independent risk factor for developing an 
addictive behaviour (Nader, Morgan et al. 2006). A PET study measured regional 
cerebral blood flow during a computerized card game of seven PD patients with PG 
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patients versus control PD patients. Testing was done once prior to dopaminergic 
medication and once following the subcutaneous injection of 3 mg of apomorphine. 
Apomorphine caused reduced blood flow only in PD patients with PG, with reduction in 
the lateral orbitofrontal cortex, rostral cingulate zone, amygdala, and the globus pallidus 
externus. In contrast PD patients without PG had an increased blood flow in these 
regions, suggesting that dopamine agonists can affect areas that are critical for 
inhibition, negative feedback learning and executive control in vulnerable patients (van 
Eimeren, Pellecchia et al. 2010).  
Functional MRI (fMRI) studies in a group of PD patients with PG and compulsive 
buying showed an increase in ventral striatum blood-oxygen-level dependent (BOLD) 
activity to reward after dopamine agonist medication. Correlation between imaging and 
behaviour suggests that impulsive PD patients have a higher positive prediction error 
and an increase in ventral striatum activity (Voon, Pessiglione et al. 2010). Another  
fMRI study in PD patients with PG patients also showed increased activation of the 
ventral striatum, mesial prefrontal and the anterior cingulate cortex following visual 
cues (Frosini, Pesaresi et al. 2010).   
Taken together these findings indicate enhanced mesolimbic but also extra-striatal 
midbrain dopamine activation (“bottom up”) and reduced cortical dopamine (“top 
down”) levels during gambling in PD patients with PG.  
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Treatment of patients with Parkinson’s disease with pathological 
gambling  
Patients starting dopamine agonist therapy should be informed of the possible risk of PG 
and other treatment related behavioural disorders. In the UK all dopamine agonists now 
contain a warning about the risk of developing PG and other treatment related 
psychiatric disturbances in the product description. The information should be provided 
wherever possible in the presence of the family, who should also be advised to promptly 
report any changes that occur in the patient behaviour during agonist treatment (Grosset, 
Macphee et al. 2006, Singh, Kandimala et al. 2007). It is equally important to discuss 
the marked benefits that can occur with dopamine agonist treatment in a positive and 
encouraging fashion to avoid nocebo effects. A record of these discussions needs to be 
kept in the patient’s case notes, and in the UK it is recommended to add a comment in 
the letter to the family physician that it has been carried out. Patients with a history of 
substance abuse, current smokers, those with younger onset of disease and who are 
single, are at increased risk of developing PG and require particularly close on-going 
supervision (Singh, Kandimala et al. 2007, Voon, Thomsen et al. 2007, Weintraub, 
Koester et al. 2010). In high risk patients L-dopa monotherapy may be a better initial 
treatment choice, regardless of the patient age. Although the highest risk of developing 
PG after dopamine agonist treatment is within the first few months (Evans, Strafella et 
al. 2009), clinicians must screen proactively for PG or other treatment induced 
psychiatric side effects at each clinic visit. If PG has developed, dopamine agonist 
therapy should be immediately reduced and in the absence of rapid improvement over 
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the next few weeks, discontinued altogether. L-dopa should be concurrently introduced 
or if the patient was already on combination therapy the dose slowly increased to control 
motor handicap.  
Previous studies finding an increased risk of treatment related behavioural side effects in 
patients treated with L-dopa monotherapy or in combination with monoamine oxidase B 
inhibitors did not screen for dopamine dysregulation syndrome, which is more common 
with L-dopa (Weintraub, Koester et al. 2010). This is relevant, since a 4 year follow up 
study after dopamine agonists were withdrawn found a complete cessation of gambling 
behaviour in 15 out of 17 PD patients with PG patients, despite an increase of L-dopa 
from 615 to 881 mg (Macphee, Copeland et al. 2009).Therefore, monoamine oxidase B 
inhibitors and L-dopa remain the first and second line option in patients with PG 
(Grosset, Cardoso et al. 2011). Despite this, dopamine agonist withdrawal symptoms, 
which include anxiety, panic attacks, dysphoria, apathy and the subjective feeling of 
being “stiff “ may occur in one in five PD patients (Rabinak and Nirenberg 2010). These 
withdrawal symptoms sometimes remain refractory to antidepressants or cognitive 
behavioural therapy as well as further increases in L-dopa (Rabinak and Nirenberg 
2010).   
Family members should be instructed to limit access to money, credit cards, and the 
internet. Cognitive behavioural therapy focussing the patient more towards non 
gambling activities can be helpful in expert hands (Hodgins and Petry 2004). If agonist 
withdrawal fails to alleviate the problem, then patients and their families may need to 
seek advice from Gamblers Anonymous or help lines such as GamCare or be referred 
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(where available) to specialist gambling clinics. Depression (Gallagher, O'Sullivan et al. 
2007), drug induced mood changes (Voon, Thomsen et al. 2007), and sleep disturbance  
(O'Sullivan, Loane et al. 2011) commonly occur in PD patients with PG and should be 
treated symptomatically with a tricyclic antidepressant (Menza, Dobkin et al. 2009) or 
an antidepressants with effects on noradrenergic uptake, for example, venlafaxine 
(Richard et al 2010, 2nd World Parkinson Congress, Glasgow Abstract P19.18), 
mirtazapine or reboxetine. Selective serotonin reuptake inhibitors (SSRIs) may not be 
the preferred initial treatment of choice for depression in PD (Skapinakis, Bakola et al. 
2010). Antidepressants are also not beneficial in reducing gambling urges per se 
(Blanco, Petkova et al. 2002, Black, Arndt et al. 2007), and the evidence for using 
antipsychotic drugs in PD patients with PG is conflicting (Sevincok, Akoglu et al. 2007, 
McElroy, Nelson et al. 2008).   
Recent preliminary studies with zonisamide and topiramate have shown promising 
initial results in reducing gambling urges in PD (Bermejo 2008, Bermejo, Ruiz-Huete et 
al. 2010). One double blind, placebo controlled, cross over study with open label 
extension using the N-methyl d-aspartate (NMDA) receptor antagonist amantadine was 
beneficial in 17 PD patients with PG patients, reducing or abolishing gambling urges 
and hours spent gambling. However, hallucinations were more common in treated 
patients and a relatively high number of patients with a disease duration over five years 
did not complete the study (Thomas, Bonanni et al. 2010). Furthermore, two other 
studies have shown that amantadine can increase the risk of PG and other treatment 
related behavioural disorders (Weintraub, Sohr et al. 2010, Lee, Kim et al. 2011).   
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Placebo responses in up to 59% in patients with PG have been reported, so that all these 
small open label studies need to be interpreted with great caution (Blanco, Petkova et al. 
2002).   
Conclusion 
Pathological gambling is a serious complication of dopamine agonist therapy in 
Parkinson’s disease. In contrast, L-dopa given in standard doses as monotherapy carries 
a very low risk of this particular dopaminergic treatment related behavioural disorder. 
Functional imaging suggests that there is a medication induced down-regulation of 
fronto-striatal connections, and up-regulation of striato-insular connections, which 
combine to induce impulsive behaviour.  Further research is needed to explore whether 
there are differences between the gambling behaviour in non PD patients and 
pathological gambling in PD, and whether there are differences in the mechanisms 
underlying pathological gambling as opposed to other behavioural disorders in PD such 
as compulsive sexual behaviour. 
Key Findings 
o PG in PD can lead to financial ruin and social isolation. 
o Early recognition is necessary, since patient’s insight may be low. 
o The main risk factor for PG in PD is dopamine agonist therapy. 
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o In patients with a previous or current history of addictive behaviours, L-
dopa monotherapy rather than dopamine agonist therapy should be 
considered. 
o In contrast to dopamine agonists, L-dopa does not increase the risk of PG 
in PD.  
o If PG has been diagnosed in PD, dopamine agonists should be reduced and 
if necessary stopped. 
o Reduction of dopamine agonist therapy can induce withdrawal symptoms 
and the subjective feeling of being more “off”. L-dopa should be 
cautiously increased in those cases to alleviate motor impairments. 
o There is insufficient evidence that antipsychotic drugs are efficacious in 
reducing PG in PD. 
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Disruption of dopaminergic pathways from the substantia nigra to the striatum are 
accepted to have major responsibility for the cardinal motor features of PD (Lees, Hardy 
et al. 2009), and are also amongst the mesocortical and mesolimbic projections 
implicated in reward processing and addiction (Koob and Volkow 2010). Treatment 
consists of dopamine replacement therapy (DRT) but can lead to a heterogeneous group 
of treatment related pathological behaviours. These behaviours have been reported more 
frequently over the past few years and fall into the category of behavioural addictions 
(Holden 2001). ICBs are defined by the impairment of social and occupational 
functioning either to the individual or their carers and include pathological gambling, 
hypersexuality, compulsive shopping, binge eating, the compulsive overuse of 
dopaminergic medication (dopamine dysregulation syndrome), and punding (O'Sullivan, 
Evans et al. 2009, Weintraub, Koester et al. 2010).  
More than a quarter of PD patients with ICBs have two or more other behavioural 
addictions (Ondo and Lai 2008, Weintraub, Koester et al. 2010). It is still unclear why a 
subgroup of PD patients develop these behaviours. Studying the cognitive differences 
and pathophysiological mechanisms implicated in ICBs may allow greater insight not 
only into the management of patients with PD, but also be relevant to the treatment of 
addiction in general.  
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Phenomenology and prevalence of ICBs in Parkinson’s disease  
The prevalence rate of ICBs in treated PD in UK and US clinics is considered to be 6% 
in PD patients without and up to 17% with dopamine agonist treatment (Voon, Hassan 
et al. 2006, Weintraub, Siderowf et al. 2006, Weintraub, Koester et al. 2010). Lower 
prevalence amongst Chinese (3.53%) PD patients may reflect cultural differences (Fan, 
Ding et al. 2009), or may be an underestimation since many patients disguise their 
behaviours due to shame, denial or they do not associate the behaviour with their DRT 
(Evans, Strafella et al. 2009). Further, these patients might lack insight regarding their 
addictive behaviour (Grosset, Macphee et al. 2006, Singh, Kandimala et al. 2007) and 
therefore might not be recognized in daily routine (Weintraub, Siderowf et al. 2006). 
However, it is also important to consider that an ICB can be tolerated or recognised as a 
disorder depending on social surroundings, ﬁnancial situation and the tolerance of the 
family(Cormier, Muellner et al. 2013). 
Compulsive sexual behaviour 
Compulsive sexual behaviour ranges from increased sex drive to paraphilia (Voon, 
Hassan et al. 2006). Amongst treated PD patients hypersexuality is considered between 
2% in smaller (Weintraub, Siderowf et al. 2006, Fan, Ding et al. 2009) and up to 3.5% 
in larger studies cross sectional multi centre studies (Weintraub, Koester et al. 2010). 
(See Table 2). It is, however, likely that compulsive sexual behaviour is still 
underdiagnosed and the actual prevalence rates might be higher. 
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Table 2.  Proposed criteria for compulsive sexual behaviour. 
 (Adapted from Voon et al.) (Voon, Hassan et al. 2006). 
Proposed criteria for pathological hypersexuality in PD 
A) The sexual thoughts or behaviours are excessive or an atypical change from baseline marked 
            by ≥ 1 of the following: 
o Maladaptive preoccupation with sexual thoughts 
o Inappropriately or excessively requesting sex from partner 
o Habitual promiscuity 
o Compulsive masturbation 
o Using telephone sex lines or viewing pornography 
o Paraphilias 
B) The behaviour must be persistent for ≥ 1 month 
C) The behaviour causes ≥ 1 of the following: 
o Marked distress 
o Attempts to control thought or behaviour are unsuccessful or result in marked anxiety or 
            distress 
o Are time consuming 
o Interfere significantly with social or occupational functioning 
D) Not occurring exclusively during (hypo)manic periods 
E) If all criteria except C is fulfilled the disorder is subsyndromal  
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Punding 
Punding is defined as stereotyped and repetitive behaviours, including an intense 
fascination with manipulations of technical equipment, the continual sorting of common 
objects, excessive hobbyism such as computer and internet use, pointless driving or 
walkabouts. Patients often describe their behaviour as soothing and calming (Evans, 
Katzenschlager et al. 2004). The prevalence of punding in PD varies between 1.4 % 
(Miyasaki, Al Hassan et al. 2007) to 4.2% (Lee, Kim et al. 2009), and up to 14% in 
patients taking higher doses (>800mg/day) of L-dopa (Evans, Katzenschlager et al. 
2004). In contrast to the previously described ICBs, patients demonstrate more 
obsessive-compulsive symptoms and their stereotypies are idiosyncratic, depending on 
individual life histories (Evans, Katzenschlager et al. 2004).  
Dopamine dysregulation syndrome 
Dopamine dysregulation syndrome (DDS) is defined as the compulsive overuse of DRT, 
and has been described in 3.4% (Pezzella, Colosimo et al. 2005) to 4.1% of treated PD 
patients (Giovannoni, O'Sullivan et al. 2000). Patients typically identify avoidance of 
the distressing negative affective state during parkinsonian “off” periods as the most 
important reason for self-escalation of their DRT without their physicians approval 
(Bearn, Evans et al. 2004). A minority of patients also acknowledge a subjective “high” 
or mood benefit after taking short acting drugs (Giovannoni, O'Sullivan et al. 2000). As 
treatment continues, drug-induced dyskinesias emerge together with socially harmful 
behaviours (O'Sullivan, Evans et al. 2009), (Table 3). 
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Table 3.  Diagnostic criteria for DDS. 
 (Giovannoni, O'Sullivan et al. 2000). 
  
Diagnostic criteria for DDS 
o Parkinson’s disease with documented L-dopa responsiveness 
o Need for increasing doses of DRT in excess of those normally required to relieve 
parkinsonian symptoms and signs 
o Pattern of pathological use: expressed need for increased DRT in the presence of  
excessive and significant dyskinesias despite being “on”, drug hoarding, drug 
seeking behaviour, unwillingness to reduce DRT, absence of painful dystonias 
o Impairment in social or occupational functioning: fights, violent behaviour, loss of 
friends, absence of work, loss of job, legal difficulties, arguments or difficulties with 
family 
o Development of hypomanic, manic or cyclothymic affective syndrome in relation to 
DRT 
o Development of a withdrawal state characterized by dysphoria, depression, 
irritability, and anxiety on reducing the level of DRT 
o Duration of disturbance for at least 6 months 
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Compulsive shopping  
In two large PD studies compulsive buying (McElroy, Keck et al. 1994) has been 
reported between 3.4% (Lee, Kim et al. 2009)  and 5.7% (Weintraub, Koester et al. 
2010), (Table 4). 
 
Diagnostic criteria for compulsive shopping 
Maladaptive preoccupation with buying or shopping that is manifested as impulses or       
behaviours that: 
o Are experienced as irresistible, intrusive and/or senseless 
o Result in frequent buying of more than can be afforded, items that are not 
needed, or 
o longer period of time than intended 
o Cause marked distress, are time consuming, significantly interfere with social and 
occupational functioning, or result in financial problems 
o Not occurring exclusive during (hypo)manic episodes  
 
Table 4.  Diagnostic criteria for compulsive shopping.  
(McElroy, Keck et al. 1994). 
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Binge eating 
Binge eating (American Psychiatric Association 2000) was reported in 4.3% of US-PD 
patients (Weintraub, Koester et al. 2010). In another study dopamine agonist use has 
been associated with food craving resulting in significant weight gain (Nirenberg and 
Waters 2006), (Table 5). 
Diagnostic criteria for binge eating and compulsive eating 
Recurrent binge eating characterized by eating large amounts in a discrete period, 
along with a loss of control  
≥ 3 of the following: 
1. Rapid eating 
2. Feeling uncomfortably full 
3. Eating large amounts when not hungry 
4. Eating alone because of embarrassment over amounts 
5. Feeling disgusted or guilty after overeating 
o Marked distress 
o Occurs 2 days/week over 6 months 
o Does not occur with compensatory behaviours or during anorexia or bulimia nervosa                                                                            
 
Table 5.  Diagnostic criteria for binge eating (DSM-IV). 
(American Psychiatric Association 2000) and compulsive eating (Nirenberg and 
Waters 2006). 
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Miscellaneous impulsive behaviours 
Reckless generosity (O'Sullivan, Evans et al. 2010), excessive hoarding (O'Sullivan, 
Djamshidian et al. 2010), impulsive smoking (Bienfait, Menza et al. 2010), reckless 
driving (Avanzi, Baratti et al. 2008), aggression and walkabouts (Giovannoni, 
O'Sullivan et al. 2000) can add to the social and occupational impairments.   
‘Green flags’ for the development of ICBs in Parkinson’s disease 
Whilst the greatest risk for the development of ICBs in PD is the use of dopaminergic 
medication, it is controversial whether higher dosage of DRT is an important risk factor 
(Gallagher, O'Sullivan et al. 2007, Weintraub, Koester et al. 2010). Although DDS and 
punding are more frequently seen in patients taking higher amounts of L-dopa (Evans, 
Katzenschlager et al. 2004), dopamine agonists are more implicated than L-dopa in 
other ICBs (Weintraub, Koester et al. 2010).   
No difference in the frequency of ICBs has been reported between pramipexole and 
ropinirole (Weintraub, Siderowf et al. 2006, Ondo and Lai 2008, Weintraub, Koester et 
al. 2010). The development of ICBs have been described in relation to newer non-ergot 
derived dopamine agonists such as rotigotine, (Wingo, Evatt et al. 2009) as well as older 
ergot-derived agonists.  
Alcohol addiction or illicit drug abuse, depression and high novelty seeking personality 
traits have also been identified as risk factors, especially in patients with DDS (Evans, 
Lawrence et al. 2005, Voon, Thomsen et al. 2007, O'Sullivan, Evans et al. 2009, Siri, 
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Cilia et al. 2010). Patients with early onset of PD, who are single and smoke, are also at 
higher risk, particularly if there is a positive family history for addictive behaviours 
(Evans, Lawrence et al. 2005, Weintraub, Koester et al. 2010). 
Novelty seeking declines with age in healthy populations (Steinberg, Albert et al. 2008) 
and in excess is associated with increased impulsivity, addiction, inability to delay 
gratification, recklessness and aggressive behaviour (Barratt 1994, Belin, Mar et al. 
2008). 
Compulsive sexual behaviour has been more frequently reported in males, whereas 
compulsive shopping and binge eating is more common in female PD patients (Voon, 
Hassan et al. 2006, Weintraub, Koester et al. 2010). Most ICBs are reversible after 
reduction of dopaminergic medication which suggests that these behaviours are 
triggered by changes in baseline dopamine levels in susceptible patients. 
Punding severity seems to be positively correlated to younger disease onset and male 
gender (Evans, Katzenschlager et al. 2004). Motor fluctuations are more common in 
ICB patients (Solla, Cannas et al. 2011) and early and severe dyskinesias (within the 
first 12-24 months) might be a warning sign for developing DDS.  
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Personality traits, decision-making and reward processing in 
Parkinson’s disease  
Although measures of cognition and reward processing in ICBs are not consistent, a 
number of findings have been reproduced, particularly regarding impulsive sensation 
seeking personality traits. PD patients with ICBs are more novelty seeking (Voon, 
Thomsen et al. 2007). This is in contrast to PD patients without ICBs who are usually 
risk averse, anhedonic and low in novelty seeking (Prick 1966, Todes and Lees 1985, 
Menza 2000, Evans, Lawrence et al. 2006, Ishihara and Bayne 2006).  
PD patients with ICBs are more aggressive, disinhibited and more antisocial than PD 
patients without behavioural addictions (O'Sullivan, Evans et al. 2009, Rossi, 
Gerschcovich et al. 2010, Siri, Cilia et al. 2010). Further, impulsive PD patients have 
higher schizotypy scores, which measures the risk of psychosis, compared to controls 
(Housden, O'Sullivan et al. 2010). Increased mania symptoms scores were also seen 
across a spectrum of PD patients with ICBs regardless of the type of their addiction 
(O'Sullivan, Loane et al. 2011). Related to impulsivity, PD patients with ICBs show 
increased temporal discounting, (the inability to delay a reward) following DRT 
(Housden, O'Sullivan et al. 2010, Voon, Reynolds et al. 2010) and have faster reaction 
times compared to non-impulsive PD patients (Voon, Reynolds et al. 2010).  
Interestingly reward learning in PD patients with ICBs has been reported to be normal in 
several studies (Housden, O'Sullivan et al. 2010, Voon, Pessiglione et al. 2010). This 
implies that ICBs in PD might be caused by risky behaviour combined with an inability 
to delay rewards in their “on” state and not necessarily related to an increased sensitivity 
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to rewards (Housden, O'Sullivan et al. 2010). Further, repeated exposure to DRT can, in 
susceptible patients, induce sensitization of the ventral striatum. DDS patients for 
example reported compulsively “wanting” their DRT without “liking” it (Evans, Pavese 
et al. 2006). This has led to the incentive sensitization theory, where drug effects are 
enhanced and cause pathological motivation in PD patients with ICBs (Evans, Pavese et 
al. 2006).  
Some studies have suggested cognitive impairment with lower scores on Frontal 
Assessment Battery (FAB) tests in PD patients with PG versus control PD patients 
(Santangelo, Vitale et al. 2009). However, these results are in contrast with several other 
studies which did not find any differences in FAB scores between PD patients with or 
without ICBs (Voon, Thomsen et al. 2007) or even showed enhanced executive function 
in the PD patients with PG (Siri, Cilia et al. 2010). Furthermore, Stroop test performance 
was similar between PD patients with and without ICBs (Rossi, Gerschcovich et al. 
2010).  
PD patients with PG only showed selective impairment on the Iowa Gambling Task 
compared to PD patients without ICBs, whilst other decision making tasks were 
unimpaired (Rossi, Gerschcovich et al. 2010). Table 6 summarizes behavioural test done 
in PD patients with ICBs until March 2011.    
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Frontal lobe function Findings  References 
Frontal assessment battery  (FAB) PD+ICB worse than PD-ICB.  Santangelo et al. 
Stroop test No difference between 
PD+ICB and PD-ICB. 
Rossi et al. 
Frontal assessment battery (FAB) No difference between 
PD+ICB and PD-ICB. 
Voon et al.          
Siri et al.  
Rey Auditory Verbal learning (RAVLT) 
Attentive matrices 
PD+ICB performed better 
than PD-ICB patients. 
Siri et al. 
Risk taking   
Iowa Gambling Task (IGT) PD+ICB had selective 
impairment on IGT. 
Rossi et al. 
Decision making   
Salience Attribution Test Normal reward learning 
compared to controls. 
Housden et al. 
Probabilistic Learning Task  Normal reward learning in 
PD+ICB “on”. 
Voon et al.  
Game of Dice Task, Investment Task No difference between 
PD+PG and PD-ICB. 
Rossi et al. 
Temporal Discounting   
Experiential Discounting Task, Kirby 
delayed discounting questionnaire 
Increased temporal 
discounting in PD+ICBs. 
Voon et al. 
Housden et al.  
Table 6.  Behavioural studies performed in PD+ICBs patients until March 2011. 
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Brain circuitry implicated in patients with Parkinson’s disease with 
ICBs 
In healthy controls pramipexole increases activity of the mesolimbic dopamine system 
during anticipation of monetary rewards, but at the same time reduces interaction to the 
prefrontal cortex (Ye, Hammer et al. 2011). This modulation of the brain circuitry due to 
dopamine agonist treatment with increased “bottom up mesolimbic dopamine release” 
might play a key role for developing ICBs (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Increased “bottom up” mesolimbic dopamine release. 
 
Dopamine originating from the ventral tegmental area (VTA) and projecting to the 
nucleus accumbens (NA) and prefrontal cortex (PFC). The amygdala (A) and the 
hippocampus (HC) send projections to the NA.  Permission to reproduce this figure 
was granted by Dr. Evans. Figure taken from (Evans, Strafella et al. 2009). 
61 
 
Mesolimbic dopamine release from the ventral tegmental area via the nucleus 
accumbens might therefore result in prefrontal cortex dysfunction.  
Functional imaging studies have strengthened the links between the ICBs seen in PD 
and addiction in general, demonstrating abnormalities of neural circuits involving the 
ventral striatum, the cingulate gyrus and the orbitofrontal cortex (Dagher and Robbins 
2009, Koob and Volkow 2010). Evans and colleagues found that PD patients with DDS 
exhibited enhanced L-dopa-induced ventral striatal dopamine release during PET 
scanning compared with L-dopa treated patients with PD not compulsively taking 
dopaminergic drugs (Evans and Lees 2004). A PET study in eleven PD patients with a 
variety of treatment related behavioural disorders and eight control PD patients showed 
greater reduction of ventral striatum [
11
C] raclopride binding in the PD group with ICBs 
following reward-related cue exposure. Reduction in raclopride binding is linked with 
higher dopamine release within the ventral striatum and occurred after patients were 
offered a variety of visual reward-related cues (O'Sullivan, Wu et al. 2011), whereas no 
differences were found when patients were exposed to neutral images (Figure 4) These 
results are consistent with a global sensitization to appetitive behaviours with 
dopaminergic therapy in vulnerable individuals (O'Sullivan, Wu et al. 2011).   
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Figure 4.  11C-raclopride binding potential between PD patients with and without 
ICBs. 
PD patients with ICBs (left) versus PD patients without ICBs (right). No group 
differences were seen when PD patients were exposed to neural images (A and B 
versus D and E). (A) PD patient with ICBs, off medication, exposed to neutral images. 
(B) PD patient with ICBs, on medication, neutral images. (D) PD patient without ICBs 
off medication, neutral images. (E) PD patient without ICBs off medication, on 
medications, neutral images. A significant reduction of 11C-raclopride was found 
when patients were exposed to rewarded images. (C) PD patient with ICB, on 
medication, reward images. (F) PD patient without ICBs off medication, on 
medications, reward images. Permission to reproduce this figure has been granted by 
Dr. O’Sullivan. Figure taken from O’Sullivan et al (O'Sullivan, Wu et al. 2011).  
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Single-photon emission
 
computed tomography (SPECT) in PD patients with PG showed 
increased brain perfusion in multiple regions, such as the orbitofrontal
 
cortex, the 
hippocampus, the amygdala, the insula, and the ventral
 
pallidum. This might reflect an 
overstimulation of an intact mesolimbic dopamine system due to DRT (Cilia, Siri et al. 
2008). This sensitization of the ventral striatum during rewarded stimuli seems to be in 
contrast with some behavioural studies which did not show an increased sensitivity to 
rewards. However, in their “on” state PD patients with ICBs have intact feedback 
learning from positive and also negative stimuli (Voon, Pessiglione et al. 2010, 
Djamshidian, O'Sullivan et al. 2012). It is therefore possible that the increased 
sensitization within the ventral striatum manifests in risky rather than hedonic 
behaviour. More specifically, the subjects may learn the objective value of rewards 
appropriately, but they may subjectively over-value large rewards, even when they are 
improbable, leading to risky decisions. 
Functional magnetic resonance imaging (fMRI) studies in PD patients with ICBs 
showed an increase in ventral striatum blood-oxygen-level dependent (BOLD) activity 
to reward after dopamine agonist medication (Frosini, Pesaresi et al. 2010, Voon, 
Pessiglione et al. 2010). One recent study recorded local field potentials of 3 groups of 
PD patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus 
(Rodriguez-Oroz, Lopez-Azcarate et al. 2010). One group had a variety of different 
ICBs, another group consisted of PD patients with dyskinesias and the third group 
included PD controls. Results showed no difference in the “off” state between these 
groups. However, in the “on” state PD patients with ICBs and PD patients with 
dyskinesias showed significant changes in the theta alpha band. While for the ICB group 
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this frequency was generated in the ventral subthalamic area and was coherent with the 
frontal premotor frontal activity, the frequency derived from the dorsal subthalamic area 
was coherent with cortical motor activity in PD patients with dyskinesias (Rodriguez-
Oroz, Lopez-Azcarate et al. 2010). Results suggest that the subthalamic nucleus might 
play an important role in generating impulsive and compulsive behaviours via its 
projections to associative limbic areas regardless of the type of addiction. This study 
also strengthens further the link between dyskinesias and ICBs.  
A recent fMRI study in PD patients with hypersexuality demonstrated an increased 
sexual desire after exposure to sexual cues in impulsive patients compared to non-
impulsive PD patients. Further, in ICB patients this desire was increased in the “on” 
versus “off” state, which correlated with enhanced activation in the ventral striatum, the 
anterior cingulate and the orbitofrontal cortex. However, no correlation was found with 
“liking” scores suggesting that in ICB patients dopaminergic medication causes 
compulsive seeking (“wanting”) for a reward, without necessarily liking it (Politis, 
Loane et al. 2013).     
Previous studies have explored the role of dopamine within the general population and 
found an inverse correlation between dopamine receptor binding and addiction. Lower 
dopamine D2 and D3 receptors within the striatum have been associated with a greater 
risk while high D2 and D3 act as a protection for developing an addiction (Volkow, 
Wang et al. 2006). Further, dopamine transporter (DAT) binding within the ventral 
striatum was reduced in PD patients with PG compared to control PD patients, which 
might reflect a genetically induced functional down regulation of membrane DAT 
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expression on intact dopamine neurons (Cilia, Ko et al. 2010). However, no differences 
in baseline ventral striatum D2 receptor binding were seen in patients with DDS (Evans, 
Pavese et al. 2006) and a variety of ICBs (O'Sullivan, Wu et al. 2011). Therefore 
abnormal baseline dopamine levels within the ventral striatum may not be a requirement 
for the development of ICBs. Despite various candidate gene studies including 
dopamine 1 and 4 receptor and the dopamine catechol-O-methyl transferase (COMT) no 
genetic marker to detect vulnerable patients has been found so far (Comings, Ferry et al. 
1996, Foltynie, Lewis et al. 2005, Lobo, Souza et al. 2010). Large genome wide studies 
are needed to identify genetic risk factors for ICBs in PD. 
Impulsive compulsive behaviour in atypical Parkinson’s disease 
ICBs in relation to dopamine agonist use have been also described in patients with 
pathologically proven progressive supranuclear palsy (PSP) (O'Sullivan, Djamshidian et 
al. 2010) and multisystem atrophy (MSA) (Klos, Bower et al. 2005).   
Illustrative case of a patient with pathologically proven PSP 
A 66 year old lady presented in 2005 with a 6 month history of unsteadiness, difficulties 
walking with occasional falls, particularly backwards, and rigidity. She had a previous 
history of depression for over 30 years. On examination she had blepharospasm, a 
flexed posture, reduced arm swing and micrographia. An MRI brain scan was normal 
and a diagnosis of possible PSP was made.  
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The introduction of L-dopa/carbidopa, with subsequent increase to 500 mg L-dopa/day 
in 2006, led to improvement of her writing and postural stability. By then a supranuclear 
vertical gaze palsy was noticed but she was still independent. In 2007 she developed 
some wearing off phenomena and treatment with rotigotine was started. She was falling 
more frequently and had become wheel-chair bound following a fractured femur, 
requiring a 24h carer. Cognitive impairment was not noted, and she denied having 
hallucinations. Her rotigotine dose was increased to 6mg/day, in addition she was taking 
800mg L-dopa per day. Soon after this, she developed reckless generosity including 
giving thousands of pounds to Christian television organisations. She died in 2009 from 
a bronchopneumonia at the age of 71 (O'Sullivan, Djamshidian et al. 2010). 
Behavioural changes after dopamine agonist therapy 
Although recent studies (Arabia, Grossardt et al. 2010) have questioned the concept of 
the typical parkinsonian personality being anhedonic (Todes and Lees 1985), metric 
tasks have shown that untreated patients have deficits in reward learning. In one study 
never medicated PD patients were given  pramipexole or ropinirole and were followed 
up for 12 weeks (Bodi, Keri et al. 2009). At baseline untreated patients had intact 
learning from negative feedback but impairment in reward learning. An opposite 
learning profile was found after dopamine agonist therapy, with significant impairment 
in avoidance of negative outcomes compared to controls but normal reward seeking 
behaviour. A similar opposite feedback learning “on” versus “off” medication was 
shown in PD patients after L-dopa administration (Frank, Seeberger et al. 2004). 
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However, in this study PD patients treated with L-dopa showed no impairment in 
negative feedback learning compared to controls (Frank, Seeberger et al. 2004). 
PD patients with ICBs showed faster learning from rewards and had a greater reward 
prediction error, defined as the difference between expected and received reward (Sutton 
and Barto 1998), after receiving a dopamine agonist (Voon, Pessiglione et al. 2010).  
An fMRI study demonstrated increased risky choice in PD patients without ICBs after 
pramipexole but not after L-dopa therapy. In this study, only pramipexole caused 
changes in orbitofrontal function with a relative increased activity during negative errors 
of reward prediction. It is possible that dopamine agonists prevent phasic decreases in 
dopamine transmission during negative feedback, which can result in risky decisions 
(van Eimeren, Ballanger et al. 2009). Consistent with these results PD patients with 
pathological gambling and compulsive shopping showed in another fMRI study 
increased risk taking behaviour after dopamine agonist therapy, which correlated with 
decreased orbitofrontal cortex and anterior cingulate function (Voon, Gao et al. 2011).  
Increased temporal discounting, the preference of a smaller immediate over a delayed 
but higher reward, compared to controls was observed in PD patients without ICBs who 
were treated with a dopamine agonist. In addition, discounting in these patients was not 
effected by medication state which may imply that dopamine agonist therapy causes 
persistent behavioural changes (Milenkova, Mohammadi et al. 2011).  
Dysfunction of reward prediction errors during a gambling task but intact orbitofrontal 
function were also found in an fMRI study in patients with restless legs syndrome (RLS) 
when treated with dopamine agonists, suggesting these patients were at risk to develop 
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pathological gambling, but intact orbitofrontal cortex activity suppresses an active ICB 
(Abler, Hahlbrock et al. 2009). 
Mechanisms underlying ICBs in Parkinson’s disease 
The reduction in “top down control” of fronto-striatal connections but increased “bottom 
up activity” of striato-insular connections might play a key role for developing ICBs. 
There are also differences in receptor binding that might explain why ICBs are more 
commonly seen under dopamine agonist treatment compared to L-dopa monotherapy. 
Ropinirole and pramipexole have a 100 fold stronger dopamine D3 receptor affinity than 
D2 receptors and both have no affinity to the D1 dopamine receptor (Gerlach, Double et 
al. 2003). Similar receptor affinity has been reported with rotigotine (Jenner 2005). The 
ergoline derived dopamine agonist cabergoline has a 10 fold stronger dopamine D3 than 
D2 receptor affinity and a more than 400 fold D3 than D1 receptor affinity (Gerlach, 
Double et al. 2003). In contrast L-dopa stimulates mainly dopamine D1, D2 and to a 
lesser degree D3 receptors (Ahlskog 2011). Critically dopamine D3 receptors are mainly 
expressed in the limbic system which might explain why dopamine agonists are more 
likely to cause ICBs (Ahlskog 2011). 
Finally dopamine agonists stimulate dopamine receptors more tonically than exogenous 
L-dopa which has consequences on learning behaviour. Reward prediction errors are 
mediated via phasic dopamine bursts during rewards (Hollerman, Tremblay et al. 1998) 
whilst pauses in dopamine firing occur during punishment (Schultz 2002). Dopamine 
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agonists might prevent dopamine dips, which are necessary for learning from negative 
consequences.  
Treatment of patients with Parkinson’s disease with ICBs  
Non-pharmacological and general management 
Doctors should inform patients and their family members of the potential risk of 
developing ICBs before prescribing dopamine agonist treatment (Grosset, Macphee et 
al. 2006, Singh, Kandimala et al. 2007). Family members should look out for 
behavioural changes and report them to the doctor. Patients who have had a history of 
illicit drug abuse in the past and have a younger onset of PD require especially careful 
monitoring (Singh, Kandimala et al. 2007, Voon, Thomsen et al. 2007, Weintraub, 
Koester et al. 2010). In these patients rescue doses and fast acting L-dopa doses or 
apomorphine pens should be avoided.   
Extra attention should be paid in patients who develop dyskinesias, since these might be 
a preceding signs of DDS or other ICBs (Solla, Cannas et al. 2011). It is important to 
consider that an ICB usually does not start abruptly and subtle behavioural changes such 
as craving for sweets or increased spending might be harbingers. Cognitive behavioural 
therapy has been beneficial in non PD patients with pathological gambling (Hodgins and 
Petry 2004) and has been recently shown to improve ICB symptoms in PD (Okai, 
Askey-Jones et al. 2013). Depression (Gallagher, O'Sullivan et al. 2007), drug induced 
mood changes (Voon, Thomsen et al. 2007) and sleep pattern abnormalities (O'Sullivan, 
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Loane et al. 2011) are frequently reported in PD patients with ICBs and should be 
treated symptomatically.  
Dopamine agonists should be slowly reduced and subsequently stopped (Evans, 
Strafella et al. 2009). Withdrawal symptoms are frequently seen in PD patients with 
ICBs and include panic attacks, dysphoria and the subjective feeling of being “off” 
(Nirenberg 2010). Frequently these symptoms do not improve after increasing L-dopa 
and escalating L-dopa in order to alleviate these non-motor symptoms might increase 
the risk of developing DDS (Nirenberg 2010). 
Usually it takes several weeks and up to several months after dopamine agonists have 
been withdrawn until the ICBs have completely vanished. However, PET studies and 
behavioural tasks have demonstrated increased impulsivity in these patients, even after 
dopamine agonist medication has been stopped (O'Sullivan, Wu et al. 2011), suggesting 
irreversible changes in wide areas of brain networks induced by dopamine agonist 
therapy in susceptible patients.  
The evidence for using neuroleptic treatment in PD patients with ICBs is conflicting 
(Sevincok, Akoglu et al. 2007, McElroy, Nelson et al. 2008). In addition antipsychotics 
lead to worsening of motor function and should therefore not be used as a long term 
treatment. Treatments found to be efficacious in ICBs in the general population may 
help PD-related ICBs, with several randomised clinical trials showing a benefit of 
opioid antagonists, particularly for pathological gambling (Leung and Cottler 2009). 
Large randomised controlled trials in the treatment of PD related ICBs are needed.  
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Management of different subtypes of ICBs 
If compulsive shopping, pathological gambling or hypersexuality has been detected 
family members should cancel credit cards or limit access to money and internet. 
Conflicting reports have been published on amantadine with beneficial reports showing 
reduced gambling urges (Thomas, Bonanni et al. 2010) and punding behaviour 
(Kashihara and Imamura 2008). However, recently it has been suggested that 
amantadine can induce ICBs in PD (Weintraub, Sohr et al. 2010) and therefore it is not 
recommended as a treatment for ICBs in PD. 
In patients with punding bed time L-dopa should be stopped, since this behaviour often 
occurs during night (Fasano and Petrovic 2010). Further, selegeline should be 
withdrawn because of amphetamine like metabolites (Shin 1997). Entacapone might be 
beneficial in preventing or reducing punding and to treat motor handicaps (Evans, 
Katzenschlager et al. 2004). Compulsive sexual behaviour is more often problematic in 
men than women and in those who continue to have hypersexuality despite stopping 
dopamine agonists, the anti-androgen cyproterone is sometimes required and involves 
endocrinological monitoring (Evans, Katzenschlager et al. 2004).  
L-dopa should be reduced in patients with DDS, the family doctor and the pharmacist 
informed to avoid multiple prescriptions and drug hoarding. Access to medication 
should be restricted and patient’s partner, spouses or carer should administer L-dopa to 
prevent misuse. During L-dopa reduction these patients are at high risk to become more 
aggressive and paranoid or experience or off period depression (Evans and Lees 2004) 
and may require hospital admission.  
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 Functional surgery in patients with Parkinson’s disease with ICBs 
Bilateral DBS of the subthalamic nucleus (STN) in PD induced PG in one small study 
(Lu, Bharmal et al. 2006). However, larger studies did not report any occurrence of 
behavioural side effects of DBS. In fact, seven patients who had PG and six who had 
DDS improved after bilateral subthalamic nucleus stimulation and reduction of the 
overall dopaminergic medication (Ardouin, Voon et al. 2006). More recently, other 
studies also found beneficial outcome in ICBs after STN-DBS (Lim, O'Sullivan et al. 
2009, Lhommee, Klinger et al. 2012). The variable outcomes regarding the effect of 
DBS on ICBs may reflect the retrospective nature of studies, where ICBs were not well 
recognised pre-operatively (Lim, O'Sullivan et al. 2009). Additionally, the potential 
influence of DBS electrode placement requires further investigation. The subthalamic 
nucleus has three subdivisions and ideally only the dorsolateral motor part of the 
subthalamic nucleus should be stimulated. In contrast, the medial region of the 
subthalamic nucleus is strongly associated with the limbic system (Groenewegen and 
Berendse 1990), whereas stimulation of the more ventral part may induce apathy 
(Drapier, Drapier et al. 2006).   
PET studies have shown that subthalamic nucleus DBS is associated with increased 
regional cerebral blood flow in the anterior cingulate cortex (Limousin, Greene et al. 
1997). The subthalamic nucleus has a volume of approximately 240mm
3 
(Hardman, 
Henderson et al. 2002), with previous studies suggesting that there is an expected 
current spread of approximately 3mm radius (113mm
3
 volume) (Saint-Cyr, Hoque et al. 
2002). It is therefore possible that the differing responses to DBS in ICBs may be due to 
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the presence or absence of spread of stimulation effects into the “limbic” portion of the 
subthalamic nucleus (Broen, Duits et al. 2011). Factors predictive of good behavioural 
outcome post-DBS may include physician vigilance, motor outcome and patient 
compliance regarding rapid decreases of DRT (Lim, O'Sullivan et al. 2009). 
Conclusion 
ICBs in PD remain a challenge in clinical practise, and vigilance in the prescribing 
physician is of paramount importance. Awareness of risk factors may help detect those 
patients at risk, in particular young age at PD onset, the use of dopamine agonists, 
previous evidence of impulsivity, familial or personal history of alcoholism, and early 
onset dyskinesias. 
Imaging studies have provided additional support to strengthen the link between  
dopamine replacement therapy induced up-regulation of mesolimbic dopaminergic 
pathways, impairment of “top down” control and ICBs in PD. Behavioural studies 
suggest increased novelty seeking, risky behaviour with an inability to delay 
gratification as important hallmarks of ICBs. 
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Key Findings 
o ICBs in PD occur in about 15% of patients, but these numbers might be 
underestimated as some patients might hide their addictive behaviour due 
to shame or denial. 
o Punding and DDS are more associated with L-dopa therapy, in contrast 
compulsive shopping, hypersexuality, binge eating and PG are more likely 
triggered by dopamine agonists. 
o Risk factors for developing an ICB in PD are a previous or current history 
of addictive behaviours and younger onset of PD. 
o STN-DBS may be a therapeutic option for ICBs in PD, although further 
studies are needed, as the data is still conflicting. 
o Reduction of dopamine agonist therapy often results in a complete 
cessation of ICBs. 
o In patients with DDS L-dopa needs to be reduced, which is, however, often 
challenging. 
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Introduction 
Impulsivity may be looked upon as “a behaviour that is performed with little or 
inadequate forethought” (Evenden 1999) or the failure to resist an impulse. Self-rating 
scales have significant shortcomings in this area. For example impulsivity might directly 
interfere with the completion of the questionnaire, since impulsive people might give 
less consideration to responses. Further, insight into aberrant personal behaviours might 
be lower in impulsive patients and direct neuropsychological tests have been used more 
recently to assess impulsivity (Verdejo-Garcia, Lawrence et al. 2008).   
Laboratory tests have been developed to assess mainly three categories of impulsivity. 
These include response inhibition, which measures the ability to stop an automatic 
response, temporal discounting, defined as the preference of a smaller immediate reward 
over a delayed higher reward and finally the broad concept of cognitive impulsivity. 
Cognitive impulsivity includes reflection impulsivity, which originally referred to the 
ability to gather and evaluate evidence before making a choice and decision making 
under risk (Verdejo-Garcia, Lawrence et al. 2008). 
The relationship between dopamine levels and cognitive function in PD has been the 
subject of much interest (Frank, Seeberger et al. 2004, Cools 2006, Shiner, Seymour et 
al. 2012). In PD patients without ICBs L-dopa has a dual effect on cognition. While 
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dopaminergic medication (L-dopa plus dopamine agonists) improved task switching 
behaviour relative to the “off” state, anti-Parkinson medication also impaired reversal 
learning (Cools, Barker et al. 2001). This discrepancy may be explained by the fact that 
task switching relies on networks connecting the dorsolateral prefrontal cortex to the 
dorsal striatum, which is severely depleted in PD. In contrast reversal learning depends 
on orbitofrontal cortex and the ventral striatum, which is relatively intact in PD patients 
without ICBs (Cools, Barker et al. 2001). These results are also in keeping with the 
‘overdose hypothesis’. In early PD there is a greater depletion in the dorsal striatum than 
in the ventral striatum (Kish, Shannak et al. 1988). Effective dopamine replacement in 
the dorsal striatum designed to reverse bradykinesia might, therefore overstimulate the 
relatively intact ventral striatum and lead to undesirable cognitive changes, referred to as 
the ‘cognitive overdose hypothesis’ (Gotham, Brown et al. 1988). 
Dopaminergic state has also an effect on feedback learning. Non-impulsive PD patients 
“off” medication were more sensitive to negative feedback and had impaired positive 
feedback learning. An opposite learning profile was found after dopaminergic 
medication (Frank, Seeberger et al. 2004). These results were recently expanded by 
another study which showed that during an acquisition phase non-impulsive PD patients 
learned equally well in their “on” and “off” state to discern which of the two stimuli was 
more likely to be rewarded. However, during a performance phase when novel stimuli 
pairs were introduced and no feedback was given PD patients on medication were 
significantly better in selecting the correct image compared to those who were off 
medication. This suggests that PD patients off medication have intact learning, but have 
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difficulties transferring this knowledge and making correct choices when new stimuli 
were introduced (Shiner, Seymour et al. 2012).   
Dopamine plays also a major role in addictive behaviours and most, if not all addictive 
drugs cause dopamine release (Robbins and Everitt 1999). Further, lesions within the 
dopamine system have been shown to reduce the rewarding effects of drugs in rodents 
(Robbins and Everitt 1999). Addiction can be regarded as an impairment of decision 
making, learning from previous outcomes and motivation (Berke and Hyman 2000). 
Hallmarks of an addiction are tolerance, dependence and sensitization. Psychostimulants 
initially increase well-being and alertness. After repeated use these acute effects 
diminish and patients develop tolerance. Other effects of the drugs might be enhanced 
(sensitization). Over time the repetitive use of addictive drugs can become habitual and 
compulsive (Berke and Hyman 2000, Dagher and Robbins 2009). The outcome of an 
action then becomes less important and the patient’s behaviour shifts from “goal 
directed” to “stimulus-response” behaviours in which the stimulus (and not an outcome) 
drives an action. In contrast to goal directed behaviour, where actions have to be 
reassessed and learning is obligatory, habit-responses are automatic and are believed to 
be processed via the dorsolateral striatum (Muresanu, Stan et al. 2012).  
Links between behavioural addictions in PD and drug addiction have been illustrated 
previously (Dagher and Robbins 2009). Given the central role of dopaminergic 
medication in triggering ICBs in PD, for this thesis the majority of PD patients were 
assessed prior to and after their usual anti-Parkinson medication.   
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Neuropsychological tests used for this thesis 
One of the most well-known tasks to measure decision making under risky situations is 
the Iowa Gambling Task (IGT). In this task participants are required to choose from four 
decks of card, two are high risk decks offering high rewards but also high losses and are 
disadvantageous in the long run, whereas the two remaining decks offer smaller rewards 
but also smaller losses leading to overall gains. Through trial and error healthy 
volunteers learn to select the “good decks” that offer the smaller rewards from the “bad 
decks” that are leading to losses (Bechara, Damasio et al. 1994).  
The IGT was used in PD patients with pathological gambling and results showed that 
these patients performed poorer than PD patients without addictive behaviours. In this 
study the authors also assessed risk taking but found no group differences (Rossi, 
Gerschcovich et al. 2010).  
There are, however, some disadvantages of the IGT as this task includes both elements 
of risk taking and feedback learning. In other words, poorer performance on the IGT 
could be either because of impaired learning to identify the advantageous decks or 
because of increased risk taking behaviour. Therefore, for this thesis PD patients with 
and without ICBs performed a separate feedback learning and risk taking task to 
disentangle these two factors.  
Another hypothesis was that PD patients with ICBs have a poorer working memory 
function, causing reduced capacity to store information and thus leading to immediate 
actions. Working memory was assessed using a digit forward span, measuring 
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immediate recall and a digit backward span, where mental manipulation of numbers is 
required. 
PD patients with ICBs were also tested once prior to and once after their medication on 
an altruistic punishment task to examine whether they recognize norm violations and 
want to correct unfair behaviours towards themselves. Further, it was speculated that PD 
patients with ICBs punish more in their “on” compared to their “off” state.  
The stroop test was performed to assess response inhibition as it was speculated that PD 
patients with addictive behaviours would perform worse than those without.  
Increased novelty seeking in PD has been reported as a risk factor for developing 
pathological gambling (Voon, Thomsen et al. 2007) and DDS (Evans, Lawrence et al. 
2005), but has not been assessed with a metric task in PD patients with a variety of 
different ICBs. Further, it was unclear whether increased novelty seeking is a 
personality trait or is caused by increased dopamine levels. To differentiate between 
“medication state versus personality trait” PD patients were tested once prior to and 
once after their usual dopaminergic medication. The prediction was that all PD patients 
with ICBs would be more novelty seeking than PD controls, regardless of their 
medication status.  
The last task used was an information sampling task to assess “jumping to conclusion 
behaviour”, to assess cognitive impulsivity. PD patients with and without ICBs were 
directly compared to two patient groups who both did not have PD but had either 
pathological gambling or had a history of intravenous drug abuse. This study was 
performed to test the hypothesis that ICBs in PD resemble drug addiction. Results of 
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this study lead on to a follow up experiment to assess whether dopamine agonists or 
deep brain stimulation is causing impulsive choice on this task.    
These tasks were selected to assess mainly two aspects of impulsivity, response 
inhibition (which was assessed with the stroop test) and cognitive impulsivity, which 
involves decision making under risk , feedback learning and information sampling 
(Verdejo-Garcia, Lawrence et al. 2008).  
PD patients were screened for ICBs using suggested guidelines in a semi structured 
interview. In addition, a self-rated questionnaire for impulsive compulsive disorders in 
Parkinson’s disease (QUIP) (Weintraub, Hoops et al. 2009) was used, after this 
questionnaire was validated. However, the disadvantage of the QUIP is that it does not 
measure the severity of the addiction. Therefore, semi structural interviews were 
necessary for all studies.  
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Introduction 
This study sought to assess the learning profile, working memory (WM) performance 
and risk taking behaviour in PD patients with and without ICBs and compare results to 
healthy matched volunteers.  
The prediction was that PD patients with ICBs (PD+ICB) would have significantly 
worse WM than both PD patients without ICBs (PD-ICB) and controls. Further, given 
the role of dopamine in learning, it was speculated that PD+ICB patients would be 
significantly more risk prone than PD-ICB patients and controls. Another hypothesis 
was that PD patients with associated ICBs may have elevated levels of dopaminergic 
activity in the ventral striatum, due to their symptom profile (Evans, Pavese et al. 2006, 
Steeves, Miyasaki et al. 2009). This would mean that their behavioural profile “off 
medication” would come to resemble that of PD patients “on medication”, with 
relatively enhanced learning from positive feedback (reward) compared to negative 
feedback (punishment). 
Patients and methods  
Patients were recruited from a database of attendees at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London,UK. Controls were usually 
recruited from amongst the patients' partners. Written informed consent was obtained 
from all participants. All patients were screened for sub-classes of ICBs.   
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Patients were asked to take no anti-parkinsonian medication overnight (12-18h) and 
were tested first between 8.00 a.m. and 9.00 a.m. prior to their morning medication. 
Patients then took their first L-dopa dose and the tests were repeated 50 minutes later. 
The therapeutic motor response to L-dopa was assessed by UPDRS scores (part 3) 
during “off” and “on” state. All patients had an excellent L-dopa response and had 
switched “on” at the second test. LEU (Levodopa equivalent units) were calculated as 
described previously (Evans, Katzenschlager et al. 2004) as followed:  
L-dopa dose + L-dopa dose × 1/3 if on entacapone + bromocriptine (mg) × 10 + 
cabergoline or pramipexole (mg) × 67 + ropinirole (mg) × 20 + apomorphine (mg) × 8. 
Testing was performed in the patient’s homes using a laptop computer. Distractions 
were minimized so that full attention could be devoted to the task. Controls were tested 
following a similar sequence: They were tested once, and then re-tested after 50 
minutes, but received no medication. Patients who scored under 27/30 points on the 
Mini Mental State Examination (MMSE) were excluded from this study. Four controls 
performed just the working memory test. Two controls did not perform the computer 
tests. Two PD+ICB patients denied having active impulsive or compulsive behaviour at 
the time of testing but both had significant behavioural abnormalities within the last 12 
months. 
Patients also filled out a self-rating questionnaire and rated themselves on a 1-5 point 
rating scale for alertness, attentiveness and interest, where 1 is associated with “not at 
all” and 5 with “extremely”. On average patients scored 3.2 points on alertness, 3.5 on 
attentiveness and 4 on interest prior to treatment and 3.8 points for alertness, 3.9 points 
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for attentiveness and 4.3 points for interest one hour after L-dopa treatment and thus 
showing no signs of lack of motivation or concentration during this study.  
Working memory task 
The first task was a forward and backward digit span test (Wechsler 1997) to assess 
working memory. Instant recall was measured by the digit forward span, whilst attention 
and manipulation of the numbers was necessary for the digit backward span (Lezak 
2004).  
Forward span:                   Backward span: 
5-8-2   6-9-4    2-4   5-8
6-4-3-9   7-2-8-6    6-2-9   4-1-5 
4-2-7-3-1  7-5-8-3-6   3-2-7-9   4-9-6-8 
6-1-9-4-7-3  3-9-2-4-8-7   1-5-2-8-6  6-1-8-4-3 
5-9-1-7-4-2-8  4-1-7-9-3-8-6   5-3-9-4-1-8  7-2-4-8-5-6 
5-8-1-9-2-6-4-7  3-8-2-9-5-1-7-4   8-1-2-9-3-6-5  4-7-3-9-1-2-8 
2-7-5-8-6-2-5-8-4                 7-1-3-9-4-2-5-6-8                  9-4-3-7-6-2-5-8  7-2-8-1-9-6-5-3
  
 
Example of the digit forward and backward span (Wechsler 1997) used for this study.  
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Learning Task  
The second task was an associative learning task in which participants were required, in 
each of four blocks of trials, to learn which of two stimuli was most often rewarded 
(Pessiglione, Seymour et al. 2006, Averbeck and Duchaine 2009). In each trial they 
selected one stimulus and were then told whether or not they had won on that trial. 
Winning probabilities for the two stimuli (75%/25% and 65%/35% were used in 
different blocks) were constant throughout each block and balanced across stimuli 
across blocks. Subjects were required to select one stimulus on each trial. After selecting 
the stimulus they were told whether they had lost money (5 pence) or earned a reward 
(10 pence). Participants were told to pick the most often rewarded stimulus as many 
times as possible to maximize their total wins. They were also told that their 
performance would influence their reward at the end. The task was administered in four 
blocks of 34 trials each. Between blocks subjects were told that the probabilities were 
being re-selected and that they should again determine which image was most often 
rewarded. In two of the blocks one of the stimuli was rewarded 65% of the time and the 
other 35% of the time and in the other two blocks one of the stimuli was rewarded 75% 
of the time and the other 25% of the time. The stimulus which was most often rewarded 
was balanced across blocks and the order of the high/low probability blocks was 
randomized across subjects and sessions. The block types were 75/25, 65/35, 25/75 and 
35/65, where the first fraction refers to the reward for stimulus 1 and the second fraction 
refers to the reward for stimulus 2. The order of these block types was balanced, as 
much as possible, across subjects. (Figure 5A,B). 
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Risk task 
The final task was a gambling task which was designed to probe the risk aversion of the 
subjects and programmed to match the description given of the task in Huettel et al. 
(Huettel, Stowe et al. 2006).   
In each trial subjects were given a choice between two gambling options which were 
presented on the left and right of the screen. Each option had either a single sure 
outcome, or two possible outcomes. The probabilities associated with each outcome 
were represented by a pie.   
For example, if the subjects had a 25% chance of winning £20 and a 75% chance of 
winning £5, the pie would be split 75/25, with the winning amount represented in each 
pie section. The sure options were simply solid circles, representing the 100% outcome. 
After selecting their preferred gambling choice subjects were told which of the two 
possibilities for the chosen gamble they had “won”. (Figure 5C,D).  
Despite telling participants that their reward depended on their performance they all 
received a modest financial reward (£20) after completing the study.  
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Figure 5.  Learning and risk task.  
Learning task:  A: Screen 1: Participants had to select between these two objects and 
pick the rewarded stimulus as often as possible. B: Screen 2: Feedback was given 
immediately after making the choice. Individuals could either win 10p or lose 5p.   
Risk task: C: Screen 1: Two gambles were presented. £10 for sure (left) or 
£0/£50(right), where participants had a 1/10 of a chance winning £50. D: Screen 2: 
After the choice, feedback was given immediately.  
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Statistical analysis 
Working memory task 
The raw scores of the digit span were converted to z-scores according to the age of the 
participant by using normative tables (Wechsler 1997). A mixed model ANOVA was 
then performed with the z-scores as the dependent variable. Task (backwards and 
forwards digit span) and condition (off versus on medication or 1
st
 and 2
nd
 trial in 
healthy controls) were modeled as within subject factors and group (PD, PD+ ICB and 
control) was modeled as a between subject factor. The model also included subject as a 
random factor, and the interactions between the three fixed factors (task, condition and 
group). All post-hoc comparisons were corrected by the Bonferroni method, and 
assumptions for the ANOVA were checked by examination of the residuals, which were 
found to be normally distributed.   
Risk and learning tasks 
Data analysis for the risk and learning tasks was carried out by fitting parametric 
decision making models to the behaviour of each individual subject, and comparing the 
distributions of parameter fits from the model between groups in a within subject design. 
Thus, the parameters of the model summarized the behaviour of each individual subject 
in each task, and by comparing the distributions of parameters differences in behaviour 
among groups were examined. Mixed effects ANOVA models were fit to behavioural 
variables. Subject was treated as a random effect nested under group. Group and session 
88 
 
were treated as fixed effects and session was treated as a within subject effect. All post-
hoc comparisons were corrected using Tukey’s HSD test. ANOVAs were carried out on 
parameters from computational models fit to the behavioural data of individual subjects. 
Learning was assessed using a Bayesian decision making model (Averbeck and 
Duchaine 2009). Because the outcome was either win or lose after one stimuli was 
chosen, the model was based upon a binominal distribution. For the learning task two 
parameters were fitted, which were treated as within subject factors. The first parameter 
characterized the amount that positive feedback, after selecting one of the stimuli, 
affected future decisions and the second parameter characterized the same for negative 
feedback. For the risk task two parameters were fitted. The first characterized how much 
the subjects valued large versus small rewards. Larger positive values of this parameter 
imply that subjects prefer small, sure rewards to large rewards with a lower probability. 
Thus, this parameter characterizes the amount of risk to which subjects are prone. The 
second parameter characterized whether subjects became more risky following a win. 
For the risk analysis, the ANOVAs were carried out separately for each parameter. 
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Results  
Demographic characteristics  
All patients fulfilled the Queen Square Brain Bank criteria for PD (Gibb and Lees 1988) 
and were taking L-dopa. Twelve patients with idiopathic PD without ICBs (3/12 female) 
and 18 PD patients with ICBs (5/18 female) were compared against 22 healthy controls 
(10/22 female). All PD+ICB patients had at least two ICBs. PD+ICB patients had an 
earlier disease onset (t28 = 2.1, p = 0.04). The average time lag between the diagnosis of 
an ICB and the testing was 5.6 months. Nine PD patients with impulsive compulsive 
behaviour were tested during reduction of their dopamine agonist medication. Seven PD 
patients had already reduced their dopamine agonist medication which had improved 
their addictive behaviour. At the time of testing they still fulfilled the criteria of ICBs 
with the exception of two patients, who had fulfilled these criteria within the previous 
twelve months. All patients with ICBs developed their behavioural abnormalities as a 
direct result of medication. An ANOVA to test difference between ages in the 3 groups 
just failed to reach significance (F2,49 =  3.2, p = 0.051). Post hoc comparisons were not 
significant between the PD-ICB group versus the control (p = 0.07) or PD+ICB group (p 
= 0.098). There was no difference in the morning(t28 = 1, p = 0.3) and daily L-dopa dose 
between the patient groups (t28 = 0.9, p = 0.36).  The timing of the last dopaminergic 
medication was not significantly different between the patient groups (t25 = 0.3, p = 0.2). 
Years of education was assessed in 17/22 controls, 9/12 PD-ICB patients and 14/18 
PD+ICB patients and was not significantly different (F2,37 = 1.98, p = 0.15).  
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Table 7.  Risk and learning task: Demographic characteristics.   
DDS = Dopamine Dysregulation Syndrome; UPDRS = Unified Parkinson’s Disease 
Rating Scale; LEU = L-dopa equivalent units; DA = dopamine agonist.  All values are 
mean ±  sem.  Pathological gambling assessed with DSM IV criteria, compulsive 
shopping assessed with McElroy’s criteria (McElroy, Keck et al. 1994), hypersexuality 
assessed with questionnaire suggested by Voon et al. (Voon, Hassan et al. 2006) and 
punding.   
   Controls   PD-ICB   PD+ICB   p value  
 
Participants in total (no.) 
Age (yrs) 
Currently 
At disease onset 
 
 22 
 
 55 ± 3.0 
       -        
 
 12  
  
 63.6 ± 2.2 
 50.9 ± 2.2 
 
 18 
 
  55 ± 2.1 
  43.9 ± 2.1 
 
 
  
 0.051 
 0.04 
Disease duration 
 (yrs) 
Education (yrs) 
DDS 
Pathological Gambling 
Hypersexuality 
Compulsive Shopping 
Binge Eating 
Kleptomania 
Punding 
       - 
 
 13.8 ± 0.7 
       - 
       - 
       - 
       - 
       - 
       - 
       - 
 12.7 ± 2.1 
 
 14.2 ± 1.3 
       - 
       - 
       - 
       - 
       - 
       - 
       - 
 10.9 ± 1.2 
 
 12.2 ± 0.9 
 6 
 10 
 9 
 5 
 7 
 1 
 2 
 0.8 
 
 >0.15 
Morning L-dopa dose (mg) 
Total L-dopa dose (mg)  
LEU dose (mg) 
DA (patients) 
MAO inhibitor(patients) 
Entacapone (patients) 
       - 
       - 
       - 
       - 
       - 
       - 
 170 ±  21  
 604 ± 73 
 732 ± 203 
 7  
 5 
 5 
 185 ± 32 
 752 ± 109 
 971 ± 183  
 9 
 6 
 6 
 0.3 
 0.36 
 0.1 
 0.89 
 0.6 
 0.6 
UPDRS OFF medication        -  24 ± 1.6 
  
 38 ± 3.4 
  
 0.002 
UPDRS ON 
medication 
Average improvement in 
UPDRS (%) 
       -   
 
 13 ± 1.4 
 
  
 46 
18 ± 2.2 
 
 
 53 
 0.12 
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Working memory task 
The WM task showed a main effect of group (F2,47 = 6.9, p = 0.002) and task 
(F1,131=16.0,  p < 0.001), and a significant interaction between these factors (F2,131 = 3.3, 
p = 0.040), but no effect of “off” versus “on” (F1,131 = 0.007, p = 0.9). To examine these 
effects in more detail, two additional ANOVAs with post-hoc comparisons were carried 
out, which revealed that the overall WM (digit forward + backward span) was 
significantly impaired in the PD+ICB group compared with both the control (p = 0.006) 
and the PD-ICB groups (p = 0.014), but there was no difference between the PD-ICB 
group and controls (p = 1.00; Figure 6A). More specifically PD+ICB patients performed 
significantly worse on the forward task than the PD-ICB and control groups (both p < 
0.001) and also performed significantly worse on the backward task than the PD-ICB (p 
= 0.01) and control groups (p < 0.001).  
There were no significant differences between PD-ICB patients and controls in the 
forwards task (p = 0.09) but the control group was significantly better than the PD-ICB 
group in the backwards task (p = 0.01) (Figure 6B).   
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Figure 6.  WM performance. 
A. Box plot showing the median (horizontal line) within a box containing the central 
50% of the observations (i.e., the upper and lower limits of the box are the 75th and 
the 25th percentiles) and extremes of the whiskers containing the central 95% of the 
ordered observations. Controls, Parkinson’s disease without (PD) and with impulsive 
compulsive behaviours (PD+ICB). Outliner is shown as circle.  
B. Working memory between the three groups, split by tasks (forwards backwards). 
Values are mean (± 1 sem). Significant differences were labelled with “*” in both 
figures. 
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Learning task 
Learning was assessed in the instrumental task using a recently developed Bayesian 
decision making model (Averbeck and Duchaine 2009). The models were first fit 
separately to the 65/35 blocks and the 75/25 blocks in the learning task, but there were 
no significant differences between parameters (p > 0.05) so one model was then fit to all 
4 of the blocks. Overall, the number of times that subjects picked the most rewarded 
image was similar between on and off conditions (Figure 7A-C).  
The choices of the subjects were compared to an ideal observer that always made the 
optimal decision given the feedback up to the current trial in each block. All subject 
groups made the same choice as the ideal observer at above chance levels (PD+ICB off, 
t19 = 4.7, p < 0.001; PD+ICB on, t19 = 4.1, p = 0.001; PD-ICB off, t11 = 3.2, p = 0.009; 
PD-ICB on, t11 = 3.1, p = 0.010; Control 1, t16 = 3.8, p = 0.002; Control 2, t16  = 3.8, p = 
0.002). A comparison of group and session in a mixed model ANOVA showed no 
significant effect of group (F2,46  = 1.17, p = 0.319), session (F1, 46  = 0.14, p = 0.71) or 
interaction  (F2,46  = 0.15, p = 0.857). 
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Figure 7.  Learning from positive and negative feedback. 
PD patients with and without ICBs and controls.  All values are mean (± 1 sem).         
A. Learning from positive and negative feedback on and off medication for PD+ICB.   
B. Same as A for the PD group without ICBs.  C.  Learning from positive and negative 
feedback in first and second test session in control subjects.  D. Within subject 
difference in learning from positive versus negative feedback for PD patients with 
ICBs versus non-impulsive patients off and on medication.  
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Next, learning from positive and negative feedback was compared across groups. When 
all three groups were compared, there was a significant effect of valence (F1,46  =  65.9, p 
< 0.001) but there were no other significant effects. Subsequently, an ANOVA was 
carried out directly comparing the PD and ICB groups, excluding the control group. In 
these groups, there was a main effect of valence (F1, 30 = 83.07, p < 0.001) but no other 
main effects or 2-way interactions. There was, however, a 3-way interaction between 
valence, group and session (F1,30  = 6.55, p = 0.016; Figure 7D). Separate ANOVAs in 
the two individual groups showed a significant interaction between session and type of 
feedback for the PD+ICB group (Figure 7A; F1,19  = 4.8, p = 0.041), as well as a 
significant main effect of feedback valence (F1,19  = 12.43, p = 0.002). The PD-ICB 
group showed a main effect of feedback valence (Figure 7B; F1,11  = 14.6, p = 0.003), but 
no interaction between session and valence (F1,11 = 2.83, p = 0.121).  
Risk task  
Two effects in the risk task were modeled. The first was an overall risk aversion term 
and the second was whether subjects became more or less risk averse if they won in the 
previous trial. First, controls showed an increase in risk aversion in the second test 
session, whereas both patient groups showed an increase in risk preference in the second 
session relative to the first session (Figure 8). An ANOVA that included all three groups 
had no significant main effects of group or session but did show a significant interaction 
between group and session (F2,48 = 4.2, p = 0.021). Post-hoc comparisons of the 
difference of the sessions showed that the controls were significantly different than the 
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PD-ICB subjects (p = 0.036) but did not differ significantly from the PD+ICB group (p 
= 0.052). Next, an ANOVA was carried out on only the PD-ICB and PD+ICB groups 
which showed no significant differences. However, when the PD-ICB group was 
compared to the subset of PD+ICB patients that had PG (n = 10 gamblers, Figure 8) 
there was a main effect of group (F1,21 = 7.9, p = 0.011) and session (F1,21 = 4.77, p = 
0.040). It was also analysed whether subjects became more risk prone following a win. 
An ANOVA across all three groups showed a main effect of session (F1,48 = 5.3, p = 
0.030) but no other main effects or interactions. When the analysis was restricted to PD-
ICB and PD+ICB groups or the PD-ICB and PD+PG, there were no significant main 
effects or interactions. 
 
 
 
 
 
 
 
Figure 8.  Risk preference.   
All values are mean (± 1 sem). Risk preference by group on (2nd trial for patients) and 
off (1st trial for patients) dopamine medication.   
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Discussion 
Increasing dopamine levels improves cognitive performance in some tasks while it 
impairs others (Swainson, Rogers et al. 2000, Cools, Barker et al. 2001). The deleterious 
effects of dopaminergic medication on reversal learning mediated via the ventral 
striatum have also been shown with functional fMRI in PD patients (Cools, Lewis et al. 
2007). Functional imaging has also localized dopamine effects on reward based learning 
to the ventral striatum (Pessiglione, Seymour et al. 2006). Other studies have shown 
beneficial effects of medication on tasks which may depend more on the dorsal striatum, 
including task switching and working memory (Lange, Robbins et al. 1992, Cools, 
Barker et al. 2001). Similarly, PD patients in their “off” state have deficits in cognitive 
sequence learning (Shohamy, Myers et al. 2005) and in the “Tower of London” task 
(Lange, Robbins et al. 1992). Dopaminergic replacement improves learning from 
positive feedback but impairs learning from negative feedback while withdrawal from 
dopaminergic medication in PD patients leads to the reverse profile with increased 
learning from negative feedback but impairment in positive feedback learning (Frank, 
Seeberger et al. 2004, Cools, Altamirano et al. 2006). Consistent with this, similar 
results have been seen in drug naïve PD patients who were then treated with dopamine 
agonists (Bodi, Keri et al. 2009) and in healthy subjects given either dopamine agonists 
or antagonists (Frank and O'Reilly R 2006). 
The results showed that PD+ICB patients had an opposite profile of effects on learning 
from positive versus negative feedback, depending on whether they were on or off 
medication compared with PD-ICB patients. The PD+ICB patients showed better 
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learning from positive versus negative feedback off medication compared to on 
medication, whereas the PD-ICB group showed a trend towards the previously described 
learning effects (Frank, Seeberger et al. 2004). A similar trend with relative improved 
negative feedback learning of PD+ICB patients in their “on” versus their “off” state was 
found in another study (Voon, Pessiglione et al. 2010). However, gain learning differed 
between this study and the study by Voon et al. They found improved reward learning in 
PD+ICB patients in their “on” state (Voon, Pessiglione et al. 2010) which was not found 
in this study. There are fundamental differences between their approach and the 
approach in this study that may account for these discrepancies. They used interleaved 
win (i.e. win $10/lose $0) and loss (i.e. lose $10/win $0) conditions and fit one learning 
rate parameter to the win condition and one to the loss condition. In this study, separate 
parameters to positive and negative outcomes were fit within a single condition. Further, 
Voon and colleagues tested for effects of dopamine agonists whereas in this study the 
acute effect of L-dopa on decision making was examined. The results presented in this 
thesis are also consistent with a more recent study which demonstrated that increased 
dopamine levels in the PD+ICB group increased sensitivity to negative feedback 
(Djamshidian, O'Sullivan et al. 2012).  
WM in the forward and backward digit span was significantly reduced in PD+ICB 
patients compared to the PD-ICB and the control groups. PD-ICB patients showed 
impairment in the digit backward span test compared to controls, consistent with a 
previous study (Mamikonyan, Moberg et al. 2009). There was, however, no effect of 
medication despite the fact that dopamine levels are known to play an important role in 
working memory (Cools, Gibbs et al. 2008, Landau, Lal et al. 2009). Previous studies 
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have shown that working memory is reduced in impulsive patients with attention 
deficit/hyperactivity disorder and healthy controls who scored highly on an impulsivity 
questionnaire. These subjects had lower total striatal dopamine levels which seem to be 
associated with lower WM capacity (Cools, Sheridan et al. 2007, Frank, Santamaria et 
al. 2007). Other studies have shown impaired spatial memory in patients with impulse 
control disorders (Voon, Reynolds et al. 2010). 
The prefrontal cortex is also involved in WM capacity (McNab and Klingberg 2008, 
Landau, Lal et al. 2009). In addition to the mid ventrolateral prefrontal cortex, which is 
activated during the digit forward span, the mid dorsolateral prefrontal cortex is 
activated for the backward digit span (Owen 2000) and patients with large lesions in the 
prefrontal cortex have defective decision making (Manes, Sahakian et al. 2002). 
PET studies of dopamine release have shown that dopamine medication leads to 
elevated ventral striatal dopamine release in PD+ICB patients relative to PD patients 
without ICBs (Evans, Pavese et al. 2006, Steeves, Miyasaki et al. 2009). These 
observations and results of this study are consistent with the hypothesis that PD+ICB 
patients have elevated baseline dopamine levels in the ventral striatum, and that 
dopaminergic medication increases the levels further, reducing learning from positive 
feedback. This might be explained by the “inverted U” shape hypothesis (Williams and 
Goldman-Rakic 1995, Cools, Barker et al. 2003) where the ability to pick the rewarded 
stimulus might be impaired when PD+ICB subjects are pushed off the upper end of the 
curve by their medication. 
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The risk task was designed to test the hypothesis that patients with ICBs are more risk-
prone than non-ICB patients (Voon, Thomsen et al. 2007). Previous authors have 
described the premorbid parkinsonian personality as one characterised by caution, risk 
aversion and anhedonia (Todes and Lees 1985). In contrast PD+ICB patients have a 
behavioural profile characterized by increased impulsiveness or novelty seeking (Voon, 
Thomsen et al. 2007) similar to subjects prone to substance abuse and behavioural 
addictions (Sher, Bartholow et al. 2000). Overall PD+ICB patients showed a trend to be 
more risk prone relative to non-impulsive PD patients, which did not reach significance. 
However, PD+PG patients were significantly more risk prone than the non-impulsive 
PD group. A tendency towards risky behaviour has also been found in pathological 
gamblers (Brand, Kalbe et al. 2005). Furthermore, dopaminergic medication led to 
increased risk preference in the PD-ICB group relative to healthy controls, and just 
missed significance in ICB patients versus controls. This is particularly interesting since 
risk taking decreases with age (Deakin, Aitken et al. 2004) and there was a trend for the 
non-impulsive PD group to be older than both groups. These findings are consistent 
with two recently published studies which showed that dopamine agonists lead to 
increased novelty seeking and a reduction in negative feedback learning (Abler, 
Hahlbrock et al. 2009, Bodi, Keri et al. 2009).    
It is important to consider the limitations of this study. First, unbalanced gains (10 
pence) and losses (5 pence) were used in the learning paradigm, so it might be the 
differential magnitude that the PD+ICB patients are sensitive to. However, it is unlikely 
that differential sensitivity to reward magnitude could underlie the group differences 
with respect to the effects of medication, as results showed that dopaminergic 
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medication status affected risk preference (which measures sensitivity to reward 
magnitude) in the same way in PD and PD+ICB patients, and yet medication had 
contrasting effects in the learning task. The valence effect that was seen across groups, 
however, could be due to the unbalanced gains and losses, as all groups appeared to 
learn more from gains than losses. Second, in order to minimise the effects of this study 
on patients, data collection was performed in one morning in fixed order; “off” 
medication then “on” medication. Thus practice effects cannot be separated from the 
“on” medication effects. Accordingly, healthy volunteers were also tested twice to 
attempt to control for practice effects through the morning. However, the latter does not 
negate the possibility of an interaction between practice and disease, so that practice 
effects may have been different in patients. In the light of the effects demonstrated in the 
current study a follow-up study is planned in which the order of drug states is 
counterbalanced across patients. 
Conclusion 
This study demonstrates differences in learning between PD patients with and without 
ICBs. These differences could be explained by higher ventral striatal dopamine levels in 
PD+ICB patients. In addition, PD patients with PG were more risk prone compared to 
non-impulsive PD patients and healthy controls. These findings may have therapeutic 
and clinical implications. The reduction in the overall dopaminergic medication with 
positive reinforcement of non-impulsive behaviour is likely to be more beneficial than 
aversion therapy in PD+ICB patients.  
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Key Findings 
o PD+ICB patients performed worse than controls and PD-ICB patients on a 
digit forward and backward span. 
o PD+ICB and PD-ICB patients showed an opposite learning profile 
depending on their dopamine status. 
o All PD patients were more risk prone after dopaminergic medication, with 
PD+PG patients being significantly more risk prone than the PD-ICB 
group. 
 
Limitations 
o No counterbalanced testing. 
o Unbalanced gains and losses in the learning task. 
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Introduction  
Altruism derives from the Latin word “alter”-the other. Altruism can be regarded as the 
opposite of egoism since it does not result in a personal benefit and might even bear at a 
personal cost (de Quervain, Fischbacher et al. 2004). Violation of social norms or unfair 
behaviour by members of a group induces a desire for society to punish the miscreants 
(Fehr and Gachter 2002). Punishing violators of social norms is gratifying, as people are 
prepared to accept personal loss in order to serve up justice. Punishment when there is 
personal cost is known as altruistic punishment, and has been shown to reduce the 
amount of unfair behaviour within groups (Fehr and Gachter 2002). 
A functional imaging study in healthy volunteers has shown that the dorsal striatum, in 
particular the caudate nucleus is critically involved in mediating punishment and greater 
activation in the ventral caudate is associated with higher altruistic punishment. This 
study also indicated that people derive satisfaction from punishing
 
norm violations (de 
Quervain, Fischbacher et al. 2004). Other fMRI studies have demonstrated that the 
dorsolateral prefrontal cortex, the insula (Sanfey, Rilling et al. 2003) and the caudate 
nucleus (King-Casas, Tomlin et al. 2005) play important roles in processing fair and 
unfair behaviour. The dorsal-lateral prefrontal cortex and the caudate are directly 
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connected in a frontal-striatal loop (Haber, Kim et al. 2006), and therefore both regions 
are likely to be relevant in mediating responses to fair and unfair behaviour. 
The dopamine innervation of the dorsal striatum is severely depleted in PD, leading to 
bradykinesia and rigidity. Dopaminergic replacement is used to correct the depleted 
dopamine levels and improve motor deficits. Patients with PD are commonly anhedonic 
(Todes and Lees 1985), but there is a subgroup of patients who during chronic 
dopaminergic treatment exhibit ICBs including pathological gambling, hypersexuality, 
compulsive shopping, binge eating, reckless generosity, punding and the compulsive use 
of dopaminergic medication (DDS) (American Psychiatric Association 2000, Lawrence, 
Evans et al. 2003, Weintraub and Potenza 2006, Brewer and Potenza 2008, O'Sullivan, 
Evans et al. 2009). Clinical data suggest that dopamine replacement medication, 
especially dopamine agonists, directly provoke these compulsive behaviours 
(Weintraub, Koester et al. 2010) and a recent study has demonstrated a positive 
association between impulsivity and altruistic punishment (Crockett, Clark et al. 2010). 
PD+ICB and PD-ICB patients were tested “on” and “off” medication and results were 
compared with healthy controls matched for age and education. As PD+ICB patients 
violate social norms themselves, and given their deficits in learning from negative 
feedback, the hypothesis was that “off medication” they are less likely to punish others 
that violate social norms. It was further speculated that on dopaminergic medication 
both groups of patients would punish to a greater amount and more frequently than 
when off medication given the role of the striatum in mediating punishment, and the 
important role of dopamine in modulating behaviours mediated by the striatum.    
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Patients and methods  
Patients were recruited from a database of attendees at the National Hospital for 
Neurology and Neurosurgery Queen Square, London, UK. All patients fulfilled the 
Queen Square Brain Bank criteria for the diagnosis of PD (Gibb and Lees 1988) and 
were taking L-dopa medication. Controls were usually recruited from amongst the 
patient’s spouses or partners. Participants, who provided written informed consent to 
protocols approved by the UCLH Trust local ethics committee, were included. Patients 
who scored under 27/30 points on the MMSE were excluded from this study.  
The study was performed between-groups, such that no patients were tested both off and 
on: this eliminates the possibility of order effects, which may be more likely with the 
task used in this study than other studies. Thirteen PD+ICB patients were tested off 
medication and 14 on medication. Similarly 12 PD-ICB patients were tested off 
medication and 14 on medication. Results were compared with 26 healthy controls. 
Table 8 includes detailed demographic information on all subjects.  
All patients were screened for sub-classes of ICBs. Pathological gambling was defined 
using the DSM IV criteria, compulsive shopping was defined using McElroy’s criteria 
(McElroy, Keck et al. 1994), hypersexuality was defined as suggested (Voon, Hassan et 
al. 2006). All PD patients were additionally screened for punding (Evans, 
Katzenschlager et al. 2004). Patients who were tested “off” performed the test between 
8.00 a.m. and 9.00 a.m. prior to their morning medication and had not taken their 
medication for at least 12 hours.   
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 Control  PD+ICB  
on med.  
PD+ ICB 
off med. 
PD- ICB  
on med.  
PD - ICB 
off med. 
F value 
except * 
 
p-
value 
Participants  
Age (yrs) 
Gender(male) 
At disease 
onset (yrs) 
26 
58±11 
15 
 
 - 
14 
55.0 ± 11.9 
11 
 
44±10.5 
13 
56.6±6.4 
9 
 
49±7.6 
14 
66.3±8.0 
12 
 
54.1±9.5 
12 
64.2± 8.3 
10 
 
53.1±8.8 
 
3.5 
χ 2=5.1 * 
 
3.5 
 
0.01 
0.28 
 
0.023 
Disease 
duration 
Education  
  - 
 
13.5±3 
11.3±5.2 
 
12.3± 2.3 
7.7±4.7 
 
14.7±3.5 
12.2±7 
 
14.0± 4.3 
11.1±6.9 
 
15.2±4.0 
1.45 
 
1.54 
0.24 
 
0.2 
LEU (mg) 
L-dopa (mg) 
DA  
 - 
 - 
 - 
858±348 
692.9±281 
8 
801±479 
521±227 
9 
812±346 
604±315 
10 
825±378 
466±247 
9 
0.05 
1.6 
χ 2=1.8 * 
0.98 
0.19  
0.6 
Active ICB  
Gambling 
Sex 
Shopping 
Punding 
Kleptomania  
- 
- 
- 
- 
- 
- 
8 
4 
6 
6 
2 
1 
8 
3 
8 
8 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 NS 
NS 
NS 
NS 
NS 
NS 
UPDRS on 
UPDRS off 
 
Change in 
UPDRS (%) 
 - 
 - 
 
  
19.4±8.0 
36.8±15.4 
 
 
46 
14.1±5.2 
29.2±11.1 
 
 
52 
17.7±10.9 
27.7± 9.5 
 
 
36 
12.5±4.0 
24.0± 7.0 
 
 
48 
1.8 
2.3 
0.16 
0.09 
Table 8.  Altruistic punishment: Demographic characteristics. 
Controls, PD patients with and without ICBs. NS = not significant. 
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Patients who were tested on medication were assessed at a similar time of the morning 
when they felt that their motor symptoms had been well controlled, about 1 hour after 
their usual morning anti-Parkinson medication. The therapeutic motor response to L-
dopa was assessed by UPDRS scores (part 3) during “off” and “on” state. All patients 
had an excellent L-dopa response. Levodopa equivalent units (LEU) were calculated as 
described previously (Evans, Katzenschlager et al. 2004). Testing was usually 
performed in patient’s homes or a hotel room using a laptop computer. Distractions were 
minimized as much as possible.  
Altruistic punishment task 
The task was a computerized trust game (de Quervain, Fischbacher et al. 2004) designed 
to assess altruistic punishment in fair and unfair rounds. Participants were told that they 
were playing live against eight human players, but in fact all were playing against the 
computer. To ensure that the participants believed they were playing against human 
participants several precautions were taken. The tests were administered on a laptop, 
often in the participant’s homes. Therefore an external modem which initiated a 
connection to the internet was used. During this connection process the screen displayed 
“connecting to the first player” and later on during play “your decision has been sent to 
your first partner”. Random time delays were also used while subjects waited to see if 
their “partner” would reciprocate.   
Participants received an allowance at the start of play and were told that they could start 
the game by entrusting £10 or nothing to each of the eight trustees, as done previously 
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(de Quervain, Fischbacher et al. 2004). Participants played with one trustee per round. 
Thus, a single decision at the start of play dictated the amount entrusted by the player in 
all subsequent rounds. None of the subjects chose not to entrust the £10 at the start of 
play. Participants were told that each trustee had been given £10 already and that in each 
round the invested £10 was quadrupled. Thus, each of the eight players (trustees) 
received £50 in total. The trustee could either respond in a trustworthy manner and share 
(send back £25) or could keep all the money (£50). Following this the participants were 
given an additional £10, and had the option to punish the trustee which would result in a 
decrease in the amount of money the trustee was left with. However, participants were 
informed that they would lose £1 for every £2 they chose to punish the trustee. Their 
punishment options were £0, £5, £10, £15 and £20, at costs to the participant of £0, 
£2.50, £5.00, £7.50 and £10. In three of the eight rounds participants were treated in a 
fair manner (receiving £25 back), in the rest of the rounds they were treated in an unfair 
manner (receiving £0 back). All participants understood the rules. Participants either 
pressed the necessary computer key by themselves or if more convenient gave verbal 
commands and I pressed the keys on their behalf. Participants were given the average 
outcome across all rounds of play. Controls received on average £14, PD+ICB patients 
off medication on average £13, PD-ICB patients off medication £10 and PD patients on 
medication from both groups £9 for completing this study.  
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Statistical analysis 
Analyses were carried out on the amount that the patients chose to punish in each round.  
The raw scores were 1 if participants did not punish or respectively 2 = £5, 3 = £10, 4 = 
£15 and 5 = £20. Analyses using standard linear models were carried out and presented 
in the results section. For the linear model, a mixed model ANOVA was performed with 
the scores as the dependent variable. Trials (round 1 to 8) and valence (fair and unfair) 
was modeled as within subject factors, with trial nested under valence. Group (PD-ICB 
off medication, PD-ICB on medication, PD+ICB off medication, PD+ICB on 
medication and controls) was also modeled and subject was included as a random factor 
nested under group. Interactions between the fixed effects were also assessed. All post 
hoc comparisons were Bonferroni corrected. 
A second ANOVA on just the PD-ICB and PD+ICB groups was used to examine 
explicit medication and group (PD-ICB versus PD+ICB) effects. This model was 
identical in all other factors to the above model, except the group variable, which had 5 
levels in the first analysis, was split into 2 factors each with 2 levels (as controls were 
excluded): patient diagnosis (+ICB/-ICB) and medication (on/off dopaminergic 
therapy).  
As the dependent variable values took on a discrete set of values, a generalized linear 
model (SPSS) with a multinomial cumulative logit link function was also used to assess 
significance. The cumulative logit maintains the ordinal relation of the responses 
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without making the Gaussian assumption on the residuals. Wald chi-square was used to 
assess statistical significance. The results were closely replicated and listed below.  
Results 
Demographic characteristics 
Groups were generally well matched demographically. However, there was a significant 
effect of age between the 5 groups (F4,74 = 3.5, p = 0.01; controls, PD-ICB on, PD-ICB 
off, PD+ICB on and PD+ICB off). Post hoc analysis revealed that the PD-ICB on group 
was older than the PD+ICB on (p = 0.03) but not to the PD+ICB off group (p = 0.12). 
There was no difference between the control and the PD-ICB on group (p = 0.13), no 
difference between the PD-ICB off and the PD+ICB on group (p = 0.2) and all other 
patients groups (p > 0.57). There was also a significant effect of age of onset (F3,49 = 3.4, 
p = 0.03). Post hoc analysis showed that the PD+ICB on group had an earlier disease 
onset (p = 0.03) than the PD-ICB on group, consistent with previous studies (Weintraub 
and Potenza 2006, Voon, Thomsen et al. 2007). There was no difference in age of 
disease onset between the PD+ICB on group and the PD-ICB off group (p = 0.08) nor 
between the other groups (p > 0.92). There was also no difference in the LEU dose (F3,48 
= 0.05, p = 0.98) or the daily L-dopa dose (F3,48 = 1.6, p = 0.19). 
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Analysis of punishment behaviour 
Mixed model ANOVA 
An ANOVA with dependent variable the amount of punishment was carried out, with 
group entered as five levels (PD-ICB on, PD-ICB off, PD+ICB on, PD+ICB off, 
controls). There was a significant main effects of group (F4,73 = 11.17, p < 0.001) and 
valence (F1,73 = 265.83, p < 0.01), where valence was fair versus unfair outcome. There 
was also a significant interaction between group and valence (F4,73 = 4.54, p = 0.002). 
Given the interaction with valence, separate ANOVAs on the fair and unfair rounds 
were carried out. In the fair rounds there was no effect of group (F4,73 = 1.95, p = 0.111).  
In the unfair rounds there was a main effect of group (F4,73 = 9.24, p < 0.001). 
Next the PD-ICB and PD+ICB groups were compared to directly examine a diagnosis of 
ICB as well as the effects of medication. Thus, group was split by ICB diagnosis 
(+ICB/-ICB) and medication (on/off dopamine replacement therapy). The main effect of 
group just missed significance (F1,48 = 3.71, p = 0.060). There was, however, a 
significant main effect of medication (F1, 48 = 5.76, p = 0.020) and a significant 
interaction between group and medication (F1, 48 = 7.68, p = 0.008). There was also a 
valence by group interaction (F1,336 = 4.97, p = 0.026) and a significant valence by group 
by medication interaction (F1, 336 = 9.71, p = 0.002).  
As there was a difference in age between groups, age was added as a covariate but did 
not affect significance of any parameters. Given the interactions with valence, this 
ANOVA was split by valence and separate ANOVAs were performed. In the fair rounds 
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there was no effect of group (F1, 48 = 0.04, p = 0.852) or medication (F1, 48 = 1.2, p = 
0.279) (Figure 9A). In the unfair rounds, however, there was a main effect of group (F1, 
48 = 4.05, p = 0.050), an interaction between group and medication such that PD-ICB on 
and off punished strongly, whereas PD+ICB on also punished strongly, but PD+ICB off 
punished less (F1, 48 = 8.24, p = 0.006) (Figure 9B). The main effect of medication just 
missed significance (F1, 48 = 3.96, p = 0.052).   
Next, pairwise post-hoc comparisons between all five groups in just the unfair rounds 
(Bonferroni corrected) were carried out. This analysis showed that PD-ICB on, PD-ICB 
off and PD+ICB on punished significantly more than controls (p < 0.01) whereas the 
PD+ICB off group punished similarly to controls (p = 1.000).  
Furthermore, PD-ICB on and PD+ICB on punished significantly more than the PD+ICB 
off group (p < 0.05), but PD-ICB off only reached trend level versus the PD+ICB off 
group (p = 0.067).   
As dopamine loss in PD progresses over the course of the disease a correlation between 
disease duration and the amount of punishment was made. However, correlations 
between disease duration and the amount of punishment in the unfair condition showed 
no significant effects (p > 0.345). There was also no correlation between UPDRS scores 
and punishment (p > 0.405).   
  
113 
 
Generalized linear model 
A generalized linear model was used, with group entered as five levels (PD-ICB on, PD-
ICB off, PD+ICB on, PD+ICB off, controls). There was a significant main effects of 
group (Wald χ2 = 15.76, p = 0.003) and valence (Wald χ2 = 224.43, p < 0.001) and a 
significant interaction between group and valence (Wald χ2 = 10.20, p = 0.037).  
Comparison to the PD-ICB and PD+ICB groups on and off medication showed no main 
effect of group (Wald χ2 = 1.70, p = 0.192). There was, however, a significant main 
effect of medication (Wald χ2 = 8.38, p = 0.004) and a significant interaction between 
group and medication (Wald χ2 = 4.54, p = 0.033). There was also a valence by group 
interaction (Wald χ2 = 4.39, p = 0.036) and a significant valence by group by medication 
interaction (Wald χ2 = 6.23, p = 0.044).  
Figure 9.  Average punishment score of participants in fair and unfair rounds.  
Error bars are ± 1 sem. 
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Discussion 
This study demonstrated increased altruistic punishment behaviour in PD+ICB patients 
on dopaminergic medication compared to controls. These patients behaved similarly to 
controls off medication, whereas PD-ICB patients punished more than controls whether 
they were medicated or not.  
The decision to punish is likely influenced by the participant’s response to the amount 
returned by the trustee. When the trustee reciprocates, the investor makes money on the 
transaction, and when the trustee withholds the investor loses money. Winning and 
losing money engage learning processes in non-social contexts, and extensive studies 
have shown that dopamine levels in PD are related to learning from positive and 
negative feedback (Cools, Barker et al. 2001, Frank, Seeberger et al. 2004, Bodi, Keri et 
al. 2009). Additionally, many subjects may be unwilling to punish trustees, even if they 
have a strong negative affective response to the lack of reciprocation, whereas others 
may punish even though they feel little resentment. 
Results showed that PD+ICB patients off medication punished to the same degree as 
controls, whereas the PD+ICB group on medication punished more. Thus, even though 
dopamine medication can lead to the development of ICBs, and ICBs are inconsistent 
with social norms, PD+ICB patients enforce social norms more strongly on than off 
medication.  
It is possible, therefore, that the PD+ICB off group may punish less than all the other 
patient groups because they are less sensitive to the lack of reciprocation by the trustee. 
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Additionally, dopaminergic medication has been shown to increase impulsive choice in 
PD+ICB patients (Voon, Reynolds et al. 2010) and impulsivity correlates positively 
with altruistic punishment in the “Ultimatum Game” (Crockett, Clark et al. 2010). 
Increased punishment in the PD+ICB group on medication could, therefore, be due to 
sensitivity to negative feedback and increased impulsivity.   
The PD-ICB group punished more than controls both on and off medication. When the 
PD-ICB group was compared to the PD+ICB group, there was an interaction between 
medication status and group, and the difference between PD-ICB off and PD+ICB off 
just failed to reach significance. Interactions between medication and group have 
already been observed across a range of behaviours including impulsive choice (Voon, 
Reynolds et al. 2010), learning (Voon, Pessiglione et al. 2010), affective states and 
reward responsivity (Evans, Lawrence et al. 2010). In this study, only the PD+ICB 
patients were sensitive to behavioural changes induced by their dopaminergic 
medications. This is consistent with the observation that clinically impulsive behaviour 
arises due to medication in the PD+ICB group, but not in the normal PD group (Voon, 
Reynolds et al. 2010).  
There are also differences in the pre-morbid personalities of PD-ICB and PD+ICB 
patients. PD-ICB patients have a lower premorbid risk of smoking, and tend to be 
anhedonic, moralistic, punctual, risk averse and altruistic with a strong adherence to 
social norms (Prick 1966, Todes and Lees 1985, Menza 2000, Evans, Lawrence et al. 
2006, Ishihara and Bayne 2006). Recent studies have suggested that some of these 
behaviours may be related to the prefrontal cortex (Abe, Fujii et al. 2009).  
116 
 
In contrast, PD patients who develop ICBs are higher novelty seekers with an increased 
premorbid incidence of illicit drug or alcohol addiction (Potenza, Voon et al. 2007, Lim, 
Evans et al. 2008). The PD-ICB group therefore may punish more than the PD+ICB 
group off medication, due to their inherent personality traits. However, the exact 
neurobiological mechanisms that underlie these personality and task behavioural 
differences are not yet clear. 
Brain imaging studies using a similar task have shown that the medial caudate nucleus is 
activated during punishment, and a ventral caudate focus correlates with the amount of 
punishment (de Quervain, Fischbacher et al. 2004). The desire to punish altruistically 
appears to be driven by negative emotions brought about by the fact that trustees fall 
short of social norms when they do not reciprocate (Fehr and Gachter 2002). However, 
it is unclear whether punishment in the patient groups is only driven by altruism or 
whether other factors such as aggression have to be taken into account.  
Clinically PD+ICB patients can become quite aggressive and do not have insight that 
their behaviours are unacceptable to others. This would mean that punishing or 
criticizing PD+ICB patients for bad behaviour off medication would not be effective 
since they do not recognize norm violations which might contribute to the patient’s low 
insight. 
Further behavioural studies which include self-rating questionnaires to tap the 
motivation of altruistic punishment are required to clarify findings of this study.  
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Conclusion 
Results of this study showed that PD patients with ICBs respond differently than non-
impulsive PD patients in a trust game in which patients can deliver punishment 
altruistically. Both groups of medicated patients punished more than controls, but off 
medication the PD-ICB group still punished more than controls, whereas there was no 
difference between the PD+ICB patients and healthy controls. Unravelling the factors 
that lead to these differences will provide important insight into impulsive compulsive 
behaviours, as well as the neural, pharmacological and anatomical mechanisms that 
underlie these tasks. 
 
Key Findings 
o PD-ICB patients punished more often than controls regardless of 
dopaminergic state. 
o PD+ICBs punished more than controls on medication, but similar to 
controls off medication. 
o Only PD+ICB patients changed their behaviour after dopaminergic 
medication. 
o PD+ICB patients on medication might therefore want to enforce social 
norms, but have difficulties following them.  
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Introduction 
The Stroop Colour Word test is a simple but reliable and well researched test for 
examining cognitive flexibility. The task requires participants to respond to the ink 
colour and suppress the more familiar word identity. Several versions of the Stroop test 
exist. In the standard form participants have to read out 100 congruent and incongruent 
words and the total time for each card is recorded. In the computerized form congruent, 
incongruent and neutral non coloured words are presented one at the time and reaction 
time can be recorded (Lansbergen, Kenemans et al. 2007). Whilst responses in 
congruent settings are relatively automatic, incongruency between the letters and ink 
colour requires keen attention and leads to slower responses. Stroop interference is 
defined as the difference between naming the colour of a word in incongruent versus 
congruent or neutral trials (Lansbergen, Kenemans et al. 2007). 
Impairment in the Stroop test has been described in patients with frontal lobe damage, 
drug abusers (Simon, Domier et al. 2002), patients with schizophrenia (Barch, Carter et 
al. 2004) and PD patients (Hsieh, Chen et al. 2008). However, an item by item Stroop 
test has never been used in PD patients with ICBs such as pathological gambling, 
compulsive shopping, hypersexuality, and binge eating. These patients have poorer 
working memory assessed by the digit span as described earlier, but it is unclear 
whether fast cognitive updating as required in the Stroop test will be also impaired. 
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Further, PD+ICB patients develop these behavioural abnormalities as a direct result of 
dopaminergic medication. Therefore, all patients were tested once prior and once after 
dopaminergic medication to assess the effect of medication on cognitive flexibility. The 
hypothesis was that PD+ICB patients would perform worse than PD-ICB patients and 
normal controls on a task that requires inhibition of competing responses. It was 
predicted that all patients would show improvement in cognitive flexibility, reflecting an 
improved ability to respond to changing task demands, after dopaminergic medication. 
Patients and methods 
Twenty-four PD-ICB, 28 PD+ICB patients and 24 healthy controls were tested on an 
item by item Stroop test. Most PD+ICB patients had more than one addictive behaviour, 
which is in line with the hypothesis that all ICBs share common risk factors regardless 
of their type of impulsive compulsive behaviour (Torta and Castelli 2008). The ICBs 
included compulsive sexual behaviour (13 patients), pathological gambling (11 
patients), compulsive buying (8 patients), punding (4 patients) and kleptomania (1 
patient). None of the patients was clinically depressed at the time of testing and only 4 
out of 28 PD+ICB patients and 2 out of 24 PD-ICB patients were taking antidepressant 
medications (see Table 9). All patients were recruited from the National Hospital for 
Neurology and Neurosurgery, Queen Square, London. Healthy controls were mainly 
recruited from amongst the patient’s partners. Participants who provided written 
informed consent to protocols approved by the UCLH Trust local ethics committee were 
included. Patients who scored under 27/30 points on the Mini Mental State Examination 
120 
 
were excluded. Testing was done in a quiet environment either in the patient’s home or 
in a hotel room using a laptop computer and a microphone. The patient groups were 
matched for disease duration, motor disability and medication.  
PD patients were tested in either an on or off medication state in a counterbalanced 
order. Results were compared with 24 healthy volunteers who were matched to the 
PD+ICB group.  
Patients who were tested “off” first performed the task between 8.00 a.m. and 9.00 a.m. 
and had not taken their medication for at least 12 hours. They were then retested in their 
on medication state 1 hour after taking their first dopaminergic medication of the day. 
Those patients who were tested on medication first performed this task usually in mid-
morning at a similar time of the day when their symptoms were well controlled. They 
were revisited on the following day prior to their medication for the second test, again 
between 8.00 a.m. and 9.00 a.m. Controls were tested in the same way, but did not take 
any anti-Parkinson medication. All patients had an excellent L-dopa response which was 
assessed by the UPDRS (part 3) motor score during the off and on state. Levodopa 
equivalent units (LEU) were calculated as described previously (Evans, Katzenschlager 
et al. 2004).   
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 Controls PD+ICB PD-ICB t value 
except * and ** 
p-value 
Participants (no.) 
 
Age (yrs) 
 
Gender (male) 
At disease onset (yrs) 
24 
57.8 ± 10.7 
14 
 - 
28 
54.6 ± 9.2 
21 
44.5 ± 8.7 
24 
64,2 ±10.1 
21 
52.5 ± 9.6 
 
F = 7.0 **  
χ 2 = 5.3 * 
t = 3.1 
 
0.002 
0.071 
0.03 
Disease duration (yrs) 
 
Education (yrs) 
 - 
13.2 ± 2.9 
10.1 ± 5.5 
13.4 ± 3.0 
11.7 ± 7.2 
14.7 ± 3.6 
t = 0.88 
F = 1.7 ** 
0.39 
0.18 
LEU dose(mg/day) 
DA (patients) 
- 
- 
832 ± 425 
14 
821 ± 400 
16 
t = 0.1 
χ 2 = 1.4 
0.9 
0.27 
UPDRS on 
UPDRS off 
Improvement in UPDRS (%) 
- 
- 
- 
15.5 ± 8.3 
27.3 ± 9.1 
43.2 
14.4 ± 5.8 
26.8 ± 6.7 
46.2 
t = 0.5 
t = 0.2 
0.6 
0.8 
Gambling 
 
Hypersexuality 
 
Shopping 
 
Punding 
Kleptomania  
- 
- 
- 
- 
- 
11 
13 
8 
4 
1 
- 
- 
- 
- 
- 
  
Table 9.  Stroop test: Demographic characteristics.     
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Stroop test 
To account for age related differences in performance an item by item Stroop test 
consisting of four colours (green, red, blue or yellow) was used and measured reaction 
time for each trial separately. Each word appeared centrally on a black background. 
Participants were asked to name the colour of the word as quickly as possible and had a 
maximum of 4 sec to respond. Sixteen trials were recorded, 8 were congruent and 8 
incongruent in a pseudo randomized order, giving four possible patterns of testing 
namely incongruent followed by incongruent trial, congruent by incongruent, 
incongruent by congruent and congruent by congruent trials (Figure 10C). A standard 
microphone (Logitech) was used for recording responses. Reaction time (RT) was 
computed by finding significant (p < 0.01) deviations of the recorded variance in the 
speech signal, relative to a 200 ms initial baseline.  
Statistical analysis 
A mixed model ANOVA was performed. The dependent variable was either the error 
rate or the reaction time, averaged by condition. Condition (off versus on and 1
st
 and 2
nd
 
session in normal controls) were modeled as within subject factors and group (PD-ICB, 
PD+ICB and normal controls) was modeled as a between subject factor. Subject was 
included as a random factor. Since there was a significant age-difference between the 
groups age was added as a cofactor in all analyses.   
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Results 
Demographic characteristics 
There was a significant effect of age between the 3 groups (F(2,74) = 7.0, p = 0.002). Post 
hoc analysis revealed that the PD-ICB group was older than the PD+ICB (p = 0.001) 
and a trend to be older than the control group (p = 0.058). Results showed a significant 
effect of age of onset between the patient groups (t49 = 3.1, p = 0.03). There was no 
difference in the LEU dose, disease duration and UPDRS (part 3) motor score, across 
the groups (see Table 9). 
Analysis of Stroop test 
PD-ICB and PD+ICB groups were compared “off” and “on” medication to healthy 
controls and pairwise (Bonferroni corrected for 4 comparisons) comparison was made.  
For errors (Figure 10A) there was a main effect of group. PD-ICB patients off 
medication (F(1, 34) = 7.18, p = 0.037) and PD+ICB patients off medication (F(1, 36) = 
8.25, p = 0.022) made more errors than controls. Thus, off medication all patients made 
more errors than healthy volunteers, but on medication there was no difference between 
patients and healthy volunteers (p > 0.05). In all cases there were significant effects of 
congruency, i.e. whether the trial was congruent or incongruent (p < 0.01). There were 
no other significant effects or interactions. For RT there were no significant differences 
between groups (Figure 10B).   
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Comparing PD-ICB and PD+ICBs on and off medication showed a main effect of 
congruency (F(1, 164) = 51.82, p < 0.001) and an effect of medication (F(1, 164) = 3.89, p = 
0.050), but no main effect of group (F(1, 39) = 0.21, p = 0.649) on the error rates. There 
were no significant interactions (p > 0.535). For RT there were no significant main 
effects or interactions (p > 0.153).   
The data for the PD-ICB and PD+ICB subjects was then split depending on whether the 
trial followed a trial of the same type, or switched (i.e. congruent followed by congruent, 
or congruent followed by incongruent, etc.) to examine cognitive flexibility (Figure 
10C).  
Thus, in addition to a main effect of congruency an effect of switch versus no switch 
was included, which reflected the previous trial type. For errors there was no main effect 
of group (F(1, 32) = 0.04, p = 0.847) and the main effect of medication just missed 
significance (F(1, 1402) =3.66, p = 0.056). There was a main effect of congruency (F(1, 1402) 
= 15.69, p < 0.001) and a switch by congruent interaction (F(1, 1402)  = 13.85, p < 0.001).  
For RT there was no significant effect of group (F(1, 35) = 2.35, p = 0.135), but there was 
a main effect of medication (F(1,1406 ) = 7.41, p = 0.007) and a switch by congruent 
interaction (F(1, 1406) = 5.69, p = 0.017).   
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Figure 10.  Stroop test: Behavioural results. 
A. Error rates for each subject group. Blue = PD patients with ICB, red = PD patients 
without ICB.  
B. Reaction times. C. Reaction times for switch and non-switch trials in the patient 
group. Solid lines = off medication, dotted lines = on medication, I = incongruent, 
C = congruent.  
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Discussion 
There was a significant Stroop interference effect in all participants. Furthermore, 
results demonstrated that all PD patients made more errors than healthy volunteers when 
off medication. Results showed that in their “on” state patients had a shorter RT on 
switching behaviour between congruent and incongruent trials, in keeping with previous 
studies (Jahanshahi, Ardouin et al. 2000, Cools, Barker et al. 2003). Findings of this 
study are also consistent with previous studies showing improvement of Stroop 
performance in PD patients with and without deep brain stimulation (Jahanshahi, 
Ardouin et al. 2000, Fera, Nicoletti et al. 2007). There was no difference in RT between 
PD patients and controls in keeping with previous studies (Fera, Nicoletti et al. 2007). 
Further, patients on medication showed a trend to be slower in RT in congruent trials 
followed by incongruent trials compared to incongruent trials followed by incongruent 
trials (Figure 10C). This might be explained by an increased awareness caused by the 
previous conflicting trial. There was no difference in error rates between the patient 
groups which implies that the inability to suppress automatic responses and the inability 
to suppress, for example, the urge to gamble depend on different processes and neural 
systems. Findings of this study are also in line with two other studies which have shown 
no impairment on the FAB scores in PD patients with pathological gambling compared 
to those without ICBs (Voon, Thomsen et al. 2007, Siri, Cilia et al. 2010). Thus, 
PD+ICB patients seem to be unimpaired in tasks that are mediated by frontal cortex, as 
for example occurs also with response suppression tasks (Botvinick, Nystrom et al. 
1999). Results of this study are also consistent with another study done in PD patients 
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with pathological gambling, which showed impairment in a risk assessment task but not 
in other cognitive domains including a Stroop test (Rossi, Gerschcovich et al. 2010). 
The results of this study extend the current literature and demonstrate that there is no 
difference in cognitive flexibility between PD controls and patients with impulse control 
disorders irrespective of the type.  
Brain imaging studies in non PD pathological gamblers versus controls, which used a 
Stroop test paradigm, showed differences only in the left ventromedial
 
prefrontal cortex 
(Potenza, Leung et al. 2003). These minor changes might explain why impairment in the 
Stroop test in impulsive patients could be found in some (Kertzman, Lowengrub et al. 
2006) but not all reported studies (Potenza, Leung et al. 2003). Furthermore, 
performance of the Stroop test might not trigger mesolimbic dopamine release and could 
fail to activate limbic and “reward centres” of the brain which are known to be abnormal 
in PD+ICB patients. In line with this notion is the finding that there was no correlation 
between amygdala activation and Stroop performance (Glahn, Lovallo et al. 2007).   
Since cognitive performance may vary during the day (West, Murphy et al. 2002), 
patients were tested in their “off” condition on average at about 8.30 a.m. and patients of  
the “on” group at a similar time point, on average at 10.30 a.m. 
There are, however, some limitations in this study. Patients who were tested first “on” 
then “off” were tested on separate days, whereas patients tested first “off” and then “on” 
were tested on the same day. Thus, the test-retest interval differed between the two 
groups and conceivably might have influenced the results. However, results of this study 
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are within-subject effects comparing “off” versus “on”, and they did not depend on the 
order of testing.  
Conclusion 
There was no difference in the Stroop test performance between PD patients with and 
without ICBs suggesting that response inhibition is not a hallmark of ICBs in PD.  
Future work using an emotionally charged Stroop test, which is more likely to activate 
the limbic system, could potentially demonstrate differences between the two PD 
groups.  
Key Findings 
o All PD patients made more errors prior to their usual medication than 
controls which resolved after medication. 
o All patients on medication made fewer errors and had a shorter RT.  
o Response inhibition required in the Stroop test does not differentiate 
impulsive from non-impulsive PD patients. 
 
Limitation 
o The test-retest interval between PD “off” and “on” groups was 
significantly different. 
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Introduction 
 
Humans and animals are inherently attracted to new stimuli as these can be potentially 
rewarding (Daffner, Mesulam et al. 1998, Hughes 2007). High novelty seeking is part of 
adolescence and may help in normal development and the acquisition of independence 
(Kelley, Schochet et al. 2004): adults with  novelty seeking personality traits on the 
other hand often have increased impulsivity, addiction, inability to delay gratification, 
recklessness and aggressive behaviour(Barratt 1985, Belin, Mar et al. 2008).  While self-
report questionnaires have suggested that the subgroup of PD+ICB patients with DDS 
(Evans, Lawrence et al. 2005) and those with pathological gambling (Voon, Thomsen et 
al. 2007) have high levels of novelty seeking, this has not been formally studied using 
metric tests. 
The trade-off between choosing options of known value and exploring novel options is 
known as exploration vs. exploitation (Daw, O'Doherty et al. 2006).  Exploring novel 
choices and learning the value of stimuli based on reward feedback have been linked to 
the ventral striatum, the substantia nigra and the ventral tegmental area of the midbrain 
(Wittmann, Daw et al. 2008, Guitart-Masip, Bunzeck et al. 2010) as well as the 
hippocampus (Guitart-Masip, Bunzeck et al. 2010, Voon, Pessiglione et al. 2010).  
These areas either contain dopamine neurons or receive strong dopaminergic 
innervation. Additional studies have examined the dopamine link to learning and 
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exploration. For example, behavioural studies in PD have shown that dopamine levels 
play an important role in reward learning (Cools, Clark et al. 2002, Frank, Seeberger et 
al. 2004, Voon, Pessiglione et al. 2010).   Complimenting this work, functional magnetic 
resonance imaging (fMRI) studies in healthy controls and positron emission tomography 
(PET) studies in PD+ICB patients have localized reward responsivity to the ventral 
striatum (O'Doherty, Critchley et al. 2003, Steeves, Miyasaki et al. 2009, Evans, 
Fleming et al. 2010).  
One of the circuits that has been proposed to mediate novelty effects includes the 
hippocampal projection to the ventral striatum.  Specifically, the hippocampus forms a 
functional loop with the ventral striatum and the mid-brain dopamine neurons.  The 
hippocampus is activated by novel information (all information that is not stored in long 
term memory) and regulates, via the ventral striatum, dopamine neuron firing rates 
(Lisman and Grace 2005). Neuropathological studies have shown that the 
parahippocampal gyrus is affected in later stages of PD (Braak, Ghebremedhin et al. 
2004). Thus, abnormal and increased activity in the ventral striatum might be triggered 
by earlier neuropathological changes in the hippocampus in PD+ICB patients.   
The aim of the present study was to compare novelty seeking between impulsive and 
non-impulsive PD patients, and also to examine the role of dopaminergic medication on 
novelty seeking. It was hypothesized that PD+ICB as a group would be more novelty 
seeking than PD-ICB patients on a task which allows for exploration of novel options.   
PD+ICB and PD patients without ICB (PD-ICB) were tested on and off their 
dopaminergic medication on a modified “three armed bandit” choice task (Wittmann, 
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Daw et al. 2008), where all participants played for real money. Results of PD-ICB and 
PD+ICB patients on and off their medication were compared with a group of healthy 
controls who were matched for age and education to the patients group.  
Patients and methods 
 
PD patients were recruited from a database of attendees at the National Hospital for 
Neurology and Neurosurgery Queen Square, London. All patients fulfilled the Queen 
Square Brain Bank criteria for the diagnosis of PD (Gibb and Lees 1988) and were 
taking L-dopa medication. Patients with structural lesions on their brain scans were 
excluded from this study.  Some of the patients had also had raclopride PET scanning 
and results of this study are presented elsewhere. (O’Sullivan et al, Brain 2011).  All 
patients showed a significant improvement (>35% improvement) after L-dopa intake 
which was assessed by the UPDRS (part 3) motor score. There was no significant 
difference in UPDRS motor scores between the 2 patient groups. L-dopa equivalent 
units (LEU) of patients’ regular daily dopamine replacement therapies were calculated 
as described elsewhere (Evans, Katzenschlager et al. 2004).  Controls were usually 
recruited from amongst the patient’s spouses or partners. Participants who provided 
written informed consent to protocols approved by the UCLH Trust local ethics 
committee were included.  Patients who scored under 27/30 points on the Mini Mental 
State Examination (MMSE) (Folstein, Folstein et al. 1975) were excluded from this 
study.  
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Twenty seven PD+ICB and 25 PD-ICB patients were recruited and results were 
compared with 24 healthy controls. PD+ICB patients were diagnosed using proposed 
criteria (Lawrence, Evans et al. 2003, Evans, Katzenschlager et al. 2004, Voon, Potenza 
et al. 2007). Most PD+ICB patients had more than 1 ICB. The ICBs included 
compulsive sexual behaviour (12 patients), pathological gambling (11 patients), 
compulsive buying (8 patients), punding (4 patients) and kleptomania (1 patient).  
Novelty task 
A three-armed bandit task, modified from the “four armed bandit choice task” used 
previously  was performed (Wittmann, Daw et al. 2008).  The task was administered on 
a laptop computer.  Participants performed 60 trials of the task.  In each trial three black 
and white picture post-cards were presented on the screen (Figure 11). After 
presentation of the pictures, the participant was required to select one of the three 
pictures, and after the option was selected, they were told whether they had “won” or 
“lost”.  Auditory feedback (5 Khz for winning and 2.5 Khz for losing) to reinforce 
feedback learning was provided.  Following an inter-trial interval, during which the 
screen was blank, the participants were again presented with the 3 choice options and 
they could make another decision.  The location of each picture was randomized from 
trial to trial to prevent habituation.  The participants were told to pick the most often 
rewarded picture as many times as possible to maximize their winnings.   
During the task, as the participants were making their choices and learning the reward 
value of the pictures, novel stimuli were introduced. This was done by replacing one of 
the images from which participants had been choosing with a new image, which was 
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then a novel choice option.  A novel choice option was introduced on 20% of trials, or 
on average every 5 trials.  These novel choices were of two types - unfamiliar and 
familiar. 
 
Figure 11. Sequence of events in 3-armed bandit task.   
After familiarization, participants were asked to choose one of the three pictures. 
Images were presented at randomized positions that changed on each trial. 
Unfamiliar and familiar pictures appeared during the test. Participants were told 
that each picture had some probability of winning 20p and participants should pick 
the rewarded picture as many times as possible. Visual and acoustic feedback was 
given immediately after each trial. 
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Unfamiliar stimuli were images that the patients had never seen before, whereas familiar 
stimuli were images that the patients had seen in pre-task training.  It is important to 
note that both unfamiliar and familiar images refer to pictures that were introduced into 
the on-going 3-armed bandit task, replacing one of the pictures that the participants had 
been selecting from.  Familiarization was done by sending 18 black and white pictures 
to participant’s homes prior to the experiment, and asking them to guess which country 
each picture was taken from. I called all participants prior to testing to ensure that 
participants were familiar with the set of images. On the day of testing and prior to each 
session I familiarized participants again. Different sets of pictures were used for each 
session.  Therefore, participants were re-familiarized with nine of the 18 pictures prior 
to the first session, and the other nine pictures prior to the second session.  Pictures were 
counterbalanced from the set with which the subjects were familiarized across 
medication conditions, so approximately half the subjects were familiarized with one 
half the pictures for their medicated session, and the other half of the subjects were 
familiarized with the other half of the pictures for their medicated session.  None of the 
subjects knew the purpose of familiarization. There were no differences in reward 
values between familiar and unfamiliar pictures in the choice task.  At the beginning of 
each of the two choice experiments, in the first trial, all participants were asked: “which 
picture is unfamiliar?” They all recognized the unfamiliar image among the three in the 
first trial.    
PD patients were tested prior and after their usual anti-Parkinson medication in a 
counterbalanced sequence to account for order effects. All patients who were tested in 
their “off medication state” did not take their usual anti-Parkinson medication, including 
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both L-dopa and any dopamine agonists, for at least 12 hours. Results were compared 
with 24 controls who were matched for age to the PD+ICB group. Patients who were 
tested first prior to their usual anti-Parkinson medication (“off medication”) performed 
the task between 8.00am and 9.00am. They were then retested in their “on medication” 
state one hour after taking their first dopaminergic medication of the day.  Those 
patients who were tested “on medication” first performed this task usually in mid-
morning when their motor symptoms were well controlled. They were re-visited on the 
following day prior to their medication for the second test. Controls were tested in the 
same way but did not take any anti-Parkinson medication. At the end of the study all 
participants got a modest amount of money depending on their final score (usually £5-
£10).  
Statistical analysis 
Statistical analyses were performed using SPSS, version 18.  For the demographic 
variables, age, gender, years of education, age of disease onset UPDRS scores, LEU 
dose were used as dependent variables and group (PD-ICB, PD+ICB and control) was 
modelled as a between subject factor.  ANOVA, t-test or χ 2  test was used where 
appropriate. For the behavioural variables models were fit to the choice data of 
individual participants to parameterize the value they assigned to novel stimuli, which in 
effect characterized the probability that they would select a novel stimulus.  A higher 
value indicates a higher probability of selecting a novel stimulus.  An ANOVA was then 
fit to the parameters derived from the model comparing the effect of novel stimuli in PD 
and ICB groups off and on medication.   
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Reinforcement learning model 
A reinforcement learning model was also fit to the choice behaviour of the subjects to 
assess whether or not they were disposed to selecting novel stimuli.  This model 
computes the value of a novel stimulus, to the participant, before it has had any reward 
feedback.  In general, the model updates the value, v, of the chosen option, i, based on 
reward feedback, r in trial t as: 
  vi(t) = vi(t -1) + α(r(t) - vi(t -1)). 
Thus, the new value of an option is given by its old value, vi(t-1) plus a change based on 
the reward prediction error (r(t)-vi(t-1)), multiplied by the learning rate parameter, α.  
When a novel stimulus is introduced in trial t, there is no reward history.  The value of 
that image to the participant can be interfered, by examining how often the participant 
picks that image, relative to how often they pick the other options with known reward 
histories.  Thus,  it is possible to fit, vi(t), where t = the first trial for a novel option, i, as 
a free parameter.  Different parameters, vi(t), for example vfamiliar(t) and vunfamiliar(t) were 
fit, to allow us to examine the effects of familiarization on the initial values.   
Effectively the participants will have some on-going value estimates of the options, i, 
and the relative propensity of the participants to pick the novel option allows us to 
estimate the value of that option relative to the other options.  If participants tend to pick 
the novel option, it implies that new options are relatively more valuable than the other 
options, with which the participant has some experience.  The model is fit by 
maximizing the likelihood of the choice behaviour of the participants, given the model 
parameters.  Specifically, the choice probability di(t) was calculated using:                  
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                            exp(vi(t)) 
          di(t) =        
                          ∑3   exp(vk(t)) 
                           
        k=1 
                      
And then calculate the log-likelihood as 
                                           T                a 
ll = ∑  log ∑  ck(t)dk(t),
 
                                          t=1            k=1 
Where ck(t)=1 when the subject chooses option k in trial t and ck(t)=0 for all unchosen 
options.  Thus, ck(t) is an indicator variable which selects the choice probability dk that 
corresponds to the choice the subject made in trial t, such that the log-likelihood is 
summed over the chosen options across trials.  In other words, the model maximizes the 
choice probability (dk(t)) of the actual choices the participants made.  T is the total 
number of trials in the session for each participant.  Parameters were maximized using 
standard techniques (Averbeck and Duchaine 2009). 
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Results 
Demographic characteristics 
There was a significant effect of age between the 3 groups (F(2,73)=7.58, p=0.001).  Post 
hoc analysis revealed that the PD-ICB group was older than the PD+ICB (p=0.001) and 
a trend to be older than the control group (p=0.055). There was no difference between 
controls and PD+ICB patients (p=0.54). Further, PD+ICB patients had a significantly 
younger age of disease onset (t49=3.39, p=0.001). There was no difference in the LEU 
dose, disease duration, UPDRS motor score (part 3) and years of education across the 
groups (Table 10).  Of note, 15 out of 27 PD+ICB patients and 5 out of 25 PD-ICB 
patients tested report a sweet tooth, and these proportions were significantly different (χ2 
= 6.9, p = 0.009).  All patients had an excellent response to L-dopa and improved by 
more than 35% on the UPDRS (part 3) motor score in their ‘on state’ compared to their 
‘off state. There was no significant difference in UPDRS motor scores between the two 
patient groups . There was also no difference in MMSE scores between the patient 
groups, t(50)=0.56, p=0.57 (mean MMSE scores in the PD+ICB group=28.7 vs PD-
ICB=28.9). Further all patients were tested on a stroop task which showed no difference 
between impulsive and non-impulsive PD patients. Thus, the PD+ICB and PD-ICB 
groups were matched for disease duration and other variables, but differed in age.  
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 Controls PD+ICB PD-ICB t value, χ 
2 
 and 
F-value 
p-value 
Participants (no) 
 
Age (yrs) 
 
Gender (male) 
At disease onset 
24 
57.8 ± 10.7 
14 
 - 
27 
54.2 ± 9.2 
22 
44.1 ± 8.7 
25 
64.2 ± 8.0 
21 
52.8 ± 9.5 
 
F = 7.6  
χ 
2 
= 5.2  
t = 3.2 
 
0.001* 
0.073 
0.001* 
Disease duration (yrs) 
 
Education (yrs) 
 - 
13.2 ± 2.9 
10.2 ± 5.5 
13.4 ± 3.0 
11.4 ± 7.2 
14.7 ± 3.5 
t = 0.68 
F = 1.5  
0.5 
0.23 
LEU dose(mg/day) 
DA (patients) 
- 
- 
832 ± 425 
14 
805 ± 400 
16 
t = 0.2 
χ 
2 
= 3.7 
0.8 
0.4 
UPDRS on 
UPDRS off 
Improvement in 
UPRDS (%) 
- 
- 
 
- 
16.6 ± 9.4 
27.3 ± 9.0 
 
39.2 
14.4 ± 5.8 
26.9 ± 6.7 
 
46.4 
t = 0.8 
t = 0.19 
0.4 
0.85 
Table 10. Novelty task: Demographic characteristics.  
All values are mean ± SD.  Significant differences are labelled with “*”.      
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Analysis of Novelty task 
An ANOVA on the PD and PD+ICB groups was carried out, with main effects of group, 
medication, and image familiarization, to assess whether or not there were differences in 
choice patterns for novel stimuli (Figure 12). An age covariate was included in all 
ANOVAs.  There was a main effect of group (F(1, 45) = 7.03, p = 0.011), such that ICBs 
selected novel stimuli whether they were unfamiliar or familiar more often than PDs 
(Figure 12A).  The main effect of medication showed a non-significant trend (F(1, 45) = 
3.2, p = 0.076) with patients on medication being less likely to select novel images.  
There was however no effect of unfamiliar relative to familiar new images (F(1, 45) = 
1.63, p = 0.205), and there were no significant interactions.  The effects of medication in 
PD patients with and without ICBs was examined by running separate ANOVAs within 
each group, with main effects of medication and image familiarity.  There was no 
significant effect of medication in the PD group (F(1, 24) = 0.84, p = 0.364) or in the ICB 
group (F(1, 21) = 2.59, p = 0.112).  Next, the 4 clinical groups (PD and ICB off and on 
medication) were comapred pair-wise with the control group (Bonferroni corrected).  
The ICB group off (F(1, 38) = 10.75, p = 0.002) and on (F(1, 38) = 4.86, p = 0.034) 
medication selected novel stimuli more often than controls.  The PD group did not differ 
significantly from controls off or on medication.   
In the final analysis the learning rate parameter, which measures the extent to which 
subjects integrate feedback to update their decisions was assessed (Figure 12B).  There 
were, however, no significant differences after controlling for the effects of age (F(1, 45) = 
1.91, p = 0.174). 
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Figure 12. Novelty seeking task: Behavioural results. 
A. Weight given to unfamiliar and familiar novel stimuli by each group of subjects.  
Off indicates off medication, on indicates on medication.  Unfamiliar refers to stimuli 
with which the subjects had not seen prior to the choice task and familiar refers to 
stimuli with which subjects had seen. Inset shows residual of ANOVA model.  B. Values 
for learning rate parameter for each group. 
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Discussion 
Results demonstrated that PD+ICB patients were more attracted to newly introduced 
pictures, than either the PD-ICB patients or normal controls, regardless of their 
medication status and across a group of ICBs with various diagnoses. This was true 
regardless of whether the novel picture came from the set with which the patient had 
been familiarized (familiar) or from the set with which the patient had never seen before 
(unfamiliar). This result is consistent with previous studies which have shown high 
novelty seeking personality traits in PD patients with DDS (Evans, Lawrence et al. 
2005) and patients with pathological gambling (Voon, Thomsen et al. 2007) using self-
rating questionnaires.  Although self-rating questionnaires are helpful in diagnosis they 
must be interpreted with care, especially in patient groups where insight may be low, 
such as PD patients with ICBs (Ferrara and Stacy 2008, Lim, Evans et al. 2008), and 
patients with substance abuse (Goldstein, Craig et al. 2009).  PD+ICB patients  are also 
known to have significantly higher schizotypy scores than PD patients without ICBs 
(Housden, O'Sullivan et al.) another factor known to reduce the validity of 
questionnaires (Lenzenweger 2010).  Thus, results of this study bring novelty seeking 
into an explicit metric framework using a task with a known neural substrate (Wittmann, 
Daw et al. 2008). 
fMRI studies using a four option choice task have shown that activation of the ventral 
striatum significantly correlated with reward predication errors and exploring novel, 
unfamiliar stimuli (Wittmann, Daw et al. 2008).  An increase in ventral striatal 
dopamine levels, measured with PET, has been demonstrated in the PD+ICB group in 
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response to medication, gambling and reward-related cues (Steeves, Miyasaki et al. 
2009, O'Sullivan, Wu et al. 2011). Related work has shown reduced levels of the 
dopamine transporter (DAT) in the ventral striatum of PD patients who had pathological 
gambling relative to a control group of PD patients without pathological gambling 
(Cilia, Ko et al. 2010).  Reduced membrane DAT levels could lead to the increased 
synaptic dopamine levels.  Thus, converging evidence suggests increased ventral-striatal 
dopamine levels in the PD+ICB group.  In some cases, this increased dopamine 
signalling appears to contribute to increased sensitivity to behaviours mediated by the 
ventral striatum, including temporal discounting (Voon, Reynolds et al. 2009) and 
feedback learning (Voon, Pessiglione et al. 2010).  Also consistent with this, many of 
the PD+ICB patients tested report a sweet tooth with a penchant for chocolate, and a 
recent study has shown an association between sweet liking, novelty seeking and 
addictive behaviour (Lange, Kampov-Polevoy et al. 2010). 
In spite of the data which suggests that increased dopamine levels contribute to 
impulsivity in PD, there was no effect of acute changes in dopamine levels on novelty 
seeking in the current study.  This suggests that the mechanism that mediates novelty, as 
has been operationalized, may be unrelated to acute changes in dopamine levels brought 
about by withholding medication for at least 12 hours. Thus, long-term changes brought 
about by chronic increases in dopamine levels, rather than an acute change of dopamine 
level, might trigger novelty seeking behaviour in PD.  This is one factor which may 
account for differences between our study and a previous study which found increased 
novelty seeking in PD-ICB patients after dopamine agonist therapy (Bodi, Keri et al. 
2009).   Thus, the effects seen in the Bodi et al. study may be mediated by chronic 
144 
 
changes in levels of dopamine stimulation, as opposed to the acute changes that was 
used here.  Specifically, the Bodi et al. study compared a group of never medicated 
patients, to a group of patients medicated for periods of several months with dopamine 
agonists.  There are other important differences between the Bodi et al., study and this 
study.  First, patients in this study were treated with a combination of dopamine agonists 
and L-Dopa, as opposed to just dopamine agonists.  When patients were tested off 
medication, both the dopamine agonists and the L-dopa were withheld, but only acutely.  
Second, the study of Bodi et al., found increased novelty seeking using self-report 
questionnaires, as opposed to a metric behavioural task.  It is not clear that self-report 
questionnaires and metric behavioural tasks measure the same construct.  Thus, the 
inconsistencies between the study of Bodi et al. and this study are likely due to 
methodological differences. 
Although participants were pre-trained on a set of pictures, so that novel stimuli could 
be either unfamiliar or familiar, these manipulations reached only trend levels and were 
not significant, unlike previous studies (Wittmann, Daw et al. 2008).  It is possible that 
the pre-training was not sufficient in this group of elderly participants, as there was also 
no an effect in matched controls, although, participants were all able to identify the 
novel picture in the first trial of the task.  All participants scored higher than 27 on the 
MMSE examination and were non-demented. Therefore,  it unlikely that they were not 
able to remember 9 pictures prior to each session. Additional exposure to the pictures 
may have been useful, however, in finding an effect of unfamiliar versus familiar 
images.  It is also possible that familiarity biases are smaller in elderly adults, and that 
more extensive training might not overcome this. 
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Results have shown that impulsive PD patients are more novelty prone.  However, 
animal studies have used outbred rats to separate novelty seeking, operationalized as an 
increased locomotor response in a novel environment, and impulsivity, operationalized 
as premature responses in a serial reaction time task (Belin, Mar et al. 2008).  This study 
found that rats prone to novelty seeking tended to acquire cocaine self-administration 
more readily than their impulsive counter-parts, whereas impulsive rats tended to 
convert to compulsive drug use more readily than their novelty seeking counterparts.  
This suggests that the combination of these traits would lead individuals to be 
particularly prone to developing addictive behaviour.  Novelty seeking could lead, for 
instance, to playing slot machines, which is not only the most commonly played gamble 
in PD but is considered to be the “crack cocaine” of gambling with the highest addictive 
potential (Dowling, Smith et al. 2005).  Novelty seeking could lead to initiation of a 
potentially addictive behaviour, which then turns into addiction as a consequence of  an 
impulsive personality trait. 
Conclusion 
In summary increased novelty seeking in all PD+ICB patients was found using a 3 
option choice task.  Overall, these results are consistent with the hypothesis, that the 
ventral striatum underlies novelty seeking, perhaps due to input from the hippocampus.  
Additional work within this setting may further clarify the role of the ventral striatum in 
various choice behaviours and in social processing. 
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Key Findings 
o All PD patients with ICBs were more novelty seeking than PD patients 
without ICBs and healthy controls. 
o Dopaminergic medication had no effects on novelty seeking in PD 
patients, suggesting that increased novelty seeking in the ICB patients 
might be a personality trait.  
o There was no difference in feedback learning across the groups.  
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Introduction 
Although not necessarily maladaptive, impulsive decision making is often linked with 
addiction and has been reported in patients with substance abuse and pathological 
gambling (Simon, Mendez et al. 2007, Michalczuk, Bowden-Jones et al. 2011). It is also 
seen in PD patients who develop ICBs on dopaminergic medication (Voon, Reynolds et 
al. 2010). It remains unclear why some PD patients are predisposed to ICBs, but 
identified risk factors include younger age of disease onset, male gender and a 
premorbid or family history of substance abuse. ICBs have also been associated with 
‘behavioural addictions’ (Stacy 2009) sharing clinical withdrawal symptoms of 
dysphoria, depression and anxiety with substance abuse (Koob and Volkow 2010, van 
Eimeren, Pellecchia et al. 2010). Functional imaging studies have demonstrated  
aberrant striatal dopaminergic “reward pathways” and altered function in frontal cortical 
regions in PD+ICB and non-PD patients with addictive behaviours (Potenza 2008, 
Dagher and Robbins 2009, Koob and Volkow 2010). 
The ‘beads task’ (Huq, Garety et al. 1988) was used to compare decision making in PD 
patients with and without ICBs, pathological gamblers and substance abusers. In 
addition to the MMSE, a WM task was included to assess whether impairments in 
decision making reflected a more generalized cognitive deficit. The beads task assesses 
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how much information participants gather before making a decision that has been 
referred to as  “reflection impulsivity” (Evenden 1999, Clark, Robbins et al. 2006). This 
differs from ‘motor’ impulsivity, the inability to stop an on-going process and from 
‘waiting’ impulsivity, the inability to delay an action (Dalley, Everitt et al. 2011). Early 
decision on the beads task or ‘jumping to conclusions’ has been also seen in patients 
with schizophrenia (Fine, Gardner et al. 2007). Delusional patients gather minimal 
further information in situations where more information is available and yet are highly 
confident with their decisions (Warman, Lysaker et al. 2007). The advantage of using 
the beads task in assessing decision making processes is that this task is emotionally 
neutral which ensures that general reasoning is being studied and not decision making 
under salient conditions (Warman, Lysaker et al. 2007). In a modified version of this 
task a positive association between impulsivity and problem gambling or recreational 
gambling has been reported (Mishra, Lalumiere et al. 2010).  
The prediction was that all impulsive patient groups would jump to conclusions and that 
PD+ICB patients would perform similarly to illicit substance abusers and make choices 
which were more impulsive than PD-ICB. Another hypothesis was that both PD groups 
would perform worse than matched controls and that gamblers would gather less 
information than the PD-ICB group. 
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Patients and methods 
All participants provided written informed consent according to the declaration of 
Helsinki and the study was approved by the UCLH Trust and the University of Lvov 
ethics committee. 
PD and elderly control groups 
Twenty seven PD-ICB and 26 PD+ICB patients were recruited from the National 
Hospital for Neurology and Neurosurgery, Queen Square, London. All patients fulfilled 
the Queen Square Brain Bank criteria for the diagnosis of PD (Gibb and Lees 1988) and 
were taking L-dopa. Twenty-one of 27 PD-ICB patients were taking a dopamine 
agonist, whereas only 13 of 26 PD+ICB patients were still on a dopamine agonist. 
Eighteen healthy elderly volunteers, mainly the PD patient’s spouses or partners, 
matched for age, gender and education were recruited. Patients who scored under 26 of 
30 points on the MMSE were excluded. All participants were screened for sub-classes of 
ICBs in a semi-structured interview, using accepted diagnostic criteria for pathological 
gambling (American Psychiatric Association 2000), compulsive shopping (McElroy, 
Keck et al. 1994), compulsive sexual behaviour (Voon, Hassan et al. 2006) and punding 
(Evans, Katzenschlager et al. 2004). A self-rated validated questionnaire for impulsive 
compulsive disorders in Parkinson’s disease (QUIP) was also used (Weintraub, Hoops et 
al. 2009) (see appendix). 
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PD patients performed the beads test only on medication to minimize off dysphoria and 
anxiety (Lim, Evans et al. 2008).  
For the working memory task, patients were tested both off and on medication, in a 
counterbalanced order. Patients, who were tested off medication did not take their anti-
Parkinson medication for at least 12 hours and performed the task between 8.00 a.m. 
and 9.00 a.m. They were then retested in their on medication state the following day, 
usually mid-morning. Those patients who were tested on medication first performed this 
task usually in mid-morning when their motor symptoms were well controlled. They 
were revisited on the following day prior to their medication for the second test. Elderly 
controls were tested in the same way but did not take any anti-Parkinson medication. 
The therapeutic motor response to L-dopa was assessed by UPDRS (part 3) scores 
during “off” and “on” state. All PD patients had an excellent L-dopa response.   
L-dopa equivalent units (LEU – Table 11) were calculated as described previously 
(Evans, Katzenschlager et al. 2004). 
Pathological gamblers, substance abusers and matched controls 
All these patient groups were tested only once usually mid-morning. Twenty-three 
patients with pathological gambling, according to DSM-IV criteria (American 
Psychiatric Association 2000) were recruited from the National Problem Gambling 
Clinic, UK. None had a current history of substance abuse, one patient had taken illicit 
drugs in the past but not in the 3 months prior to testing. All gamblers had stopped 
gambling only recently. Thirteen patients with a recent history of illicit drug abuse, 
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meeting DSM-IV criteria for substance dependence (American Psychiatric Association 
2000) were also tested. Patients were recruited from the Replacement Therapy Unit of 
Lviv, regional Clinical Narcological Dispensary and were receiving buprenorphine. 
None fulfilled DSM-IV criteria for dementia. Twelve out of 13 patients had a long 
standing history of intravenous opioid abuse, for a detailed list of drugs of abuse see 
Table 10.  
All the gamblers, who agreed to participate in this study and 12/13 of the illicit 
substance abusers, were males. Their results were compared with 18 age matched male 
controls.  
Beads task  
The beads task was performed on a laptop computer, usually in the participant’s home 
or in a quiet room to minimize distractions. Participants were required to guess from 
which of two cups coloured beads were being drawn. The cups differed in the 
proportion of blue and green beads they contained. For example, one of the cups may 
have contained 80% blue beads and 20% green beads, whereas the other cup may have 
contained 80% green beads and 20% blue beads.  
Participants were first shown a bead draw, which was either blue or green. They were 
then asked whether they wanted to draw another bead, or guess that the bead was being 
drawn from the predominantly green or blue cup (Figure 13). This was repeated until 
they chose to guess one of the cups. The behavioural measures of interest were the 
number of beads drawn before the participant guessed a cup and whether the cup choice 
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represented a rational (e.g. if more blue beads were drawn the participant guessed blue) 
or irrational (i.e. the cup colour guessed was not most probably correct, given the beads 
drawn) choice. This is referred to as opposite colour choice.   
Participants completed 4 blocks of 3 trials each. Two blocks contained an 80/20 ratio of 
beads and 2 blocks a 60/40 ratio of beads in each cup.  They won 10 units for correct 
choices. For incorrect choices they lost nothing in two blocks, or 10 units in two blocks. 
Thus there were four blocks: 80/20 loss of 10, 80/20 loss of 0, 60/40 loss of 10 and 
60/40 loss of 0. Participants were informed of the loss condition and beads ratio before 
each trial.   
They knew that they could draw up to 10 beads before making a decision. They were, 
however, “charged” 0.2 units for each additional draw, so additional draws reduced the 
amount they would win. After finishing the test participants received a monetary reward, 
depending on the units they accumulated during the experiment (usually between £8-
£15). The four conditions were presented in a randomized order. 
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A: The blue cup contained more blue beads than green beads, the green cup more 
green than blue beads. The computer drew from one of these cups and showed a 
coloured bead. Participants could then ask for up to 10 additional draws before 
deciding from which cup they thought the bead was drawn.    
B: Two different ratios were used. One 60/40 split where the ratio is closer to chance 
(above) and one 80/20 split (below).  
   A                                                                                                      B 
Figure 13.  Beads task. 
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To practice and explain the task, I brought two cups, with the blue cup containing more 
blue than green beads and vice versa for the green cup. The distribution in these cups 
resembled an 80/20 condition. Three practise trials were performed to make sure that all 
participants understood the rules.   
Statistical analysis 
For the behavioural variables analyses using a generalized linear model (SPSS) were 
performed because the dependent variables were counts and not continuous values. 
Beads ratio (80/20 or 60/40) and loss condition (loss, no loss), were modelled as fixed 
factors. Group (PD-ICB, PD+ICB, Control-Old, Control-Young, non PD gamblers and 
illicit substance abusers) was modelled as a between factor and participant was a 
random factor nested under group. Age was also included as a cofactor in the analysis of 
the beads data. However, it did not change any results and thus, all results were reported 
without it included.   
A further analysis was carried out in which the number of draws in the 80/20 condition 
was used to predict group membership, between PD+ICB and PD-ICB. The number of 
draws was submitted to linear discriminant analysis in SPSS, using leave-one-out cross 
validation and covariance matrices pooled across groups.  
For cross validation, one participant was pulled from the data, discriminant functions 
were calculated using the remaining participants, and then those discriminant functions 
were used to classify the participant which had been held out. This was repeated for all 
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participants. Thus, this analysis attempts to estimate how well a novel participant would 
be classified. 
Working memory task 
PD patients were tested prior and after their usual anti-Parkinson medication in a 
counterbalanced sequence to account for order effects. Twenty four trials of a WM task 
were completed on a laptop computer (Figure 14). Participants were asked to memorize 
either 2 or 3 geometric figures which were shown for 3 seconds on a black background, 
followed by a delay of 2 seconds.  
During the delay, distractor images were shown. Then another geometric figure was 
presented and participants were asked whether this figure was within the set that they 
had to remember before. In half of the trials (12 of 24) 2 geometric figures and in the 
other half 3 had to be remembered.  
Participants had to press either “Y” for yes or “N” for no. Distractors could be positive, 
neutral or negative images taken from the validated International Affective Picture 
System (Lang, Bradley et al. 2008).  
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Figure 14.  WM task. 
A: Participants were asked to remember either 2 or 3 geometric figures. 
B: Distractors, in this case neutral ones, were shown for 2 seconds. C. Another 
geometric figure was shown and participants were asked whether this figure was in 
the set that they had to remember before. 
At the end participants were shown 24 distractor images on a black screen and were 
asked whether they thought they had seen the images before. In half of the 24 trials 
distractors that had been used during the WM task were shown. Participants had to press 
“Y” for yes or “N” for no.   
Positive pictures had a valence above 6.4. Negative pictures had a valence below 3.1 
and neutral pictures had valence from 4.5 to 5.5 (Figure 15). Salient and neutral pictures 
contained mainly human characters. Both geometrical figures and distracters were 
presented in colour. Positive distractors contained food or sexual motives, negative 
pictures included scenes of violence.  
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Figure 15.  WM task: Positive and neutral distractors.  
Four Samples of neutral distractors (A) and 4 samples of positive distractors (B) 
shown during WM task. Negative distractors not shown. 
Analysis was done using a generalized linear model (SPSS) with a binary logistic 
function encoding whether the participant was correct or not on each trial. Distractor 
type (positive, neutral or negative), number of memoranda (either 2 or 3 geometric 
figures), choice and actual shown picture were modelled as fixed factors. Group (PD-
ICB, PD+ICB, Control-Old, Control-Young, pathological gamblers and illicit substance 
abusers) was modelled as a between factor and subject was a random factor nested under 
group. When analysing the recall of distractors, correct versus incorrect was again 
modelled as a binary dependent variable. Distractor type, choice, and whether the 
distractor was actually shown, were modelled as fixed factors, with group and subject 
modelled as described above. 
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Results 
Demographic characteristics 
Demographic variables (Table 11) were analysed using ANOVA, t-test or χ2 tests where 
appropriate. There were no differences between the control groups and the matched 
patient groups on any demographic variables. Significantly more PD-ICB (21 of 27) 
than PD+ICB (13 of 26) patients were taking a dopamine agonist (p = 0.024), which is 
in line with accepted clinical guidelines of managing an ICB in PD.  
Consistent with the literature PD+ICB patients had a significantly younger disease onset 
relative to PD-ICB patients (t52=3.28, p = 0.002). There was no difference in LEU dose, 
UPDRS (part 3) motor scores or disease duration between the PD groups. LEU doses 
were calculated as previously described (Evans, Katzenschlager et al. 2004) as followed: 
L-dopa dose + L-dopa dose × 1/3 if on entacapone + bromocriptine (mg) × 10 + 
cabergoline or pramipexole (mg) × 67 + ropinirole (mg) × 20 + apomorphine (mg) × 8. 
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 CO-O CO-Y PD+ICB PD-ICB Addicts Gambler t value, 
χ 2  and 
F-value 
p-value 
Participants(no.) 
 
18 18 26 27 13 23   
Age (yrs) 
 
 
58.9±12.
7 
33.2±5.5 58.7±10.0 65.3±5.3 32.0±7.1 38.0±9.3 F=58.8 <0.001* 
Gender (male) 15 18 22 24 12 23 χ 2=6.8 0.25 
At PD onset (yrs)   47.7±9.5 55.3±7.4   t=3.28 0.002* 
PD Disease duration 
(yrs) 
 
 
 
 
 
11.0±4.1 
 
10.0±6.5 
 
 
 
 
 
t=0.52 
 
0.48 
 
Education (yrs) 13.6±3.2 
 
13.9±2.2 
 
13.1±2.8 
 
14.8±2.5 
 
12.0±1.9 
 
14.5±2.0 
 
F=3.1 0.011* 
ICB current 
ICB (>3-12months) 
Gambling (yrs) 
Gambling  stopped 
(months) 
Drug abuse (yrs) 
Opioid therapy (yrs) 
 
 
 
 
 
20 
6 
 
 
 
 
 
 
 
12.0±5.1 
1.4±1.3 
 
 
12.1±7.4 
1.8±2.7 
 
 
 
LEU dose(mg/day)   934.2±407 740.1±369   t=1.8 0.072 
PD patients on DA 
(N) 
 
 
 
 
13/26 21/27  
 
 
 
χ 2=5.1 0.024* 
UPDRS on 
UPDRS off 
Improvement in % 
  16.2±10.6 
31.0±11.3 
47.7 
21.1±9.0 
32.1±10.6 
34.2 
  t=1.7 
t=0.5 
0.09 
0.6 
Hypersexuality 
PG  
Casino games 
Sport betting 
Stock markets 
Slot machines 
Bingo 
Scratch cards 
Punding 
Shopping 
Substance abuse 
i.v. opiods 
i.v.heroin 
cannabis 
cocaine 
morphine 
  12 
13  
- 
2 
- 
8 
4 
2 
7 
5 
3(past) 
 
 
 
 
3  
 
 
 
 
 
 
 
 
13 
12 
4 
3 
1 
1 
 
23 
15 
12 
2 
3 
- 
- 
 
 
1 (past) 
  
Table 11.  Beads task: Demographic characteristics.    
LEU = L-dopa equivalent units; DA = dopamine agonists.  All values are mean ± SD.  
Significant differences are labelled with “*”. Controls (CO-O, elderly controls; CO-Y, 
young controls), PD patients with (PD+ICB) and without (PD-ICB) impulsive 
compulsive behaviours, illicit substance abusers and pathological gamblers.  
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As expected there was a significant age difference between the younger participants 
(young controls, illicit substance abusers, pathological gamblers) and the older 
participants (PD groups and elderly controls; F(5,118)=58.8, p < 0.001). Post hoc analysis 
showed that the PD-ICB group was borderline-significantly older than the PD+ICB 
group (p = 0.10). There was no difference between the PD groups and the elderly 
control group (p > 0.22). There was a significant difference in years of education 
between the groups (F(5,108)=3.1, p = 0.011). Post hoc analysis showed that the PD-ICB 
and the pathological gambling groups had significantly higher education than illicit 
substance abusers (PD-ICB versus illicit substance abusers: p = 0.01, pathological 
gamblers versus illicit substance abusers: p = 0.047). There was no difference between 
the other groups (p > 0.29).   
QUIP questionnaires 
Consistent with previous studies (Weintraub, Hoops et al. 2009, Papay, Mamikonyan et 
al. 2011) results showed a high sensitivity to detect an ICB (96.1%) for both the patient 
and caregiver rated QUIP. A total of 40.7% of PD-ICB patients, who did not meet the 
diagnostic criteria for having an ICB, had at least one ICB symptom either self-rated or 
by their caregiver, consistent with a previous study (Papay, Mamikonyan et al. 2011). 
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Correlation of the QUIP and drawing behaviour 
There was no correlation between drawing behaviour on the beads task and scores on 
the QUIP for the PD-ICB group (r= -0.273, p = 0.2) or for the PD+ICB group (r= 0.69, 
p = 0.7). 
Beads task 
First, the number of draws each participant made in the different conditions was 
examined (Figure 16).  
Results showed a significant effects of group (Wald χ2 = 191.0, p < 0.001), beads ratio 
(Wald χ2 = 167.9, p < 0.001). There was also a significant beads ratio by loss condition 
interaction (Wald χ2 = 9.4, p = 0.002). There was no significant difference between the 
two control groups (Wald χ2 = 1.0, p > 0.3). Further, the correlations between age and 
number of draws in the control groups was examined but showed no significant effect 
(r=-0.15, p > 0.37). Thus, the two control groups were combined to simplify analyses.  
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Figure 16.  Beads task: Average number of draws per condition by group.  
One bead is always shown before the participant must make a decision, so total beads 
seen are mean draws plus one. 
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Pairwise comparisons between the control group, the PD+ICB group and the other 
groups were made to examine whether or not the PD+ICB group would perform similar 
to the other groups.  
Results showed significant group effects (always PD+ICBs drawing fewer than the other 
group) for PD+ICBs versus PD-ICBs (Wald χ2 = 27.1, p < 0.001), pathological gamblers 
(Wald χ2 = 13.9, p < 0.001) and controls (Wald χ2 = 75.1, p < 0.001). For completeness 
all other group comparisons were reported (See Table 12).  
Opposite colour choice 
Next, the number of times participants made an irrational choice, summed across all 
conditions was examined (Figure 17). There was a main effect of group (Wald χ2 = 72.1, 
p < 0.001) and therefore pairwise comparisons between groups were made. Again there 
was no differences between the two control groups (Wald χ2 = 0.07, p = 0.8), so they 
were combined.  
Pairwise comparisons showed that illicit substance abusers chose the opposite colour 
significantly more often than PD+ICBs (Wald χ2 = 12.2, p < 0.001) and PD+ICBs chose 
the opposite colour significantly more often than controls (Wald χ2 = 30.3, p < 0.001).  
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Table 12.  Beads task: Pairwise comparisons. 
Pairwise comparisons between groups for number of draws (above) and for opposite 
colour choices (below).  All p-values shown are uncorrected. Values less than 0.0125 
(highlighted in bold) for the PD+ICB group are significant. All p-values in this and 
subsequent tables are for main effect of group.  
 
Group 
(χ2, p-value) 
PD-ICB Illicit substance 
abusers 
Gamblers Controls 
PD+ICB   
Draws 
Opposite  
 
27.1, p < 0.001 
4.0, p = 0.044 
 
0.38, p = 0.53 
12.2, p < 0.001 
 
13.9, p < 0.001 
3.6, p = 0.055 
 
75.1, p < 0.001 
30.3, p < 0.001 
PD-ICB  
Draws 
Opposite  
  
13.4, p < 0.001 
29.4, p < 0.001 
 
0.45, p = 0.8 
0.001, p > 0.97 
 
65.1, p < 0.001 
15.0, p < 0.001 
Addicts 
Draws 
Opposite  
   
8.3, p = 0.004 
24.0, p < 0.001 
 
34.8, p < 0.001 
60.8, p < 0.001 
Gamblers 
Draws 
Opposite  
    
34.0, p < 0.001 
13.9, p < 0.001 
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Figure 17.  Beads task: Number of times participants chose the opposite colour.  
Classification of PD+ICBs on the basis of drawing behaviour 
Additional analyses were carried out in which the drawing behaviour of individual 
participants in the 80/20 loss condition was used to try to predict group membership 
between the PD+ICB and PD-ICB groups. Twenty-five out of 26 (> 96%) PD+ICB 
patients were correctly classified. Further, 44% of PD-ICB patients were also correctly 
classified as not having an ICB, giving a positive predictive value of 62.5% and a 
negative predictive value of 92.3%.  
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Working memory task 
First working memory performance was analysed (Figure 18). As there was no effect of 
medication within the PD-ICB (Wald χ2 = 0.16, p = 0.68) or the PD+ICB group (Wald 
χ2 = 0.24, p = 0.62) the PD-ICB and the PD+ICB groups were collapsed across 
medication. There was a significant effect of group (Wald χ2 = 24.0, p < 0.001), a 
significant effect of distractor type (Wald χ2 = 29.6, p < 0.001), and a borderline effect 
of working memory load (2 or 3 items) (Wald χ2 = 6.9, p = 0.08). 
Pairwise comparison showed that all groups performed better than substance abusers 
(Table 13). Results confirmed that there was no correlation between WM and beads 
performance across the groups (Pearson correlation=0.79, p > 0.4) or during pairwise 
comparisons. 
Next it was examined how well the groups recalled the distractors that had been used 
during the working memory task (Figure 19). There was a main effect of group for 
remembering distractors in the WM task (Wald χ2 = 59.7, p < 0.001) and pairwise 
comparisons showed that PD+ICB patients (Wald χ2 = 7.2, p = 0.007) and pathological 
gamblers (Wald χ2 = 15.4, p < 0.001) remembered distractors significantly better than 
PD-ICB patients. Again, there was no effect of medication within the PD-ICB (Wald χ2 
=0.18, p > 0.9) or the PD+ICB groups (Wald χ2 =1.2, p = 0.26) so the PD-ICB and the 
PD+ICB groups were collapsed across medication (see Table 14).   
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Figure 18.  WM performance.   
Plot shows fraction of correctly remembered images for each group, as a function of 
distractor type. 
 
 
168 
 
 
 
 
 
 
Group 
(χ2, p-
value) 
PD-ICB Addicts Gamblers Controls 
Old 
Controls 
Young 
PD+ICB 2.05,p = 0.15 7.2,p =  0.007 0.3, p > 0.58 4.3, p = 0.038 0.74, p = 0.38 
PD-ICB  17.0,p < 0.001 0.44, p > 0.5 0.86, p > 0.35 0.1, p > 0.74 
Addicts   9.3, p = 0.002 18.8,p < 0.001 10.1, p = 0.001 
Gamblers    1.9, p = 0.16 0.78, p > 0.7 
Controls 
Old 
    1.1, p > 0.28 
Table 13.  WM task: Pairwise comparisons for WM performance.  
All p-values shown are uncorrected.  Values less than 0.0125 (highlighted in bold) 
for the PD+ICB group are significant. All p-values in this and subsequent tables are 
for main effect of group.  
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Figure 19.  WM task: Remembering distractors (positive, neutral, negative).    
Plot shows fraction of distractors that were recognized when tested following the 
working memory task. 
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Table 14.  WM task: Pairwise comparisons for recalling the distractors.  
All p-values shown are uncorrected. Values less than 0.0125 are significant and 
highlighted in bold for PD patients with ICBs. 
Group 
(χ2, p-
value) 
PD-ICB Addicts Gamblers Controls Old Controls 
Young  
PD+ICB 22.8,p < 0.001 0.6, p > 0.4 12.2, p < 0.001 5.1, p = 0.023 0.002, p > 0.9 
PD-ICB  10.1, p = 0.001 59.8, p = 0.001 2.4, p = 0.1 15.8,p < 0.001 
Addicts   13.8, p < 0.001 1.6, p = 0.2 0.46, p = 0.5 
Gamblers    24.3, p = 0.001 8.2, p = 0.004 
Controls 
Old 
    3.7, p = 0.055 
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Sensitivity of the beads task versus the QUIP in detecting impulsive 
behaviours in PD 
Both, the QUIP and the beads task show a high sensitivity to detect a current or past 
history of ICB in PD (>96%). Using the QUIP questionnaire around 41% PD patients 
without an ICB, had at least one ICB symptom which is in line with studies using a 
larger sample size (Papay, Mamikonyan et al. 2011).  
In contrast using the beads task 56% of PD-ICB patients were classified as being 
impulsive and the minority was classified as being non-impulsive. Consistent with this 
classification are the results of this study, which demonstrate that non-impulsive PD 
patients resembled pathological gamblers who were waiting to be treated.  
Of particular interest is, however, that all PD-ICB patients were also treated with a 
dopamine agonist and it is possible that a proportion of these patients will develop an 
addictive in the future. My results suggest that the beads task may be an even more 
sensitive tool than the QUIP to detect subclinical impulsivity in PD. A disadvantage of 
the QUIP rating scale is that it does not assess the severity of the addictive behaviour. 
However, at this point the sample size of PD patients with and without ICBs tested on 
the beads task is too small to confirm this hypothesis. Therefore, a prospective study in 
drug naïve PD patients is currently underway and a multicentre study in a larger cohort 
of PD patients with and without ICBs is planned to address this question.   
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Discussion 
In this study, ‘reflection impulsivity’ was examined using the beads task, an information 
gathering paradigm in which participants controlled the amount of information they 
gathered before making a decision (Furl and Averbeck 2011). PD patients with and 
without ICBs, pathological gamblers and substance abusers were compared and results 
showed evidence for impairment even in treated PD patients without clinically apparent 
ICBs. Across groups results showed an effect of the beads ratios, such that participants 
drew more when the beads ratios were closer to chance (60/40) than when the ratio was 
greater between the cups (80/20). In addition, the loss condition interacted with the 
beads ratio condition, such that subjects drew relatively more in the higher loss 
conditions.  
Despite all groups showing behaviour adaptive to the specific condition, the PD+ICB 
group drew significantly fewer beads than controls, PD-ICBs and pathological gamblers 
before making a decision. Significantly less PD+ICB than PD-ICB patients were taking 
a dopamine agonist and yet they still gathered less information. The fact that the 
PD+ICB group drew fewer beads than pathological gamblers is interesting, given that 
half of the PD+ICB patients had clinically defined pathological gambling. Slot 
machines, scratch cards and bingo were the most commonly played gambles in PD. 
Pathological gamblers preferred skilled games, such as spread betting and electronic 
casino games (Gallagher, O'Sullivan et al. 2007, Wardle, Sproston et al. 2007). This 
difference in the type of preferred gambling may be of relevance in the interpretation of 
the results. 
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Direct comparison between groups on the beads task suggests greater similarities 
between PD+ICB patients and illicit drug abusers, compared to the pathological 
gamblers or PD-ICB patients. PET studies have shown sensitization of the ventral 
striatum in PD+ICB patients (Evans, Pavese et al. 2006, Steeves, Miyasaki et al. 2009) 
and also in patients with substance abuse (Dagher and Robbins 2009, Kaplan, Leite-
Morris et al. 2011). Furthermore, ‘reflection impulsivity’ does not recover, even after 
prolonged abstinence in substance abusers (Clark, Robbins et al. 2006). This is 
consistent with the fact that dopamine agonists have often been withdrawn for a long 
period in the PD+ICB group, leading to alleviation of impulsive symptoms, and yet they 
still make impulsive choices in the beads task. PD+ICB patients also become irritable 
when their addictive behaviour is restricted (Evans, Katzenschlager et al. 2004, Evans, 
Strafella et al. 2009), reminiscent of withdrawal symptoms in drug abusers. 
Analysis of the QUIP revealed that 41% of PD-ICB patients had at least 1 symptom of 
an ICB, either self-rated or rated by their caregiver consistent with previous studies 
(Papay, Mamikonyan et al. 2011). Using the beads tasks 56% of PD-ICB patients were 
classified as having tendencies towards impulsivity, suggesting that this task may be a 
more sensitive screening tool to detect hidden impulsive traits. Consistent with this, 
there was no difference in the behavioural pattern between PD-ICB patients and 
pathological gamblers. This finding is particularly interesting, because none of the 
gamblers had received any treatment for their impulsivity and none of the PD-ICB 
patients had clinically defined ICBs. Further, PD-ICB patients also drew significantly 
less than matched controls.   
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Several studies have demonstrated increased impulsivity and changes on behavioural 
tasks in PD-ICB patients after starting dopaminergic medication (Cools, Barker et al. 
2003, Frank, Seeberger et al. 2004, Bodi, Keri et al. 2009) in contrast to treatment naïve 
PD patients who perform similarly to controls (Poletti, Frosini et al. 2010). Whether 
impulsivity arises as a result of increased impulsive drive, decreased inhibitory control 
or a combination of both is still unclear. However, the results in the PD-ICB group 
could reflect an underlying increased impulsivity driven by excessive dopamine levels 
in the ventral striatum. In PD, there is much less dopamine loss in the ventral than the 
dorsal striatum (Gotham, Brown et al. 1988). Therefore, treatment with dopaminergic 
medication to increase dopamine levels in the dorsal striatum may lead to excessive 
levels in the ventral striatum. This may result in a tendency, in all treated patients, to 
increased impulsivity, which, however, does not manifest as clinically significant 
impulsiveness due to intact inhibitory cortico-striatal pathways. Hypoactivation of the 
orbitofrontal cortex is seen in pathological gamblers, illicit substance abusers (Potenza 
and Winters 2003, Volkow, Fowler et al. 2004) and in treated PD+ICB patients, but not 
in PD-ICB patients (van Eimeren, Pellecchia et al. 2010). The ventromedial plus the 
orbitofrontal part of the prefrontal cortex is important for impulse control (Bechara, 
Tranel et al. 2000, O'Doherty, Kringelbach et al. 2001, van Eimeren, Pellecchia et al. 
2010) and is associated with ‘jumping to conclusions’ on the beads task (Lunt, 
Bramham et al. 2012). Thus, intact inhibitory control driven by these cortical areas 
might prevent PD-ICB patients from clinical impulsivity (van Eimeren, Pellecchia et al. 
2010). 
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Jumping to conclusions can also occur in psychosis (Garety and Freeman 1999). In line 
with this, previous work has shown that PD+ICB participants score highly on measures 
of schizotypy, a personality trait related to psychosis (Housden, O'Sullivan et al. 2010). 
Delusional thinking, defined as a belief based on incorrect inference (American 
Psychiatric Association 2000), has been reported in PD+ICB patients (Gallagher, 
O'Sullivan et al. 2007, Wolters, van der Werf et al. 2008) and has been positively 
correlated with fewer draws on the beads task in delusional patients with and without 
schizophrenia (Fine, Gardner et al. 2007). Both PD groups also guessed the opposite 
colour more often than controls and anecdotally some stated that they “anticipated” that 
the opposite colour was more likely and therefore chose the less likely cup. Others said 
“that the computer tried to trick me, so I chose the opposite cup to outsmart the 
computer”. In fact there was no group difference between the PD group and patients 
with pathological gambling. However, patients with substance abuse chose the opposite 
colour significantly more often than all other groups. Excessive dopamine levels in the 
associative striatum have been consistently reported in PET studies in patients with 
schizophrenia (Abi-Dargham, Gil et al. 1998, Kegeles, Abi-Dargham et al. 2010). 
Substance abuse is relatively common in schizophrenia (Gut-Fayand, Dervaux et al. 
2001) and patients with schizophrenia are also more impulsive than matched controls 
groups (Enticott, Ogloff et al. 2008).  
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Early decisions in this task are also not likely related to temporal discounting. The 
standard temporal discounting task (Voon, Reynolds et al. 2010) is more closely related 
to self-report questionnaires than metric tasks, and measures sensitivity to rewards 
delayed by weeks or months.  In contrast to this, drawing more in the current task only 
delayed possible rewards by seconds. Further, in the beads task, not drawing often leads 
to not winning, or losing in the loss blocks. This is different than waiting for a larger 
reward, which is the case in temporal discounting.   
Since memory plays an important role in reward learning (Hyman, Malenka et al. 2006), 
it was tested whether the results on the beads task could have been confounded by poor 
WM. In this WM task the role of distractibility during the delay interval was examined. 
There was no correlation between the beads task and WM capacity, which suggests that 
early decisions relating to the beads task were not driven by poor cognitive capacity. 
Substance abusers had also a significantly worse WM capacity than the other groups. 
This is consistent with previous studies demonstrating poorer attention in substance 
abusers when required to ignore salient stimuli during WM tasks (Hester and Garavan 
2009). However, this finding has to be interpreted with caution since the substance 
abusers were under treatment with opioid replacement therapy, which is known to 
interfere with WM function (Rapeli, Fabritius et al. 2009).  
PD patients without ICBs remembered distractors significantly less than all other 
patients during working memory tests, which suggests that intact cortical processing in 
combination with less distractibility may protect them from developing ICBs.   
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Many patients with ICBs conceal their behaviour due to denial (Singh, Kandimala et al. 
2007). By analysing data from the 80/20 loss condition it was possible to correctly 
identify ICB patients with a sensitivity of 96%. The beads task might therefore provide a 
simple screening tool to detect patients at greater risk of ICBs or confirm a clinically 
suspected but concealed ICB. These results also suggest that a significant proportion of 
PD-ICB patients is at risk of developing impulsive behaviour and thus over time may 
develop ICBs (Joutsa, Martikainen et al. 2012). Poor performance on this task suggests 
that these patients should be monitored frequently by their treating physician and the 
results taken into consideration when deciding on the use of dopamine agonist 
treatment. This study is free from the limitations of an indirect study design (Gartlehner 
and Moore 2008) and contains a large number of different groups.  
Conclusion 
These results might have clinical implications, since they imply that PD+ICB patients 
should be treated like substance abusers rather than patients with behavioural addictions. 
Additional studies comparing PD-ICB patients “on” and “off” dopamine agonists will 
be necessary to explore the role of dopaminergic medication in cognitive impulsivity. 
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Key Findings 
o All patients gathered significantly less information and made more 
irrational choices than controls. 
o PD patients, who had an ICB, showed similar behaviour to illicit substance 
abusers on opioid replacement therapy, whereas PD patients without ICBs 
resembled more closely pathological gamblers. 
o There was no difference in working memory performance between the two 
PD groups. However, PD patients without ICBs remembered distractors 
significantly less than all other patients. 
o Analysing 3 trials of the 80/20 loss condition correctly classified 96% of 
the PD patients with respect to whether or not they had an ICB with a 
negative prediction value of 92.3%. 
o The beads task may prove to be a powerful screening tool to detect an ICB 
in PD. 
o Less distractibility in PD patients without ICBs may explain why these 
patients do not develop addictive behaviours. 
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Introduction 
Results of the beads task with increased reflection impulsivity, even in PD patients 
without ICBs, have led to a follow up study to assess effects of dopaminergic 
medication on decision making. Although L-dopa remains the most efficacious drug to 
ameliorate motor handicaps in PD, patients are often first treated with dopamine 
agonists (DA) to minimize the long term risk of L-dopa induced dyskinesias, or reduce 
current severity of dyskinesias (Tsouli and Konitsiotis 2010). More recently,  “L-dopa 
phobia” regarding its early use may be decreasing (Vlaar, Hovestadt et al. 2011), largely 
because of increased awareness of an association between DA and potentially 
devastating behavioural side effects. Although DA have been suggested to be the major 
risk factor for developing ICBs in PD (Weintraub, Koester et al. 2010), no direct 
comparison between PD patients with and without DA on metric tests has been 
performed so far.   
In a subgroup of advanced PD patients sufficient motor control cannot be achieved with 
conventional anti-Parkinson medication and deep brain stimulation (DBS) of the 
subthalamic nucleus (STN) may be necessary (Foltynie, Zrinzo et al. 2010). The motor 
benefit obtained from STN-DBS has been consistently demonstrated, and is an 
increasingly important therapeutic option for managing PD (Foltynie, Zrinzo et al. 
2010). However, clinical confidence in STN-DBS is tempered by conflicting results on 
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its clinical effect on PD-associated ICBs, with some reports showing benefit of ICBs 
after DBS (Ardouin, Voon et al. 2006, Lhommee, Klinger et al. 2012) and others 
worsening (Halbig, Tse et al. 2009, Lim, O'Sullivan et al. 2009, Zahodne, Susatia et al. 
2011). Similarly, neuropsychological tests done in PD patients with DBS showed 
impairment in decision making with increased impulsive choice (Frank, Samanta et al. 
2007) and loss chasing behaviour (Rogers, Wielenberg et al. 2011) in some studies, 
whilst others found an improvement in learning behaviour (van Wouwe, Ridderinkhof et 
al. 2011). 
In this study, the role of dopamine agonists and the role of DBS in “reflection 
impulsivity” was assessed by using the beads task (Furl and Averbeck 2011).  
The prediction was that PD patients on DA (PD+DA) would gather significantly less 
information and make more irrational choices than PD patients without DA treatment 
(PD-DA). Another hypothesis was that the PD-DA group would perform similarly to 
controls and that DBS alone would not affect performance on the beads task, but those 
patients with DBS and a DA would perform worse than all other groups.  
Patients and methods 
All participants provided written informed consent according to the declaration of 
Helsinki and the study was approved by the UCLH Trust. 
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Standard protocol approvals and patient consents 
All patients had attended the Specialist Movement Disorders Clinic at the National 
Hospital for Neurology and Neurosurgery, London, UK. Informed consent was obtained 
from all participants, and the study had local ethics committee approval.  
Patients 
All patients were recruited from the National Hospital for Neurology and Neurosurgery 
London, fulfilled the Queen Square Brain Bank criteria for the diagnosis of PD (Gibb 
and Lees 1988) and were taking L-dopa. Thirty-four PD patients, who were taking oral 
medication, were recruited. Twenty were taking L-dopa in combination with a DA 
(PD+DA) and 14 were on L-dopa therapy but were never treated with a DA or did not 
tolerate treatment with a DA due to side effects (other than ICBs) and had been off the 
DA for at least 14 months (PD-DA). Further, 27 PD patients who had undergone 
bilateral STN-DBS were included. Sixteen were treated with L-dopa in combination 
with DA (DBS+DA). Eleven patients were on L-dopa but were not taking DA (DBS-
DA).  
L-dopa equivalent units (LEU - doses) were calculated as described previously (Evans, 
Katzenschlager et al. 2004). Results were compared with 18 healthy matched elderly 
volunteers. Participants who scored under 26/30 points on the MMSE were excluded. 
Patients with a current or past history of an ICB assessed in a semi-structured interview 
using accepted diagnostic criteria for pathological gambling (American Psychiatric 
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Association 2000), compulsive shopping (McElroy, Keck et al. 1994), compulsive 
sexual behaviour (Voon, Hassan et al. 2006) and punding (Evans, Katzenschlager et al. 
2004) were excluded.  
All patients were tested in their “on” state usually mid-mornings when their motor 
symptoms were best controlled and had an excellent L-dopa response. The therapeutic 
motor response to L-dopa was assessed by UPDRS (part 3) scores during “off” and “on” 
state. 
Beads task 
The same task as described previously was used for this study. Again the task was 
performed in the participant’s home or in a quiet room to minimize distractions. A 
practice trial was performed in all participants to ensure that they understood the rules. 
Participants either pressed the keys on the laptop computer themselves, or gave verbal 
commands and keys were pressed on their behalf.  
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Statistical analysis 
For the behavioural variables a generalized linear model (SPSS) was used. Beads ratio 
(80/20 or 60/40) and loss condition (loss, no loss), DA (yes/no), DBS (yes/no) were 
modeled as fixed factors and age was included as a covariate. Subject was a random 
factor nested under DBS and DA. Demographic variables (Table 15) were analysed 
using ANOVA, t-test or χ 2 tests where appropriate and as indicated.   
Results 
Demographic characteristics 
There were significant differences in age, age at onset and disease duration across the 4 
groups as shown in Table 15. Adjustment for these confounders was therefore made in 
subsequent models. There was no difference in years of education between controls and 
patients and no difference between UPDRS (part 3) motor scores or LEU doses between 
the patient groups. DA-LEU doses did not differ between the PD+DA (216mg) and the 
DBS+DA (205mg) group.  
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 Controls PD-DA PD+DA DBS-DA DBS+DA t value, 
 χ 
2 
 and 
F-value 
p-value 
Participants 18 14 20 11 16   
Gender 
(male) 
15 11 19 10 11 χ 
2
=5.1 0.27 
Age (yrs) 
 
 
58.9±13 67.2±7.5 64.3±5.2 57.0±7.0 59.1±11.6 F=3.0 =0.023 
Age of 
diagnosis  
 61.1±2.2 53.2±1.8 42.5±2.3 43.7±2.2 F=15.9 <0.001* 
Disease 
duration 
(yrs) 
 
 
 
6.2±3.8 
 
11.1±7.0 
 
14.4±5.0 
 
15.6±6.0 
 
F=7.3 <0.001* 
DBS (yrs)    3.4±3.3 3.6±2.2 t=0.2 0.8 
Education 
(yrs) 
13.6±3.2 
 
14.8±3.1 
 
14.5±2.5 
 
13.9±2.8 
 
13.7±2.8 
 
F=0.4 0.75 
LEU dose 
DA dose 
(LEU) 
 511±321 854.2±356 
216.0±109 
739.2±409 
 
771.4±337 
204.9±97.1 
F=2.6 
t=0.3 
0.058 
0.7 
UPDRS on  16.0±2.3 19.4±11.6 16.5±4.4 17.6±4.4 F=0.5 0.6 
 
Table 15.  STN-DBS: Demographic characteristics. 
Significant differences are labelled with “*”. 
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Beads task 
The patient data, excluding controls, were analysed using a generalized linear model that 
included DBS (yes/no), DA (yes/no), beads ratio and loss as factors. Age was included 
as a covariate, although it was not significant (Wald χ2 = 0.28, p > 0.59). There was a 
significant effect of DA (Wald χ2 = 11.4, p = 0.001) and beads ratio (Wald χ2 = 34.8, p < 
0.001). There were no effects of loss condition (Wald χ2 = 0.06, p = 0.7), DBS (Wald χ2 
= 0.6, p = 0.4) and no interaction of DBS and DA (Wald χ2 = 0.03, p = 0.8) or beads 
ratio and loss condition (Wald χ2 = 1.2, p = 0.2).   
Pairwise comparison between all groups including controls was also performed. There 
was a significant effect of group (Wald χ2 = 138.4, p < 0.001). PD+DA and DBS+DA 
both drew significantly less than controls before making a decision (p < 0.001), PD-DA 
and DBS-DA patients (p < 0.001), (see Table 16, Figure 20). 
Opposite colour choice 
Next the number of times participants made an irrational choice and picked the less 
likely cup given the information they had at the time of drawing was examined.  
First effects of DA and DBS on irrational choices were compared and results showed a 
significant effect of DA (Wald χ2 = 13.8, p < 0.001) and beads ratio (Wald χ2 = 4.3, p = 
0.039).  
PD+DA made more irrational decisions than PD-DA, DBS-DA and healthy controls  
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(p ≤ 0.002). Similarly the DBS+DA group made significantly more irrational choices 
than DBS-DA (p = 0.01) and PD-DA and controls (p ≤ 0.003). Further details are 
illustrated in Figure 21. 
There was no effect of loss condition (Wald χ2 = 3.3, p = 0.07), DBS (Wald χ2 = 0.03, p 
= 0.8) and also no interaction of DBS and DA (Wald χ2 = 0.3, p = 0.6).  
Age was modeled as a covariate but was not significant (Wald χ2 = 0.01, p = 0.9). Next, 
pairwise comparisons including the control group and all patient groups were made. 
There was a significant effect of group (Wald χ2 = 32.7, p < 0.001). Age was again 
modeled as a covariate (Wald χ2 = 0.9, p = 0.3). Results of pairwise comparison between 
all groups are shown in Table 16. 
Dopamine agonist dose and task performance 
There was no significant correlation between mean draws per trial and LEU-DA dose 
(Pearson correlation = -0.18, p = 0.9). There was also no correlation between irrational 
choices and LEU-DA dose (Pearson correlation = 0.42, p = 0.8). 
 
187 
 
 
Figure 20.  STN-DBS:  Average drawing behaviour per condition of different groups. 
One bead is always shown before the participant must make a decision, so total beads 
seen are mean draws plus one. 
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Table 16.  STN-DBS: Pairwise comparisons. 
Pairwise comparisons between groups for number of draws.  All p-values shown are 
uncorrected. Values less than 0.0125 (highlighted in bold) are significant.  All p-
values in this table are for main effect of group. Age was included as a covariate. 
Group 
(χ
2
, p-value) 
PD-DA DBS+DA DBS-DA Controls 
PD+DA 
Draws 
Opposite  
 
101.6,p < 0.001 
11.1, p = 0.001 
 
0.06, p = 0.7 
0.7, p = 0.3 
 
84.6 p < 0.001 
9.1, p = 0.002 
 
87.3, p < 0.001 
13.2, p < 0.001 
PD-DA 
Draws 
Opposite  
  
71.5, p < 0.001 
12.5, p < 0.001 
 
1.4, p = 0.2 
0.2, p = 0.7 
 
0.3, p = 0.56 
0.6, p =0. 42 
DBS+DA 
Draws 
Opposite  
   
75.3, p < 0.001 
   6.1, p = 0.01 
 
63.6, p < 0.001 
9.1, p = 0.003 
DBS-DA 
Draws 
Opposite  
    
5.1, p = 0.023 
0.002, p = 0.96 
189 
 
 
Figure 21.  STN-DBS: Number of times participants chose the opposite colour.   
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Discussion 
Both DA medication (Weintraub, Siderowf et al. 2006) and DBS have been implicated 
in increased impulsivity (Frank, Samanta et al. 2007, Cavanagh, Wiecki et al. 2011). 
However, an examination of the effects of DA and DBS within a single study, while 
controlling for the effects of DA in DBS has not been previously reported. This study 
directly compared PD patients with and without DA treatment and with and without 
STN-DBS. Patients treated with a DA gathered significantly less evidence and made 
more irrational choices than patients not treated with a DA, whether or not they received 
DBS. DBS had no effect and there was no interaction between DBS and DA, which is in 
line with previous results (Halbig, Tse et al. 2009). In addition, patients not taking a DA 
did not differ from controls, whereas those that were taking a DA did. Thus, the 
hypothesis that DBS in combination with a DA would further increase reflection 
impulsivity was incorrect. Recent work has shown that the most important factor for 
risky decisions is the total amount of dopaminergic medication including a combination 
of DA and L-dopa. The authors also tested PD patients on and off STN-DBS, but found 
no group effect (Lule, Heimrath et al. 2012). Good outcome and reduction in ICBs after 
DBS has been observed in those patients who had significant reduction in dopaminergic 
medication (Demetriades, Rickards et al. 2011). One prospective study showed 
significant improvement of ICBs and dopamine dysregulation syndrome in all patients 
after STN-DBS, except for one individual in whom reduction of DA was not possible, 
suggesting that other individual factors, such as electrode misplacement outside the STN 
and consequently failure of reduction of DA, might be responsible for worsening or new 
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onset of ICBs after DBS (Lhommee, Klinger et al. 2012). In this study, total LEU doses 
were not significantly different between PD+DA and PD patients treated with DBS and 
yet only those treated with a DA made impulsive choices. Thus, DA alone appears to 
trigger impulsive choices in PD patients who do not have an ICB in the past or present. 
Increased temporal discounting, the preference of a smaller immediate over a delayed 
but higher reward was observed in PD patients without ICBs who were treated with a 
dopamine agonist. Discounting in these patients was not affected by medication state, 
which may imply that dopamine agonist therapy causes persistent long term behavioural 
changes (Milenkova, Mohammadi et al. 2011) possibly via sensitization. These results 
are also consistent with the previous study which demonstrated that PD patients without 
ICBs but on a DA were performing similarly to non PD patients with pathological 
gambling.  
My results also expand on previous studies showing no impairment in decision making 
and risk taking in drug naïve PD patients (Poletti, Frosini et al. 2010) and suggest that 
L-dopa alone or in combination with DBS does not cause increased reflection 
impulsivity. These findings also suggest that L-dopa without a DA does not increase the 
risk of pathological gambling in PD. DA are also known to change reward learning. In 
one study drug-naïve PD patients had intact learning from negative feedback but 
impaired reward learning. An opposite learning profile was found after 12 weeks of 
dopamine agonist therapy, with significant impairment in avoidance of negative 
outcomes compared to controls but restored reward seeking behaviour (Bodi, Keri et al. 
2009). 
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It has been suggested that the STN acts as a “brake” on the cortico-striatal loop in high 
conflict situations to “buy more time” before making a decision (Frank, Samanta et al. 
2007). In PD patients treated with DBS, impulsive choice is increased by reducing a 
decision threshold (Cavanagh, Wiecki et al. 2011). In this study, patients with STN-DBS 
showed no increased impulsivity. However, in the previous studies most PD patients 
were taking a DA in addition to DBS. Further, these studies examined the acute effects 
of DBS stimulation, which is known to cause impulsive behaviour (Lhommee, Klinger 
et al. 2012) whereas here STN-DBS patients under stable conditions were tested. 
Finally, the main outcome measure in previous studies was reaction time (Frank, 
Samanta et al. 2007, Cavanagh, Wiecki et al. 2011), whereas in this study the main 
interest was number of draws. Decision thresholds are, however, more clearly defined in 
this task, as an explicit choice to stop sampling must be made (Furl and Averbeck 2011). 
Therefore ‘reflection impulsivity’ is distinct from ‘motor’ impulsivity, the inability to 
stop an on-going process and from ‘waiting’ impulsivity, the inability to delay an action 
was examined (Dalley, Everitt et al. 2011). The STN may be more involved in decisions 
made under time pressure, than decisions that can be made without time pressure, as is 
the case in this task. Consistent with this, imaging work in healthy controls 
demonstrated activation of the anterior cingulate, the ventral striatum and insula during 
the beads task, but not STN (Furl and Averbeck 2011). It is possible that DA medication 
causes a reduction in “top down” cortical control of the basal ganglia. An fMRI study 
showed a reduced orbitofrontal cortex and anterior cingulate activity PD patients with 
pathological gambling and compulsive shopping after DA therapy, which correlated 
with increased risky choice (Voon, Gao et al. 2011).
 
Both brain areas are essential for 
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feedback learning and switching behaviours when necessary (Rolls 2004, Kennerley, 
Walton et al. 2006). 
Differences in the mechanisms of action of L-dopa and DA likely explain why ICBs and 
impulsive choice are more commonly seen under DA treatment than L-dopa 
monotherapy. Dopamine agonists stimulate dopamine receptors more tonically than L-
dopa, which has consequences on learning behaviour. Further, the nowadays commonly 
used DA have a much stronger dopamine D3 receptor affinity than D2 or D1 receptors 
(Gerlach, Double et al. 2003, Jenner 2005) and D3 receptors are primarily expressed in 
the limbic system (Ahlskog 2011). This might explain why DA are more likely to 
trigger ICBs (Ahlskog 2011) than L-Dopa. 
However, having excluded patients with known ICBs, a co-existing interaction between 
L-dopa therapy and STN-DBS that may be relevant in individuals or subgroups of 
patients cannot be excluded. 
Conclusion 
In summary, increased impulsive choices and irrational decisions in patients treated with 
a DA, regardless of whether they had DBS or not, was demonstrated. In contrast, there 
was no difference between controls and patients who were not treated with a DA. 
Results of this study also suggest that neither STN-DBS nor L-dopa monotherapy 
increases impulsive choices in the context of information sampling in a cohort of PD 
patients who never had an ICB.  
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Further, this study showed that PD patients treated with a DA generally have increased, 
albeit controlled, impulsivity. The clinical implication of these results is that DBS may 
be considered as a potential treatment for ICBs where motor deficits prevent decreases 
in dopamine replacement therapies. Careful preoperative planning, exact placement of 
the electrodes within the STN are in combination with post-operative reduction of DA 
likely to be key factors predictive of a good behavioural outcome.  
 
Key Findings 
o All PD patients treated with a dopamine agonist gathered significantly less 
information and made more irrational decisions than controls and PD 
patients without a dopamine agonist. 
o There was no difference in performance on the beads task between controls 
and PD patients without a dopamine agonist, regardless of whether they 
had been treated with STN-DBS or not. 
o Dopamine agonists are the main risk factor for reflection impulsivity and 
irrational choices in PD. 
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Introduction 
Methcathinone also known as ephedrone and mephedrone, is one of several homemade 
synthetic cathinones with amphetamine-like stimulant activity. Ephedrone users inject 
themselves several times per day in binges over several days. In eastern Europe, it is 
generally manufactured on a small scale using commercially available nasal 
decongestants including phenylpropranolamine (PPA) and pseudoephedrine, potassium 
permanganate (KMnO4), used as an oxidant and disinfectant (Chintalova-Dallas, Case 
et al. 2009) and vinegar. During this reaction, as a side product, manganese ions are 
formed, which then accumulate in the brain and cause dystonia, postural instability, a 
quiet slurred pallidal speech, dopaminergic unresponsive bradykinesia and later a typical 
“cock gait” (Sanotsky, Lesyk et al. 2007).  Concerns about the misuse of KMnO4 have 
led to restrictions in its sale in recent years. 
Ephedrone is often used in small groups, sharing paraphernalia and engaging in the 
practice of “front loading”, whereby drugs are transferred from one syringe to another. 
There have been no post-mortem examinsations so far, but MRI scans of the brain 
revealed that the disorder affects mainly the globus pallidus, the substantia nigra and to 
a lesser degree the subthalamic nucleus, the putamen and the caudate nucleus (Sikk, 
Haldre et al. 2011). However, DAT scans show an intact nigrostriatal pathway 
(Sanotsky, Lesyk et al. 2007). Although the white matter appears to be normal on T1-
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weighted MRI, diffusion tensor imaging studies showed extensive white matter changes 
particularly in the frontal and premotor areas and widespread damage to cortico-pallidal 
connections (Stepens, Stagg et al. 2010). Despite these extensive abnormalities on brain 
imaging only mild deficits in executive function have been reported (Selikhova, 
Fedoryshyn et al. 2008, Stepens, Logina et al. 2008, Stepens, Stagg et al. 2010). 
Individual case reports have pointed towards a tendency towards impulsivity (Yildirim, 
Essizoglu et al. 2009) but this has never been studied systematically. However, drug 
addiction is associated with executive, memory and decision making dysfunction (Koob 
and Volkow 2010). Opiate and amphetamine dependent patients have difficulties in 
planning, learning and memory (Ersche, Clark et al. 2006) which persist during opiate 
replacement therapy (Prosser, Cohen et al. 2006). Patients on opioid replacement 
therapy also make more risky decisions which may reflect abnormal patterns of 
orbitofrontal cortex activation (Ersche, Fletcher et al. 2006). 
In this study, a comparison was made between patients with ephedrone induced 
extrapyramidal symptoms to substance abusers without neurological deficits who were 
taking opioid replacement therapy and healthy volunteers on a WM, feedback learning, 
risk taking test and the beads task. The beads task examines how much information 
participants gather before making a decision sometimes referred as “reflection 
impulsivity” (Evenden 1999, Clark, Robbins et al. 2006). Again the WM and the beads 
tasks were combined because it has been suggested that jumping to conclusions might 
be a specific strategy to reduce WM load (Dudley, John et al. 1997). Emotionally salient 
and neutral distractors were also used, given the negative effects of task irrelevant 
information on WM performance (Dolcos and McCarthy 2006).  
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Apart from reflection impulsivity cognitive impulsivity also includes decision making 
under risk (Verdejo-Garcia et al 2008). For this study it was of special interest to assess 
whether reflection impulsivity is simply driven by risky choices or is triggered due to 
impaired feedback learning.   
A key role was also to assess differences between former addicts with ephedrone 
toxicity and current drug dependent patients, in the context of the distinctive structural 
MRI changes in ephedrone patients compared to normal MRI scans in opioid 
dependence. Clinical impression has suggested that most patients with ephedrone 
induced basal ganglia damage lose their craving for illicit substances and cease abusing 
drugs. It is unclear whether their physical disability or damage from the accumbens-
pallidum circuitry is responsible for this change in behaviour. Studies in rodents have 
shown that the globus pallidus plays a key role in the reinforcing effects of illicit drugs 
(Koob and Volkow 2010), and its damage might therefore abolish craving.   
It is possible that both patient groups are likely to have orbitofrontal cortex dysfunction, 
considering its important role in drug preoccupation and impulsivity (Volkow and 
Fowler 2000). Therefore, the prediction was that ephedrone patients would perform 
similarly to opiate dependent patients in tasks measuring reflection impulsivity, since 
jumping to conclusions is known not to recover even after prolonged abstinence in 
substance abusers (Clark, Robbins et al. 2006). On other tasks, such as risk taking and 
feedback learning, it was speculated that ephedrone patients would perform better than 
substance abusers on opioid replacement therapy given differences in drug craving and 
shorter duration of illicit drug abuse. It was expected that both patient groups would be 
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worse on the WM task, especially when salient distractors were presented but would on 
the other hand remember distractors significantly better than healthy controls. 
Patients and methods 
All participants provided written informed consent. The protocol was approved by the 
UCLH Trust or Ukrainian local ethics committee. All participants scored more than 
26/30 on the MMSE and were tested once usually mid-mornings. Participants received a 
modest reward (between £10-15) depending on their performance.  
Ephedrone patients 
Fifteen patients with ephedrone induced extrapyramidal symptoms were recruited from 
the department of Neurology of Lviv Regional Clinical Hospital, Ukraine. All patients 
had moderate to severe extrapyramidal symptoms, dystonia and had decrement in finger 
tapping with some axial rigidity, induced by ephedrone. Fourteen patients developed 
extrapyramidal symptoms after intravenous methcathinone abuse, 1 patient after 
recurrent oral intake. A detailed neurologic examination was performed by a movement 
disorder specialist on the day of testing. No patient had a resting tremor or was treated 
with dopamine replacement therapy. All patients had gait problems with moderate to 
severe impairment of postural stability. One patient was wheelchair bound at the time of 
assessment. Seven of 15 patients developed a characteristic “cock-gait” and had a 
characteristic pallidal speech, similar to patients with progressive supranuclear palsy. No 
patient had taken any illicit drugs within the last 2 years. Manganese levels have been 
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measured in pubic hair samples in nine of 15 patients confirming the diagnosis of 
manganese toxicity. For further details see (Selikhova et al 2008).  
Substance abusers on opioid replacement therapy 
Thirteen male patients with a recent history of illicit drug abuse, meeting DSM-IV 
criteria for substance dependence (American Psychiatric Association 2000) were 
included in this study. Eleven were recruited from the Replacement Therapy Unit of 
Lviv, regional Clinical Narcological Dispensary. Two patients were inpatients at the 
department of Lviv Regional Clinical Narcological Dispensary, Ukraine. All patients 
had clinically normal cognitive function, and were on opioid replacement therapy with 
buprenorphine. Neurological examination was normal in all patients. Twelve of 13 
patients had a long standing history of intravenous opioid abuse. (For a detailed list of 
drugs of abuse see Table 17). All tests were performed prior to their dose of 
buprenorphine. Only those patients who were able to tolerate a delay of their 
buprenorphine dose were included. Patients who suffered from clinically evident 
withdrawal symptoms were excluded. None of these patients reported taking any 
additional illicit substances at the time of testing.   
Controls 
Results were compared with 18 age matched healthy male volunteers. For additional 
demographic characteristics see Table 17. 
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 Controls Ephedrone Substance 
abusers 
t value, 
 χ2  and 
F-value 
p-value 
Participants (no) 
 
Age (yrs) 
 
 
 
Gender (male) 
Education 
18 
32.3±5.5 
 
18 
13.8±2.8 
15 
34.0±7.2 
 
13 
12.2±1.4 
13 
32.0±7.1 
 
12 
12.0±1.9 
 
0.34 
 
2.4 
5.1 
 
0.71 
 
0.3 
0.01* 
Drug abuse (yrs) 
Replacement therapy (yrs) 
Ephedrone abuse (yrs) 
Ephedrone stopped (yrs) 
Parkinsonism (yrs) 
  
 
1.5±1.2 
6.2±2.6 
7.0±2.4 
12.0±5.1 
1.4±1.3 
  
Substance abuse (no) 
i.v. opioid 
i.v.heroin 
Cannabis 
Cocaine 
Morphine 
Ephedrone (i.v/oral) 
 15 
4 
2 
3 
1 
0 
14/1 
13 
12 
4 
3 
1 
1 
0 
  
Table 17.  Ephedrone: Demographic characteristics. 
Details about past history of substance abuse presented. All values are mean ± SD. 
Significant difference is labelled with “*”.  
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Working memory task and beads task  
The same WM and beads task has been used as described earlier. In the WM task 
participants were asked to memorize either 2 or 3 geometric figures. Further, positive, 
neutral or negative distractors were shown. At the very end of the task participants had 
to say whether they thought they have been exposed previously to the distractor. 
In the beads task all participants performed a practice trial to ensure that they understood 
the rules.  
Risk task 
The same version of the gambling task was used as described earlier. Previous studies 
have shown that addicts are more risk prone on the Iowa Gambling task (Bechara 2003).   
However, the Iowa Gambling task includes both elements of risk and feedback learning.  
Therefore, these elements have been split into separate tasks for this study to get a more 
straightforward assessment. 
Feedback learning task 
The ability of participants to integrate positive and negative feedback within a learning 
context was assessed using an instrumental learning task. The task had four blocks of 24 
trials (Pessiglione, Seymour et al. 2006). In each trial participants were shown two 
stimuli and they had to select one of them. After choosing a stimulus they were 
informed of the outcome.  Each block contained a fixed probability of winning or losing 
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associated with each stimulus, and one stimulus was more often rewarded, or less often 
punished than the other. Participants were asked to select the stimulus that they thought 
was more likely to win in 2 “winning blocks” or less likely to lose in 2 “losing blocks”. 
In “winning blocks” participants could either win 0.5 units or win nothing, in the other 2 
“losing blocks” subjects should avoid a loss or could lose 0.5 units.  Feedback was given 
immediately. Winning probabilities for the two stimuli were 70%/30%.  Different 
abstract stimuli were used in each block. 
Statistical analysis 
Statistical analysis was performed using SPSS, version 18. For the demographic 
variables, age, gender, years of education were used as dependent variables and groups 
(ephedrone, substance abusers and controls) were modeled as a between subject factor.  
ANOVA, t-test or χ 2 tests were used where appropriate. Years of education was 
modeled as a cofactor for all analyses but did not change any results. 
Working memory task 
A generalized linear model (SPSS) with a binary logistic distribution was used. As a 
dependent variable score (correct response = 1 or incorrect response = 0) was used. 
Distractor (positive, neutral or negative), number of memoranda (2 or 3 geometric 
figures), choice (yes, no) and actual shown figure (yes, no) were modeled as fixed 
factors. Groups (ephedrone, substance abusers and controls) were modeled as a between 
subject factor and subject was a random factor nested under group.  
203 
 
Beads task 
Analyses using a generalized linear model (SPSS) were performed. As a dependent 
variable either the number of draws before making a decision or opposite colour choice 
was used. As these are both count variables a Poisson model, which had a loglinear link 
function, was used. For the first analysis beads ratio (80:20 or 60:40) and loss condition 
(loss, no loss) were modeled as fixed factors. Groups (ephedrone, controls, substance 
abusers) were modeled as a between factor and subject was a random factor nested 
under group.  
Risk task and feedback learning task 
Data analysis for the risk and learning tasks was carried out by fitting parametric 
decision making models to the behaviour of each individual subject, and comparing the 
distributions of parameter fits from the model between groups in a within subject design. 
Further details have been described earlier (see chapter 3.1).  
Results 
Demographic characteristics 
There was no age difference between the 3 groups (F(2,44)=0.34, p = 0.7), but there was a 
significant difference in years of education controls (F(2,42)=5.1, p = 0.01). Post hoc 
analysis showed that controls had significantly more years of education than ephedrone 
patients (p = 0.033) and substance abusers (p = 0.022).  
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Working memory task 
There was a significant effect of group (Wald χ2 = 16.0, p < 0.001), a significant effect 
of distractor type (Wald χ2 = 17.8, p < 0.001) (Figure 22) and a significant distractor by 
number of memoranda interaction (Wald χ2 = 10.0, p = 0.007).  
 
Figure 22.  Ephedrone: WM performance. 
Positive (left), neutral (middle) and negative (right) distractors.  
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Results showed no effect of memoranda (Wald χ2 =1.4, p = 0.2) (Figure 23). Pairwise 
analysis between the groups showed that substance abusers on opioid replacement 
therapy performed significantly worse than ephedrone patients (Wald χ2 =6.2, p = 0.013) 
and controls (Wald χ2 =15.4, p < 0.001). There was, however, no difference between 
controls and ephedrone patients (Wald χ2 =2.3, p = 0.12). Analysis was done to see how 
often the distractors could be remembered at the end of the experiment, but no group 
differences were found (Wald χ2 =4.3, p = 0.5). 
Beads task 
First the number of draws each participant made in the different conditions was 
examined (Figure 24). Results showed a significant main effects of group (Wald χ2 = 
73.0, p < 0.001), beads ratio (Wald χ2 = 4.5, p = 0.033), a significant group by loss 
condition interaction (Wald χ2 = 6.5, p = 0.037) and a significant group by ratio 
interaction (Wald χ2 = 9.5, p = 0.009). Subsequently a series of pairwise comparisons 
between the 3 groups were performed which showed a significant group by loss 
interaction between the ephedrone group and addicts (Wald χ2 = 5.5, p = 0.019) and a 
significant group by ratio interaction between the ephedrone and the control group 
(Wald χ2 = 9.3, p = 0.02).  
Ephedrone patients drew significantly less often than controls (Wald χ2 = 45.3, p < 
0.001) and showed a trend to draw more than substance abusers on opioid replacement 
therapy (Wald χ2 = 3.2, p = 0.076). Substance abusers also gathered less information 
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than controls (Wald χ2 = 30.0, p < 0.001). Education was added as a cofactor but there 
was no significant correlation (Wald χ2 = 0.87, p = 0.7). 
 
 
Figure 23.  Ephedrone: Effects of memoranda on WM performance.  
Two geometric figures (left) versus 3 (right).  
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Figure 24.  Ephedrone: Average drawing behaviour per condition of different groups.   
One bead is always shown before the participant must make a decision, so total beads 
seen are mean draws plus one.  
Opposite colour choice 
Subsequently the number of times participants chose the opposite colour, or the less 
probable cup, given the beads that had been drawn was examined (Figure 25). Results 
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showed a significant main effect of group (Wald χ2 = 34.6, p < 0.001). Ephedrone 
patients (Wald χ2 = 30.1, p < 0.001) and substance abusers (Wald χ2 = 34.1, p < 0.001) 
chose the less likely cup significantly more often than controls. There was no difference 
between the ephedrone group and substance abusers (Wald χ2 = 0.54, p = 0.46). 
 
  
Figure 25.  Ephedrone: Number of times participants chose the opposite colour. 
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Risk task 
There were group differences in preference for risky gambles (F2, 45 = 7.06, p = 0.002). 
Post-hoc comparisons (Bonferroni corrected) showed that the opiate addicts were more 
risk prone than controls (F1, 30=14.75, p=0.002). Ephedrone abusers were not more risk 
prone than controls (F1,31 = 4.67, p = 0.11) and did not differ from addicts (F1,29 = 2.03, 
p = 0.49) (Figure 26A). 
Learning task 
Performance on the learning task was analysed by fitting separate learning rate 
parameters to the positive and negative feedback conditions (Voon, Pessiglione et al. 
2010). All groups learned equally well (F2, 43 =1.78, p = 0.173). There was no difference 
in how groups responded to either learning to win or learning to avoid losing, measured 
as a group by feedback type interaction (F2, 4 3= 1.07, p = 0.345) (Figure 26B).   
 
 
Figure 26.  Ephedrone: Risk and learning behaviour. 
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Discussion 
This is the first study to systematically analyse WM, feedback learning, risk taking and 
information gathering in patients with ephedrone induced parkinsonism. Results were 
compared directly with substance abusers on opioid replacement therapy and healthy 
volunteers. There was no difference in WM performance between controls and 
ephedrone patients even when salient distractors were shown. Both these groups 
performed significantly better than opiate dependent patients.   
Previous studies have demonstrated poor attention in substance abusers when required 
to ignore salient stimuli during WM tasks (Hester and Garavan 2009). Results presented 
in this thesis are also consistent with previous studies showing impaired WM 
performance in opiate dependent patients (Rapeli, Kivisaari et al. 2006). All patients on 
opioid replacement therapy were tested prior to their daily buprenorphine dose and 
therefore conceivably might have had subtle withdrawal symptoms and low brain 
dopamine levels (Koob and Volkow 2010). Thus impaired WM performance in this 
group might be explained by the inverted “U-shape” hypothesis, suggesting that too low 
or excessive dopamine levels impair cognitive function (Cools, Barker et al. 2003).  
It is, however, also possible that subclinical anxiety due to withdrawal might have 
contributed to poor WM performance in this patient group. The normal WM 
performance in the ephedrone group is in keeping with other studies showing normal 
scores on MMSE and FAB scores (Sikk, Taba et al. 2007, Stepens, Logina et al. 2008). 
Interestingly, controls and ephedrone patients performed better when salient distractors 
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were presented. Emotional stimuli can enhance cognitive functions (e.g. precise recall of 
a moment during an emotional event) but can also worsen WM capacity, particularly 
when they need to be ignored (Dolcos and McCarthy 2006). Thus, the hypothesis that 
WM performance would decline with salient distractors proved incorrect. One possible 
explanation is that during high cognitive load the impact of salient distractors is reduced, 
while activity in the dorsolateral prefrontal cortex increases (Van Dillen, Heslenfeld et 
al. 2009). An easier version of the task might have led to stronger effects of distractors 
on WM performance.  
Results also showed a relative improvement of WM performance with positive 
distractors. Implicit exposure to positive images might induce striatal dopamine release 
and might boost WM performance indirectly, given the role of striatal dopamine in WM 
(Landau, Lal et al. 2009). However, there was no similar effect in opiate dependent 
patients. It is possible that in this group, due to changes of the amygdala during 
addiction (Koob and Volkow 2010), salient photos might be stimulating to a lesser 
extent and therefore fail to lead to a memory-enhancing effect. Chronic buprenorphine 
abuse has been also shown to reduce the salience of the drug-associated cues (Sorge and 
Stewart 2006), and might have reduced attention to salient cues in this task.   
Decision making on the beads task is processed via a circuit involving the anterior 
cingulate, the parietal cortex, the insula and the ventral striatum (Furl and Averbeck 
2011). Healthy volunteers who gathered more information had more parietal cortex 
activation (Furl and Averbeck 2011). The anterior cingulate is necessary for optimal 
decision making and to integrate risks (Kennerley, Walton et al. 2006). Thus, damaged 
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connections from the anterior cingulate to the striatum and globus pallidus-cortical 
circuits in substance abusers and ephedrone patients (Rogers, Everitt et al. 1999, 
Selikhova, Fedoryshyn et al. 2008, Stepens, Stagg et al. 2010), albeit due to different 
mechanisms, could explain the impaired performance on the beads task.   
In this study, controls drew significantly more beads before making a decision than 
patients. Both patient groups also made significantly more irrational decisions and chose 
the less likely cup more often than controls. Although group difference between 
ephedrone patients and substance abusers only reached trend levels, a significant group 
by loss interaction was found. Thus, ephedrone patients gathered more evidence in the 
no loss conditions than patients on opioid replacement therapy.   
Various deficits in decision making have been reported in substance abusers (Paulus 
2007). Irrational decision making has also been found in patients with ventromedial 
prefrontal cortex lesions (Koenigs and Tranel 2007). “Delusional thinking”, defined as a 
belief based on incorrect inference (American Psychiatric Association 2000), has been 
reported in treated PD patients with impulsive compulsive behaviours (Gallagher, 
O'Sullivan et al. 2007, Wolters, van der Werf et al. 2008), who also chose the opposite 
cup significantly more often than controls as described earlier. Delusional thinking has 
been also positively correlated with fewer draws on the beads task in patients with 
schizophrenia (Fine, Gardner et al. 2007). My results are also in line with other studies 
showing a positive correlation of jumping to conclusion behaviour and prefrontal cortex 
dysfunction during task performance (Lunt, Bramham et al. 2012). 
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Thus, lesions within the anterior cingulate circuit in the ephedrone patients (Stepens, 
Stagg et al. 2010) might explain poor performance on the beads task, while the 
dorsolateral prefrontal loop, necessary for WM, may be relatively intact. This 
discrepancy between impairment in “reflection impulsivity” but intact WM function is 
consistent with other studies suggesting a dissociation of WM and decision making 
processing within the prefrontal cortex (Bechara, Damasio et al. 1998). Increased reward 
seeking behaviour with a reduced sensitivity to negative feedback or more likely 
insensitivity to unpredictable future consequences are possible explanations for 
impulsivity in patients with lesions in the prefrontal cortex (Bechara, Damasio et al. 
1998). However, the feedback learning task where reward and punishment learning was 
separately assessed, did not reveal any group differences.   
Risk taking behaviour was also examined across groups and results demonstrated that 
only opiate dependent patients made more risky decisions than controls, while group 
differences between ephedrone and controls only reached trend levels.  
A limitation of this study is that participants were not tested on a full battery of standard 
neuropsychological tasks and only two tasks assessing cognitive impulsivity were 
performed. However, adding further neuropsychological tests would increase testing 
session time significantly and would possibly lead to fatigue in the subjects. The tasks 
presented here were interrelated, but each was meant to assess a distinct cognitive 
process.  
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Conclusion 
In summary results confirmed ‘reflection impulsivity’ in patients with brain damage due 
to ephedrone toxicity but intact WM and feedback learning. Additional studies are 
needed to further delineate the behavioural and neuropsychological sequelae of this 
tragic and devastating consequence of illicit drug abuse in Eastern Europe. Comparison 
with patients with chronic manganese toxicity from other causes (Schuler, Oyanguren et 
al. 1957, Josephs, Ahlskog et al. 2005) who have been reported to suffer from 
compulsive behaviour and emotional lability (Cotzias 1958) would be of considerable 
interest.  
Key Findings 
o Ephedrone patients resembled opiate dependent patients on the beads task. 
o Both patient groups gathered less information and made more irrational 
choices than controls. 
o There was no difference in WM and risk taking behaviour between 
ephedrone patients and controls.  
o Opioid dependent patients made significantly more risky decisions and had 
poorer WM compared to controls.  
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Introduction 
It is uncertain whether chronic stress can actually cause PD despite the fact that many 
patients are convinced that their illness followed shortly after a period of chronic 
emotional strain or a particular stressful event. Further, it is unclear whether being 
diagnosed with PD and experiencing progressive worsening of motor symptoms might 
actually contribute to the development of impulsivity (Potenza, Voon et al. 2007, Lim, 
Evans et al. 2008). Sometimes PD patients with ICBs justify their behaviour by saying 
that they want to enjoy their life as long as they are physically not too disabled. 
Anxiety and depression for example is more frequently seen in PD patients with ICBs 
than in non-impulsive PD patients (Leroi, Andrews et al. 2011). Off period dysphoria, 
panic attacks, withdrawal symptoms and depression are particularly common amongst 
PD patients with DDS and may induce compulsive overuse of medication (Lim, Evans 
et al. 2008).  
In this chapter I speculate that chronic stress can not only temporarily worsen the 
symptoms of PD but can also cause nigrostriatal damage. The role of salivary cortisol 
levels as a surrogate marker of stress in PD patients with and without ICBs is then 
examined.   
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The idea that chronic stress can worsen PD is not new. More than 120 years ago Charcot 
speculated that “acute moral emotions”, such as “fright, terror, the sudden 
communication of bad news” could influence the onset and severity of PD. Gowers later 
wrote that prolonged anxiety and emotional shock are “the most common antecedents of 
Parkinson’s disease” and advised that sufferers refrain from “all causes of mental strain 
and of physical exhaustion….Life should be quiet and regular, freed, as far as may be, 
from care and work.” Later in 1922 146 patients with PD were studied and the authors 
described 3 types of patient groups being more susceptible of developing PD: Six 
patients (4%) were found to have a “history of acute mental symptoms following a shock 
at or before onset of the first symptom of the disease”. These stressors “occurred within 
a year before the onset” and symptoms included “marked grief following death of wife, 
frightened by burglar, great emotional shock and strain”. The second category 
contained seven patients (4.8%) who had depression preceding onset of PD up to 10 
years. The largest group in their cohort contained 20 patients (13.7%) who were “very 
nervous, high-strung, worrisome of  nervous temperament, easily upset and excited at 
least provocation” (Patrick and Levy 1922). Jeliffe speculated that some symptoms of 
PD might be a result of some chronic conflict in the patient’s life (Jelliffe 1940) and 
Prichard hypothesized that prolonged stress might cause irreversible chemical changes 
within the brain and unmasks Parkinson’s disease (Prichard, Schwab et al. 1951).  
A clinical study in the 1960s showed that tremor was exacerbated in PD patients under 
stress such as anxiety or anger (Schwab and Zieper 1965). Others reported that fatigue 
and emotional stress greatly reduced the effect of L-dopa therapy (Lees, Shaw et al. 
1977) and that motor fluctuations can be aggravated by emotional or physical stress 
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(Shaw, Lees et al. 1980). Tremor in PD patients has been reported to be initially only 
visible in stressful situations and later on in the disease worsens in amplitude during 
stress (Fahn 2003).  
More recently others have speculated about the link between PD and stress (Smith, 
Castro et al. 2002, Miller and O'Callaghan 2008) and dopaminergic dysfunction induced 
by stress (Pani, Porcella et al. 2000).  A Swedish study showed that the incidence of 
developing PD was significantly increased after being admitted  for a psychiatric 
disorder such as a mood or neurotic personality disorder, especially before the age of 50 
(Li, Sundquist et al. 2008). Proneness to psychological stress has been associated not 
only with PD but also with other neurodegenerative diseases such as Alzheimer’s 
disease (Kelly and Filley 2004). 
Psychogenic Parkinsonism 
Psychogenic parkinsonism is rare and accounts for less than 10% of all psychogenic 
movement disorders (Hallett 2011). Physical or mental trauma has been recognized as 
the major trigger factor for developing psychogenic movement disorders, even if the 
stressors are not acknowledged by the patient due to denial or poor insight (Hallett 
2011). A significant proportion of patients considered to have psychogenic 
parkinsonism have underlying Parkinson’s disease (Hallett 2011). For example one 
study examined nine patients with suspected psychogenic parkinsonism using 
neurophysiological assessment and 
123
I-FP-CIT SPECT. Seven of those presented with 
tremor and tremor recording was compatible with the diagnosis of organic PD in 
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combination with psychogenic tremor in two (Benaderette, Zanotti Fregonara et al. 
2006). [
123
I]-FP-CIT SPECT scans were abnormal in five of nine patients and a final 
diagnosis of PD in combination with psychogenic parkinsonism was made in six of nine 
patients (Benaderette, Zanotti Fregonara et al. 2006). Similarly in another SPECT study 
two of five patients who were diagnosed having psychogenic parkinsonism had 
abnormal putaminal dopamine transporter tracer uptake (Felicio, Godeiro-Junior et al. 
2010). 
Stress induced reversible Parkinsonism 
Reversible parkinsonism has been observed in seven patients who suffered from acute 
alcohol withdrawal. Three were followed up but none developed PD even after 9-11 
years (Shandling, Carlen et al. 1990). It is possible that sympathetic overactivity may 
have been responsible for these cases as alcohol has been reported to aggravate 
parkinsonian signs in some patients with PD (Shandling, Carlen et al. 1990).  
Acute alcohol intoxication has been also reported to induce cogwheeling, dystonia and 
akathisia in patients who are taking neuroleptic medication (Lutz 1976). 
Two patients who were firmly diagnosed with PD for several years both fully recovered 
following the resolution of longstanding chronic stress. One of these was found to have 
a mildly abnormal fluorodopa PET scan and responded to L-dopa (Figure 27).    
Iatrogenic, toxic and infectious causes were not identified in either case and there was 
no history of the use of complementary therapies.  
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Figure 27.  Stress induced micrographia. 
Above: Small handwriting of a patient who was diagnosed with Parkinson’s disease. 
Below: Same patient after removal of chronic stress. 
Rare examples of stress induced reversible parkinsonism were also reported amongst the 
casualties of  ‘shell shock’, ‘neurasthenia’ and ‘war neurosis’. Chronic fatigue, joint 
pain, poor sleep, tremors, anxiety and ‘gastric troubles’ were all commonly reported in 
English, German and French soldiers (Mott 1919).  
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Although the surviving cine films of these cases showed clear signs pointing towards a 
non-organic movement disorder, a few cases closely resembled PD. In his book ‘War 
Neuroses And Shell Shock’ Mott described one World War One soldier: “The eyes were 
wide open and had a pained vacant stare […], when given a paper and a pencil to write, 
so great was his difficulty in holding the pencil, and so pronounced was the tremor, that 
the pencil only marked a tangled skein on the paper [..]. He cannot move his legs, which 
are rigid […]. As in many of these patients the sole of the foot is shuffled along the 
ground. Another form of tremor which is coarser and less rapid than the preceding, viz. 
5-6 per sec, is that which resembles paralysis agitans.”  Others observed similar 
findings reporting “On standing the head is flexed forward on the neck and protrudes in 
front of the body. Balance is maintained with difficulty since the trunk is flexed 
anteriorly and the legs are partially bent at the knees. The arms hang low and stiffly at 
the sides, giving a simian appearance to the whole posture. Coarse tremors develop in 
the hands and legs (….), the facies are mask-like without expression. The chew and 
swallow slowly as if wishing to keep food in their mouth” (Ginker and Spiegel 1943). At 
the same time similar symptoms were observed amongst German soldiers and were 
referred to as ‘Kriegszitterer’ (“War-tremblers”). In 1940 during the battle of Dunkirk, 
some soldiers developed a “coarse pill rolling tremor” and “nodding movement of the 
head” which resembled parkinsonism. Ex-prisoners of war had a significantly higher 
incidence of developing PD several decades after their release in some studies (Gibberd 
and Simmonds 1980).   
These observations emphasise that prolonged chronic stress can induce a clinical picture 
closely resembling PD, albeit being fully or at least partly reversible. Gowers reflected 
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on the body language of fear in Clifford Albutt’s System of Medicine in 1904.  “If the 
movement of escape is impossible, tremor results, and thus we have the word tremble as 
a synonym for fear. He who trembles is said to be paralysed by fear, and he is, in fact, 
for the moment suffering from paralysis agitans.” 
Stress induced neuronal damage  
Stress-induced elevated glucocorticoid levels in rodent models worsened motor 
performance and higher corticosterone levels led to a greater permanent loss of nigral 
neurons (Smith, Jadavji et al. 2008). 6-hydroxydopamine (6-OHDA) lesioned rats 
moved much more slowly, froze more often and became rigid when challenged with 
stressors but reverted to normal when left alone in their home cage (Snyder, Stricker et 
al. 1985). Foot-shock, tail-pinch or other stressors have all been shown to increase 
striatal dopamine release and turnover in rodents (Pei, Zetterstrom et al. 1990) and it has 
been suggested that this could excite striatal dopamine nerve terminals to death through 
increased oxidative stress (Hastings, Lewis et al. 1996).   
Chronic stress can lead to reduced dopaminergic activity within the ventral tegmental 
area in rodents (Moore, Rose et al. 2001) and cause increased cortisol levels. 
In rats chronic stress significantly decreased dopamine levels in the frontal cortex, 
striatum and the hippocampus (Rasheed, Ahmad et al. 2009). Catecholamines such as 
dopamine are inert when stored in vesicles but it is possible that in susceptible patients 
chronic stress shifts catecholamines into the cytosol where they become toxic via auto-
oxidation. Oxidation of cathecholamines leads to quinones which can cause lipid 
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peroxidation and membrane disruption (Goldstein 2011) and might ultimately cause 
neurodegeneration. Support for this hypothesis comes from additional preclinical 
studies, which have shown that chronic stress induces oxidative stress and increased 
protein and lipid peroxidation (Lucca, Comim et al. 2009).  
Central noradrenergic degeneration in the locus ceruleus and subsequent degeneration of 
nerve terminals in the hippocampus might explain cognitive impairment (Zweig, 
Cardillo et al. 1993) and also possibly REM sleep behaviour abnormalities (Gesi, 
Soldani et al. 2000). Profound cardiac noradrenergic denervation has been described in 
PD (Amino, Orimo et al. 2005) which might be partly responsible for fatigue 
(Nakamura, Hirayama et al. 2011). 
Stress reduces regulatory T-lymphocytes by 50% in patients who suffered from post-
traumatic stress disorder (Sommershof, Aichinger et al. 2009) and a similar profound 
reduction has been found in PD (Baba, Kuroiwa et al. 2005). Dysfunction of regulatory 
T-lymphocytes might contribute to dopaminergic cell loss and vaccination in animal 
models of PD with these regulatory lymphocytes can attenuate nigrostriatal degeneration 
(Reynolds, Stone et al. 2010). 
A convincing link between chronic stress and neurodegeneration has now been 
established in patients with Alzheimer’s disease. Emotionally stressed patients have a 
2.7% higher risk of developing the disease and stressed dementia patients have a more 
rapid disease progression. This is likely to be due to a dysregulation of the hypothalamo-
pituitary-adrenal (HPA)-axis causing dendritic remodelling, dysfunction of 
223 
 
neurogenesis, apoptosis in hippocampal neurons and result in increased oxidative stress 
(Rothman and Mattson 2010). 
Variants of stress 
Stress is part of modern society and without it life would be colourless and 
unstimulating. “Good stress” is often referred to as short self-limiting and has been 
demonstrated to improve the immune system (Segerstrom and Miller 2004). Short 
outbursts of stress, such as ‘examination nerves’, evoke “fight and flight” reactions, via 
the sympathetic nervous system, which releases catecholamines.  
In contrast chronic stress or “bad stress” is emotional draining, physically exhausting 
and induce wear and tear on brain and body. The inability of shutting down stress 
induced activation of the HPA is the hallmark of chronic stress (McEwen 2007) and can 
adversely affect the immune system (Segerstrom and Miller 2004). The “weathering 
hypothesis” suggests that socioeconomic stressors might lead to accelerate aging 
(Geronimus 1992). Indeed life-style diseases such as diabetes, gastric ulcers or 
hypertension have been linked to chronic stress (Liu and Mori 1999).  
Stress in the prenatal period or during aging was also associated with a reduction in 
hippocampal volume later in life and with depression (Lupien, McEwen et al. 2009).   
The “Glucocorticoid Cascade Hypothesis“  states that chronic stress induced prolonged 
exposure to high levels of glucocorticoids results in hippocampal atrophy which then in 
return causes higher glucocorticoid levels and more hippocampal damage (Sapolsky, 
Krey et al. 1986). Furthermore, glucocorticoid levels in the aged population have been 
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linked with memory impairment and to a 14% reduction in the volume of the 
hippocampus (Lupien, Fiocco et al. 2005). Stress can cause dendritic retractions and 
neuronal atrophy within the hippocampus (Conrad 2008), the striatum (Smith, Jadavji et 
al. 2008) and triggers neuroplasticity resulting in sensitization or habituation within the 
stress processing network, containing the limbic system, the hypothalamus and the 
brainstem (Ulrich-Lai and Herman 2009).  
Kinesia paradoxica in Parkinson’s disease 
In rare instances, such as acute life threatening stress, PD patients can dramatically 
override motor handicap which has been called paradoxical kinesia (Souques 1921). 
Such rare examples have been observed during an earthquake, after a car crash or during 
war (Bonanni, Thomas et al. 2010). There are, however, other occasions when PD 
patients can overcome bradykinesia without any strong emotions. In 1967 Purdon-
Martin demonstrated that white lines on the floor could reduce festination and freezing 
in patients with post encephalitic parkinsonism (Purdon-Martin 1967). Immobile 
patients have been shown to catch a ball when thrown at them (Schlesinger, Erikh et al. 
2007) and videos of PD patients who show improvement of freezing and festination 
during ball games can be found online (http://www.pmarc.ed.ac.uk/video/intrinsic-basis-
of-action/paradoxicalmovement.html).  
Similarly rhythmic auditory cues have been reported to improve velocity and stride 
length in PD (Rubinstein, Giladi et al. 2002) and loud unexpected auditory stimuli 
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improved reaction time and grip force in PD patients, which was independent of the 
medication state (Anzak, Tan et al. 2011).  
Following mechanisms have been postulated to explain paradoxical kinesia in PD:  
Acute severe stress can lead to noradrenalin activation, which then increases alertness 
and attention and might result in improved motor function (Schlesinger, Erikh et al. 
2007). Consistent with this, rats treated with haloperidol and showing motor 
impairments could overcome their motor deficits by stress induced noradrenalin 
activation (Keefe, Salamone et al. 1989). 
Activation of the basal ganglia reserves due to fear of reward might also induce 
paradoxical kinesia. PET studies have shown ventral striatal dopamine release in PD 
patients after administration of placebo, which was of similar magnitude to that found in 
controls after given amphetamine (de la Fuente-Fernandez, Phillips et al. 2002). 
Therefore anticipation of an event, such as reward or fear might also result in motor 
benefit.  
Whilst under these exceptional mechanisms motor performance improves, chronic 
anxiety and stress might result in reduction of striatal dopaminergic cells and lead to 
dopamine dysfunction (Moore, Rose et al. 2001), which might explain worsening of 
motor handicaps in PD.   
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Stress induced functional somatic syndromes 
Fibromyalgia  
Fibromyalgia is a chronic disorder characterized by widespread pain of unknown 
aetiology. In 1904 William Gowers introduced the term ‘fibrositis’ which he observed to 
occur frequently in elderly ladies (Gowers 1904). The term ‘fibrositis’ was modified in 
the mid-70s (Inanici and Yunus 2004) in order to emphasise that it is characterised by 
myalgia (muscle pain) and that there is no evidence of inflammation (Smythe and 
Moldofsky 1977). According to the American College of Rheumatology the diagnostic 
criteria for fibromyalgia include diffuse pain for at least 3 months and pain on palpation 
in at least 11 of 18 tender points (Wolfe, Smythe et al. 1990). A tender point is 
considered to be positive when 4kg of pressure has been applied (Schmidt-Wilcke and 
Clauw 2010). Although both genders can be affected fibromyalgia is diagnosed ten 
times more often in females (Wolfe, Smythe et al. 1990). The arbitrary cut off of 11/18 
positive tender points might artificially skew the gender distribution and make 
fibromyalgia look like an almost exclusively female disorder (Clauw and Crofford 
2003). However, all functional somatic syndromes are more commonly seen in females 
and some have speculated that biological and psychological changes are responsible for 
gender differences (Yunus 2001).  
Hyperalgesia (increased discomfort to painful stimuli) or allodynia (pain to non-painful 
stimuli) are other key components of fibromyalgia.  Prevalence rates range from 0.5% to 
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5.8% and comprise 15% of referrals to rheumatology clinics (Neumann and Buskila 
2003, Hauser, Thieme et al. 2010).  
The mean age of onset is typically in the fifth decade of life (Wolfe, Smythe et al. 1990), 
although younger onset cases do occur (Eraso, Bradford et al. 2007). Apart from pain 
patients often complain of a variety of co-morbidities including mild orthostatic 
hypotension (Bou-Holaigah, Calkins et al. 1997), insomnia (Moldofsky 2002), urinary 
frequency and urgency (Wolfe, Smythe et al. 1990, Littlejohn 1996), depression, anxiety 
and chronic fatigue (Chakrabarty and Zoorob 2007). Forgetfulness and poor 
concentration often referred to as ‘fibrofog’ occur in up to 90% of affected individuals 
(Bennett, Jones et al. 2007, Schmidt-Wilcke and Clauw 2010). 
Clinical guidelines have suggested the ‘FIBRO’ mnemonic in patients with 
fibromyalgia, where ‘F’ stands for fatigue, ‘I’ for insomnia, ‘B’ for blues (depression 
and anxiety), ‘R’ for rigidity and ‘O’ for ow! (pain and disability) (Boomershine and 
Crofford 2009). 
Chronic fatigue syndrome 
Chronic fatigue syndrome, also sometimes called ‘myalgic encephalomyelitis’ in the 
UK, is characterized by a period of persistent fatigue lasting at least six months and 
accompanied by four of eight ‘minor’ symptoms: impaired memory; sore throat; tender 
cervical or axillary lymph nodes; muscle pain, multi-joint pain without joint swelling or 
redness; stiffness; new headaches; unrefreshing sleep and post-exertional malaise 
(Fukuda, Straus et al. 1994).  
228 
 
It has been defined as severe mental and physical exhaustion, which is not attributable to 
exertion or diagnosable disease (Fukuda, Straus et al. 1994). Urinary frequency and 
urgency, painful bladder syndrome and psychiatric comorbidities such as major 
depression and anxiety are also frequently reported (Lane, Manu et al. 1991, Nickel, 
Tripp et al. 2010). Females are predominantly affected, with a peak age of presentation 
in the fourth and fifth decades of life. Estimates of prevalence vary between 0.007% and 
2.8%. However, chronic fatigue, defined as fatigue failing the diagnostic criteria of 
chronic fatigue syndrome, is common in the UK with a prevalence rate up to 11% 
(Wessely, Chalder et al. 1997).  
In many parts of the world chronic fatigue syndrome is not recognised but a similar and 
possibly identical malady termed neurasthenia is. Neurasthenia is a more generic term 
embracing all cases of chronic fatigue syndrome and usually overlaps with depression 
(Harvey, Wessely et al. 2009).  
Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is defined as chronic abdominal pain and bowel 
dysfunction without evidence of abnormalities on physical examination. Women are 
three to four times more likely to develop IBS with a peak incidence between ages 30 to 
50. Estimated prevalence rates range between 4.4% up to 21% (Drossman, Camilleri et 
al. 2002). IBS is associated with a variety of different medically unexplained co-
morbidities such as poor sleep, chronic back pain, palpitation and headaches (Riedl, 
Schmidtmann et al. 2008). Fibromyalgia is also common in IBS patients with a 
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prevalence rate between 26-65% (Sperber, Atzmon et al. 1999, Riedl, Schmidtmann et 
al. 2008).  
Chronic fatigue syndrome in IBS has been less well studied but has been considered to 
be common by some authorities (Wessely, Nimnuan et al. 1999). Excessive sleepiness 
during the day is also commonly seen in IBS (Sperber and Tarasiuk 2007). Conversely, 
IBS occurs in up to 51% of patients with chronic fatigue syndrome (Whitehead, Palsson 
et al. 2002). Urinary urgency, frequency, nocturia and incomplete bladder emptying 
occur in about half of all patients with IBS and quoted figures for sexual dysfunction 
range from 24% to 83% (Riedl, Schmidtmann et al. 2008). Psychiatric comorbidities, 
such as panic and anxiety disorder and major depression are also frequent with a 
prevalence range just under 50% (Lydiard 2001). 
Clinical overlap between functional somatic syndromes and 
Parkinson’s disease 
Musculoskeletal pain, unusual pelvic and rectal discomfort, poor sleep, fatigue and 
depression, features characteristic for functional somatic syndromes, are common in PD 
(Gallagher, Lees et al. 2010). Mental fatigue, sometimes referred to as ‘central fatigue’, 
a typical feature of patients with chronic fatigue syndrome, can be found in up to 70% of 
PD patients at some stage of the illness (Friedman, Abrantes et al. 2011). Chronic 
fatigue, depression and anxiety can sometimes lead to the misdiagnosis of a functional 
disorder, especially in younger patients and delay appropriate treatment for several 
decades (Ling, Braschinsky et al. 2011).  
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Fatigue was a common feature of the pandemic of encephalitis lethargica of 1916-1929. 
A relatively frequent sequelae of the neurasthenic phase of the illness was parkinsonism 
while other patients appeared to recover only to develop parkinsonism months or years 
later. Similarly during  an outbreak of chronic fatigue syndrome in the 1940s (Akureyi 
myalgic encephalomyelitis) three children are said to have died of juvenile PD (Gibson, 
Taylor et al. 2011).  
Features of IBS including abdominal bloating, and alternating diarrhoea and 
constipation occur commonly in PD (Edwards, Pfeiffer et al. 1991). Constipation, a 
variant of IBS associated with more abdominal colic and bloating than the IBS-
diarrhoea variant (Talley, Dennis et al. 2003), is one of the most common non-motor 
complains of patients with PD (Savica, Rocca et al. 2010) and may precede 
bradykinesia, rigidity and tremor (Ashraf, Pfeiffer et al. 1997). The long term follow up 
studies of the Honolulu-Asia Aging Study showed that constipation was associated with 
a higher risk of developing PD (Abbott, Petrovitch et al. 2001) and those who had 
constipation without PD had significantly lower substantia nigra neuronal densities and 
more incidental Lewy body pathology in the substantia nigra (Petrovitch, Abbott et al. 
2009).   
Lewy neurites have been also found on routine colonoscopies in 72% of PD patients a 
finding which correlated significantly with disease severity (Lebouvier, Neunlist et al. 
2010). 
Conversely, symptoms that are typical for PD have been found in patients with 
functional somatic syndromes. For example over 75% of patients with chronic fatigue 
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complain of ‘slow thinking’ (Lane, Manu et al. 1991), which can be an early feature of 
PD often referred to as bradyphrenia. Slowness of initiation of movement is seen in 
retarded depression and in common with PD it can be partially overcome by external 
cues (Rogers, Bradshaw et al. 2000). Reduction in stride length, slowness, impairment 
of flexing and bending knees and hips and trouble keeping up on treadmills all occur in 
patients with chronic fatigue syndrome (Boda, Natelson et al. 1995). Further, a reduction 
in velocity during simple and complex hand movements and a similar 3-5 bursts 
electromyography pattern during task performance has been observed in both depression 
and PD patients (Sachdev and Aniss 1994).  
Restless legs syndrome (RLS) and muscle and joint stiffness are frequently reported by 
patients with fibromyalgia (Stehlik, Arvidsson et al. 2009) as are tremor, stiffness and 
poor coordination (Wolfe, Smythe et al. 1990). Olfactory dysfunction with increased 
sensitivity to unpleasant smells and reduced appreciation of pleasant odours has been 
also described in fibromyalgia (Schweinhardt, Sauro et al. 2008) and PD. 
Pharmacological studies further strengthen a potential link between fibromyalgia, 
chronic fatigue and PD. Pramipexole significantly improved pain and fatigue in 
fibromyalgia after 14 weeks of treatment (Holman and Myers 2005). However, this 
result could not be replicated with two other dopamine agonists, ropinirole and 
rotigotine (GlaxoSmithKline. 2008, UCB-News. 2009). A significant proportion of 
treated patients developed pathological gambling or compulsive shopping after 
dopamine agonist treatment (Holman 2009). 
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In PD, L-dopa has been found helpful for physical fatigue (Lou, Kearns et al. 2003) but 
treatment of non-motor fatigue in PD has proved more challenging (Friedman, Abrantes 
et al. 2011). Although amantadine is often empirically used to treat fatigue in PD, no 
controlled studies have been published (Friedman, Abrantes et al. 2011) and amantadine 
is said to be ineffective in chronic fatigue syndrome (Plioplys and Plioplys 1997).  
On the other hand trials with the selective Type B monoamine oxidase inhibitor 
selegiline and the dopamine and noradrenaline reuptake inhibitor bupropion have shown 
efficacy in reducing central fatigue (Pae, Marks et al. 2009). 
Striato-thalamo-cortical alterations in functional somatic 
syndromes 
Dopamine plays an essential role in pain modulation. Electrical stimulation of the basal 
ganglia or administration of dopaminergic agents can reduce defensive reaction to pain 
in animals (Magnusson and Fisher 2000). In contrast blocking endogenous dopamine 
release or lesioning dopaminergic pathways increases nociception (Magnusson and 
Martin 2002). In PD for example L-dopa administration can significantly reduce pain 
(Nebe and Ebersbach 2009). 
Increased prolactin response to buspirone, a partial dopamine antagonist that acts on the 
pituitary gland, provided indirect evidence for altered dopamine D2 receptor 
dysfunction in patients with fibromyalgia (Malt, Olafsson et al. 2003), chronic fatigue 
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syndrome (Sharpe, Clements et al. 1996) and also in patients with non-ulcer dyspepsia, 
which is part of irritable bowel syndrome (Dinan, Mahmud et al. 2001).  
In fibromyalgia low concentrations of dopamine metabolites in the cerebrospinal fluid 
(Russell, Vaeroy et al. 1992), decreased 6-[(18)F]fluoro-DOPA tracer uptake within the 
ventral tegmental area and the substantia nigra (Wood, Patterson et al. 2007) and 
blunted dopamine release in response to painful stimuli have been reported (Wood, 
Schweinhardt et al. 2007).  
Reduction in cerebral blood flow in the caudate nucleus and the thalamus were found in 
both fibromyalgia (Mountz, Bradley et al. 1995, Kwiatek, Barnden et al. 2000) and 
chronic fatigue syndrome (Costa, Tannock et al. 1995). In addition, reduced cerebral 
blood flow in the anterior cingulate has been found in patients with chronic fatigue 
(Schmaling, Lewis et al. 2003). Dysfunction in the anterior cingulate is particularly 
interesting since it is known to have the greatest dopamine innervation in the cortex 
(Lewis, Foote et al. 1988) and has been associated with depression and apathy in PD 
(Remy, Doder et al. 2005).   
Functional magnetic imaging (fMRI) studies in IBS patients showed significant 
deactivation of the amygdala, the right cortex and the basal ganglia after inducing rectal 
pain (Bonaz, Baciu et al. 2002). Further, in these patients a significantly reduced striatal 
dopamine D2 receptor binding in the caudate nucleus was found (Braak, Booij et al. 
2012).  
This data raises the possibility that changes in the striato-thalamo-cortical loops due to 
reduction in dopamine activity may be responsible for fatigue (Chaudhuri and Behan 
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2000), pain, IBS and other neuropsychiatric symptoms commonly found in functional 
somatic syndromes. In support of this notion, axonal damage in the striato-thalamo-
cortical loops has been associated with fatigue in patients with multiple sclerosis (MS) 
(Calabrese, Rinaldi et al. 2010) and with post stroke fatigue due to lacunar infarcts 
(Tang, Chen et al. 2010).  
The prodrome of Parkinson’s disease 
Onset of PD is gradual and it is often difficult to determine when exactly bradykinesia 
and rigidity appear. Several studies have found that PD patients have a lower premorbid 
risk of smoking, and tend to be anhedonic, moralistic, punctual, risk averse and altruistic 
with a strong adherence to social norms (Todes and Lees 1985). This has led to the 
concept of the “Parkinsonian personality” suggesting that these patients are more likely 
to be emotionally inflexible, and of a neurotic type (Todes and Lees 1985), which has 
been, however, challenged more recently (Arabia, Grossardt et al. 2010).  
Ray Kennedy, the Arsenal and Liverpool international football player described non-
motor symptoms at least 14 years before the diagnosis of PD was made. “I realised that 
nobody had my after match routine. Usually the adrenaline is still pumping and most of 
the lads would be talking about what happened on the pitch, grabbing a coke or chicken 
leg. They were always doing something-all except me. I used to slump hunched in my 
seat too tired to talk or move” (Lees 1992).   
Recent papers have attempted to retrospectively examine the nature and frequency of 
these non-specific features before the diagnosis of PD. Gonera and colleagues 
235 
 
performed a retrospective case control study where the authors studied the primary 
health care medical records of 60 PD patients and 58 controls over the 10 years prior to 
the diagnosis of PD. During this period the PD patients had visited their GPs more 
frequently than age matched controls and had complained of more symptoms (Gonera, 
van't Hof et al. 1997). Neuropsychological complaints which were reported in almost 
half of the PD cases included depression, anxiety and nervousness. Musculoskeletal 
symptoms were equally common and included low back pain, shoulder pain, arthralgia 
and ischialgia. Further, 68% of these patients had fibromyalgia before the motor onset of 
PD (Gonera, van't Hof et al. 1997). In another study frozen shoulder was the initial 
complain of 8% of patients who developed PD up to 2 years later (Riley, Lang et al. 
1989). 
Symptoms suggestive of autonomic dysfunction such as fainting, cardiovascular 
disturbances including  hypertension, arrhythmia and angina and other symptoms such 
as pain, paraesthesia, headache and memory problems were also recorded more common 
in PD patients than controls (Gonera, van't Hof et al. 1997). Another interesting finding 
was that 18% of these patients had complained of diarrhoea for which no specific cause 
was found (Gonera, van't Hof et al. 1997) raising the possibility that this was irritable 
bowel syndrome.  
A significantly higher frequency of medically unexplained symptoms has been 
associated with PD (7%) and dementia with Lewy bodies (12%) compared with other 
neurodegenerative diseases such as MSA, PSP and Alzheimer’s disease (0-3%). The 
most common symptoms found were multilocalized pain with gastrointestinal 
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symptoms, hypochondriasis and paresis. These somatoform disorders preceded the 
diagnosis of PD by from 6 months up to 10 years (Onofrj, Bonanni et al. 2010). These 
findings raise the possibility that functional somatic syndromes can be a premotor 
feature of PD.  
In another study structured telephone interviews using non-motor and motor 
questionnaires, were applied retrospectively to assess in 93 PD patients their perception 
of the prodromal phase of PD. Hyposmia, disturbed sleep, depression, apathy, 
moodiness, increased sweating and constipation were the most frequently reported 
symptoms in the decade prior to the diagnosis of PD (Gaenslen, Swid et al. 2011). 
The cardinal motor features of PD only emerge when about 30% of dopaminergic 
neurons are damaged (Cheng, Ulane et al. 2010) and nigral cell loss may begin about 7 
years before the first motor symptoms appear. Alpha synuclein on colonic biopsy was 
found 2-5 years prior to the onset of motor symptoms (Shannon, Keshavarzian et al. 
2012) but Braak and colleagues based on neuroanatomical studies in which they used 
Lewy bodies as a surrogate marker for  nerve cell dysfunction have claimed that the 
disease may begin much earlier than this in the enteric nervous system, sympathetic 
ganglia, olfactory bulb and  medulla oblongata (Braak, Del Tredici et al. 2003). Non-
motor complaints were the initial presentation of 21% of pathologically proven PD 
cases. Pain (53%), urinary dysfunction (16.5%), anxiety and depression (12.1%) were 
the most commonly reported complaints (O'Sullivan, Williams et al. 2008). There is no 
data on the prevalence of chronic fatigue in the prodromal stage of PD but it is 
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recognised by experienced neurologists that fatigue frequently accompanies the earliest 
motor symptoms. 
Conclusion 
Hypersensitivity to stress is thought to be genetically determined (Gilad and Gilad 1995) 
and variations in the serotonin 5HTR2C receptor have been associated with greater 
cortisol release and emotional responses to mental stress (Brummett, Kuhn et al. 2012).  
Insufficient stress coping strategies may therefore lead to dopaminergic cell loss and 
may ultimately trigger PD in susceptible individuals. Chronic emotional stress can result 
in alterations of DNA methylation which is known to regulate α-synuclein expression 
(Babenko, Kovalchuk et al. 2012). A stochastic event triggered by chronic emotional 
stress might therefore explain why a pair of identical twins who were both Leucine-rich 
repeat-kinase type 2 (LRRK2) carriers showed a discordant phenotype after more than 
ten years of follow up (Xiromerisiou, Houlden et al. 2012). Screening PD patients and 
patients with functional somatic syndromes for polymorphisms that are known to be 
important for stress regulation may represent one important future line of epigenetic 
research.  
Physical exercise was associated with a reduced risk of PD later on in life (Thacker, 
Chen et al. 2008), and is also a recognized approach to stress management. Randomized 
controlled studies assessing whether a significant reduction of chronic stress, achieved 
for example with cognitive behavioural therapy (Fjorback, Arendt et al. 2011), may also 
lead to a reduced incidence of PD would be of significant interest.   
238 
 
Prospective long term follow up studies in the middle aged population measuring stress 
hormones such as cortisol levels from hair, which has shown to be a valid biomarker for 
measuring the long-term cortisol secretion (Meyer and Novak 2012), and inflammatory 
markers such T-lymphocytes may further clarify the role of stress in PD. 
Key Findings 
o It is possible that chronic emotional stress causes striatal damage in 
susceptible individuals and triggers PD. 
o Emotional stress can lead to reversible symptoms that resemble PD, 
including tremor, gait disturbance and postural instability. 
o Acute short lasting life-threatening stress can temporarily improve 
bradykinesia in PD. Conversely, chronic stress can worsen motor 
symptoms in patients with PD.    
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Introduction 
It has been difficult to confirm the adverse effects of chronic stress in PD with 
biological measures. However, in animal models of PD elevated cortisol levels have 
been associated with dopaminergic cell loss and motor handicap (Smith, Jadavji et al. 
2008). Higher cortisol levels have been described in depression (Bhagwagar, Hafizi et 
al. 2005), anxiety (Vreeburg, Zitman et al. 2010) and also in Alzheimer’s disease and 
PD (Hartmann, Veldhuis et al. 1997). An acute increase of cortisol levels has been 
reported during intake of illicit drugs (Goeders 2002). Although a large proportion of 
addiction-related research has highlighted the importance of dopaminergic pathways 
(Koob and Volkow 2010), there is also a line of evidence supporting the role of cortisol 
in the development of addictive or impulsive behaviours (Lovallo 2006, Koob and 
Kreek 2007). Given the link between cortisol and addiction in the non-PD population 
(King, Jones et al. 1990), and between addiction and the development of ICBs in PD, 
the hypothesis was that cortisol levels might be lower in impulsive PD patients relative 
to PD patients without ICBs.  
In this study, salivary cortisol levels from PD patients with (PD+ICB) and without ICBs 
(PD-ICB) and healthy controls were measured and correlated with the performance on a 
risk task (Huettel, Stowe et al. 2006). Increased salivary cortisol levels have also been 
positively correlated with risk taking in non-PD pathological gamblers (Meyer, Hauffa 
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et al. 2000). Therefore, a correlation between cortisol and risk taking behaviour was 
made. 
Patients and methods 
Cortisol samples from 13 PD-ICB, 15 PD+ICB patients and 14 healthy controls were 
collected. All patients were recruited from the National Hospital for Neurology and 
Neurosurgery Queen Square, London, fulfilling the Queen Square Brain Bank criteria 
for PD (Gibb and Lees 1988) and were taking L-dopa. PD+ICB patients were diagnosed 
using proposed criteria (Evans, Katzenschlager et al. 2004, Voon, Thomsen et al. 2007). 
Most PD+ICB patients had more than one ICB. Healthy controls were usually recruited 
from amongst the patient’s partners and were not taking any medication that could 
influence cortisol measurement. None of the participants was taking steroids. Written 
informed consent was obtained from all subjects according to
 
approved ethical protocols 
from the regional and local research
 
ethics committee. Participants who scored under 
27/30 points on the MMSE and who had a current or past medical history of an anxiety 
disorder and patients with current depression were excluded. Patients without a known 
previous diagnosis of anxiety or depression were screened for these conditions in a 
semi-structured clinical assessment. Further, all participants were asked to fill out the 
positive and negative affect schedule (PANAS), which has been recommended to use as 
a supplement to measure anxiety and depression (Crawford and Henry 2004). Samples 
were obtained in a quiet environment usually at patient’s homes to control for and 
reduce the amount of stress. To control for the potential effects of food (Van Cauter, 
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Kerkhofs et al. 1992) and L-dopa (Muller and Muhlack 2007) on cortisol levels, PD 
patients were asked not to take their usual anti-Parkinson medication for at least 12 
hours and not to have breakfast on the day of testing. All participants woke up between 
6.00 a.m. and 7.00 a.m. The morning samples were obtained together with me and the 
other samples were collected by the participants themselves. 
Cortisol 
Participants were instructed to collect saliva samples by turning the cotton roll for 2-
3 min in their mouth. In total five saliva samples were collected from controls and 10 
samples from patients. Samples from all participants were obtained between 8.15 a.m. 
and 8.45 a.m. -baseline level. All patients were tested in their “off condition” in the 
morning, which was assessed by the UPDRS (part 3) motor score. Further, five more 
saliva samples were collected from the patient group. One was obtained immediately 
prior to the risk task, one just after the risk test and prior to medication, the next 5 min 
after medication, then 15 min after medication, 30 min after medication and 45 min after 
medication. Sixty minutes after medication between 9.15 a.m. and 9.45 a.m. and after 
the second test (“on condition” in patients) another sample was taken, this time from 
both groups controls and patients (Figure 28). All participants then collected samples 
between 1-2 p.m., between 7-8 p.m. and 10-11 p.m. on their own. These times were 
deliberately flexible for patients to ensure that the cortisol sampling was undertaken 
approximately one hour after taking their usual dopamine replacement therapy.  
Controls were tested in the same way without taking any medication in between.   
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Figure 28.  Schematic outline of the time course of saliva samples. 
Ten salivary samples were obtained from patients and five samples from controls. 
Subjects were asked to avoid excessive physical activity, stress and heavy meals on the 
study day, and were provided with a collection diary where they entered the time of 
saliva collection and their activity during the hour prior to each cortisol sample. In 
addition participants were instructed not to eat anything at least 30 min prior to 
collecting a sample. The therapeutic motor response to L-dopa was assessed by UPDRS 
scores (part 3) during “off” and “on” state. All patients had an excellent L-dopa 
response and had a similar improvement in the UPDRS scores (see Table 18). All 
patients were “on” at the time of the second risk task. LEU (Levodopa equivalent units) 
was calculated as described previously (Evans, Katzenschlager et al. 2004). 
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Table 18.  Cortisol: Demographic characteristics. 
UPDRS = Unified Parkinson’s Disease Rating Scale; LEU = L-dopa equivalent units; DA 
= dopamine agonists.  All values are mean ± sem. Significant difference is labelled 
with “*”. Controls, Parkinson’s disease without (PD-ICB) and with impulsive 
compulsive behaviour (PD+ICB). 
  
           
Controls  
  
 PD-ICB  
  
 PD+ICB  
 t-value 
 F-value 
 χ 2 
 
  
p value  
Participants in total (no.) 
 
Gender (male) 
Age (yrs) 
At time of testing (yrs) 
At disease onset (yrs) 
 
 14 
 
 6 
 
 58 ± 3 
       - 
       -        
 13 
  
 11 
 
 64 ± 2 
 52 ± 2 
  
 15 
 
 10 
  
 56 ± 3 
 43 ± 3 
  
 
 
 χ 2=5.2, df=2 
 
 F=2.5, df=2 
 t=2.6, df=24 
  
 
 
 p=0.075 
  
 p=0.09 
 p=0.014*  
Disease duration (yrs) 
 
Pathological Gambling 
Hypersexuality 
Compulsive Shopping 
Binge Eating 
Punding 
       - 
 
       - 
       - 
       - 
       - 
       - 
 
 11 ± 2 
 
       - 
       - 
       - 
       - 
       - 
       
 12 ± 2 
  
 9 
 6 
 5 
 4 
 2 
  
 t=0.4, df=24  p=0.7 
 
  
Morning L-dopa dose (mg) 
Total L-dopa dose (mg)  
LEU dose (mg) 
DA (patients) 
       - 
       - 
       - 
       - 
 
 170 ± 22  
 580 ± 74 
 722 ± 85 
 8  
  
 185 ± 25 
 625 ± 100 
 797 ± 100  
 5 
  
 t=0.4, df=24 
 t=0.3, df=24 
 t=0.5, df=24 
 χ 2=1.6, df=1 
 p=0.6 
 p=0.7 
 p=0.6 
 p=0.2 
UPDRS OFF medication 
UPDRS ON 
       - 
       - 
 25 ± 1 
 14 ± 2 
 32 ± 4 
 19 ± 3 
 t=1.9, df=24 
 t=1.8, df=24 
 p>0.07 
 p=0.08 
Average improvement in 
UPDRS (%) 
          
       - 
  
 44 
  
 
 41 
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Risk task 
All patients were tested on a validated computerized gambling task to assess risk 
behaviour (Huettel, Stowe et al. 2006) as described in chapter 3. PD patients performed 
the task once in their “off medication” state after their first salivary cortisol sampling, 
and once in their “on medication” state approximately 50 minutes after receiving their 
usual morning anti-Parkinson medications. Controls were tested in the same way but did 
not take dopaminergic medication between the tests. Participants had to choose between 
two gambles with varying levels of risks – either a low risk or a high risk gamble, where 
participants could win real money. Feedback was given immediately. For further details 
see chapter 3.1.  
Biochemical measurements 
Saliva samples for the determination of cortisol concentration were collected in 
“Salivettes” (Sarstedt, Leicester, UK) and stored at -20 Celsius until analysed. Saliva 
cortisol concentrations were determined using the chemiluminescence assay of 
“Immulite”- DPC’s automated Immunoassay analyser (Babson 2001) and the aid of a 
Robotic Sample processor (Tecan Genesis 100). Details about the analysis were 
published elsewhere (Mondelli, Dazzan et al. 2010). 
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Statistical analysis 
Demographic and clinical features 
Data analyses were performed using SPSS, version 18. Age, gender, age of onset 
UPDRS scores, L-dopa  and LEU dose were used as dependent variables and group 
(PD-ICB, PD+ICB and control) was modeled as a between subject factor.  An ANOVA, 
t-test or χ 2  test was used where appropriate.  
Cortisol Salivary samples 
The data was positively skewed as cortisol levels show a diurnal variation with a peak 
during the morning (Figure 29A and B). As a result the data was log transformed and 
residuals were checked and found to be normally distributed.  
A linear mixed model ANOVA was performed with the log transformed scores as the 
dependent variable, group (PD-ICB, PD+ICB and control) was modeled as a between 
subject factor. The model also included subject as a random factor, and the interactions 
between the two fixed factors (time and group).  
All post-hoc comparisons were corrected by the Bonferroni method, the level of 
significance was p < 0.05. For the diurnal cortisol measurement those extra samples that 
were obtained from the patients between the tests were excluded.  
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Figure 29.  Cortisol levels of participants. 
A: Diurnal cortisol levels of all three groups. B:  Cortisol levels between Parkinson's 
disease patients without (PD−ICB) and with (PD+ICB) impulsive compulsive 
behaviour. All values are mean (±1 SE). Although not significantly different, baseline 
morning cortisol levels were lower in the PD+ICB group. 
Risk task 
Changes in risk aversion and change in cortisol levels was correlated. This is a within-
subjects analysis. Specifically, the correlation coefficient was calculated between: ΔR 
and ΔC, where ΔR =R1 – R2 is the difference in risk aversion in the first and second test 
session, ΔC was defined accordingly for cortisol levels. One value for ΔR and one for 
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ΔC was derived for each subject, and these values were then correlated using Pearson’s 
correlation test.   
Results 
Demographic characteristics 
Groups were generally well matched. There was no significant age difference between 
the groups F(2,38) = 2.5, p = 0.091. However, PD+ICB patients had an earlier disease 
onset (t24 = 2.6, p = 0.014). There was no difference in the daily L-dopa doses or the 
dose given in the morning, LEU dose, UPDRS (part 3) scores or disease duration (see 
Table 18).  
Cortisol levels 
There was a main effect of group (F(2,37)  =  4.6, p = 0.016) and a main effect of time 
(F(4,144) = 51.0, p < 0.001), with the highest cortisol level being in the morning.  
There was no interaction between time and group, (F(8,144)  = 0.9, p = 0.48). Post hoc 
analysis revealed that the PD-ICB group had significantly higher cortisol levels than the 
control group (p = 0.019) (Figure 30). There was no difference between the control and 
the PD+ICB group (p = 0.1) and no difference between the patient groups (p = 1.0). 
There was no significant difference in the morning cortisol levels between the patient 
groups after excluding the control group (t24 = 2.4, p = 0.2). There was also no 
correlation between UPDRS off score and baseline cortisol levels, (all p-values  > 0.4). 
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Figure 30.  Log scores of diurnal salivary cortisol levels. 
Controls, PD−ICB and PD+ICBs.  Box plot showing the median (horizontal line) within 
a box containing the central 50% of the observations (the upper and lower limits of 
the box are the 75th and 25th percentiles). Outliners are shown as a circle symbol. 
*Significant difference. 
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Risk task 
Participants were tested twice on a behavioural task that assessed risk taking behaviour 
(Huettel, Stowe et al. 2006), once off medication and once on medication. Cortisol 
samples were taken just before each administration of the task. The task assessed the 
extent to which participants preferred large, low probability rewards to smaller more 
probable rewards.  
This study focusses on the relationship between cortisol and risk taking behaviour. In 
the PD+ICB group, there was a significant correlation between change in risk from the 
first to the second test session (from the off medication state to the on medication state) 
and change in cortisol levels measured just before each test session (r = -0.617, p = 
0.0144, n =15). Specifically, increased risk preference was associated with increased 
cortisol levels. In the PD-ICB group the correlation was not significant (r = 0.166, p = 
0.669, n = 11).  
Furthermore, the correlation coefficients were significantly different between the PD-
ICB and the PD+ICB groups (Z = 1.99, p = 0.047), such that there was a significantly 
stronger correlation in the PD+ICB group than in the PD-ICB group.  
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Discussion 
As expected, cortisol levels were found to be highest in the morning in all participants 
and decreased over the day (Figure 25A). Furthermore, results showed a significantly 
higher daily salivary cortisol levels in PD-ICB patients compared to healthy controls but 
no difference between PD+ICB patients and controls. Increased irritability and lability, 
higher scores of disinhibition and novelty seeking and a previous history of addictive 
behaviours have been reported in PD+ICB patients (Voon, Thomsen et al. 2007, Siri, 
Cilia et al. 2010). 
In this study, it is not possible to determine whether changes in cortisol are a cause or 
effect of the impulsive-compulsive behaviours. However, impulsiveness, carelessness, 
and aggressive behaviour have been associated with attenuated cortisol levels in 
adolescences and adults (Bergman and Brismar 1994, Ramirez 2003, Susmann 2006). 
Impulsive adults with illicit drugs abuse (King, Jones et al. 1990), patients with 
antisocial behaviour (Susmann 2006) and controls with reduced negative feedback 
learning (van Honk, Schutter et al. 2003) had also lower cortisol levels. Increased 
temporal discounting, the tendency to choose earlier, smaller over delayed, larger 
rewards has been found only in PD+ICB patients (Housden, O'Sullivan et al. 2010) and 
has been associated with attenuated cortisol levels in healthy controls (Takahashi 2004). 
However, there was no difference between the two patient groups and between the 
control and PD+ICB group. Previous studies found sustained elevated cortisol levels in 
Aborigines after receiving their wages which they planned to gamble with (Schmitt, 
Harrison et al. 1998). Therefore, the expectance of being tested, the subsequent modest 
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monetary reward for completing the study could have led to an increase of baseline 
cortisol levels in PD+ICB patients. Another possible explanation is that Parkinson’s 
disease itself is associated with increased cortisol levels (Hartmann, Veldhuis et al. 
1997), while personality traits typical for PD+ICB patients are linked with lower cortisol 
levels. This might explain why there was no difference between PD+ICB patients and 
the two other groups. Critically there was, however, a change of direction of cortisol 
levels only in the PD+ICB group during gambling. This change of direction in cortisol 
levels following a stressor has been linked with antisocial behaviour (Susmann 2006). 
As reported previously all PD patients were more risk prone on medication compared to 
controls with a subgroup of PD+ICB with pathological gambling taking the most risky 
decisions. When correlating changes in cortisol levels with risk taking behaviour, results 
showed a significant interaction in the PD+ICB group but not in the PD-ICB group, 
despite both groups showing similar performance on the risk task. These findings are 
consistent with previous studies in male non-PD gamblers showing a rise in salivary 
cortisol levels (Meyer, Hauffa et al. 2000, Franco, Paris et al. 2009) and blood cortisol 
levels (Meyer, Schwertfeger et al. 2004) during gambling. Acutely raised cortisol has 
been linked with anticipation of increased chances of making money and can be 
euphorogenic (Erickson, Drevets et al. 2003, Coates and Herbert 2008). Alcohol and 
nicotine induce an increase in cortisol levels (Kirschbaum, Wust et al. 1992, Lovallo 
2006) and addicts have an increased activation of the hypothalamic-pituitary-axis during 
drug intake (Lovallo 2006). Several preclinical studies have also shown that cortisol acts 
as a positive reinforcer and causes addiction (Deroche, Piazza et al. 1993). Self-
administration of cocaine leads to elevated cortisol levels in rodents (Koob and Kreek 
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2007), non-human primates (Sarnyai, Mello et al. 1996) and humans (Heesch, Negus et 
al. 1995). 
The relative increase in cortisol in PD+ICB patients during risk taking further 
strengthens the link between biological and drug addictions. These results are especially 
interesting since L-dopa has a dual effect on cortisol and behaviour. It increases risky 
behaviour in all PD patients and high doses of L-dopa can reduce cortisol levels (Muller 
and Muhlack 2007). The latter finding contrasts with results presented here, but in the 
study by Muller and colleagues a control group was not included, morning samples were 
obtained at a time of the day when cortisol levels decrease fastest and no information on 
circadian cortisol levels was provided. 
Conclusion 
This is the first study that has tested salivary samples in PD+ICB patients. Results 
suggest that in general, cortisol levels are elevated in PD-ICB patients compared to 
controls but not in the PD+ICB group. This is in keeping with the literature which links 
lower cortisol levels with antisocial behaviour, and further links ICBs with substance 
addiction. Additionally, there was a significant correlation between risk-taking 
behaviour and cortisol levels in the PD+ICB group with higher cortisol levels being 
associated with risk prone behaviour but no significant interaction in the PD-ICB group.   
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Key Findings 
o PD-ICB patients had significantly higher diurnal salivary cortisol levels 
than healthy controls. 
o There was no difference in cortisol levels between the PD+ICB group and 
controls. 
o Increased cortisol levels correlated with increased risk taking behaviour in 
PD+ICB patients, but not in the PD-ICB group. 
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The data presented in this thesis suggests that jumping to conclusions, irrational beliefs 
and risky choices rather than hedonic behaviours or lack of response inhibition are 
responsible for ICBs in PD.  
Dopaminergic medication restored negative feedback learning, but did not enhance 
positive feedback learning in PD patients with ICBs when studied in their “on” state. 
This contrasts to the findings in PD patients without ICBs who have intact learning from 
reward but impaired learning from punishment in their “on” state and vice versa in their 
“off” state (Frank, Seeberger et al. 2004).   
Dopaminergic medication affects cognitive performance in PD patients with and without 
ICBs in a complex fashion with improvement in some tasks and deterioration in others. 
Anti-Parkinson medication improved response inhibition in both PD groups. Reaction 
times and error rates were restored on the Stroop test in the “on” state without any group 
differences. These results suggest that response inhibition is unlikely to play a 
prominent role in addictive behaviours in PD.   
On other tests such as the WM task, dopaminergic medication had no effect on 
performance. PD patients with ICBs performed significantly worse on the digit forward 
and backward span. Furthermore, there was no group difference between PD patients 
with and without ICBs on a working memory test, which utilized abstract geometrical 
images instead of digits. PD patients with ICBs, however, remembered distractors 
significantly better than the non-impulsive PD group. The ability to suppress task 
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irrelevant stimuli may prevent PD patients without ICBs from developing behavioural 
addictions.  
In an altruistic punishment task medication did not change performance in the non-
impulsive PD group, whereas PD patients with ICBs punished significantly more in 
their “on” compared to their “off” state. These findings imply that PD patients with 
ICBs recognize social norms in their “on” state but have difficulties following them.  
Cognitive impulsivity was assessed with a gambling task and the beads task. All PD 
patients became more risk prone on medication and those with pathological gambling 
made the most risky choices of all raising the possibility of “loss chasing” behaviour 
(Campbell-Meiklejohn, Woolrich et al. 2008). 
To assess “reflection impulsivity” PD patients with and without ICBs, non PD-gamblers 
and substance abusers were tested on the beads task. Results showed that all PD patients 
gathered significantly less evidence and made more irrational decisions than controls. In 
addition, PD patients with ICBs performed similarly to substance abusers on opioid 
replacement therapy and gathered significantly less information than PD patients 
without ICBs, who more closely resembled pathological gamblers. The majority of PD 
patients without ICBs were taking L-dopa in combination with a dopamine agonist.  
Thus, the combination of L-dopa and dopamine agonists likely triggers reflection 
impulsivity in all PD patients, but intact cortical inhibition prevents the majority from 
developing an ICB. It remains, however, possible that more of these patients will 
develop an ICB in the future as treatment continues. Half of the PD patients with ICBs 
had been weaned off dopamine agonist therapy at the time of testing but were still as 
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impulsive as those ICB patients still receiving a dopamine agonist. These findings imply 
that dopamine agonists may cause lasting changes within cortico-striatal-pallidal-
thalamo-cortical networks and strengthen the link between ICBs and drug dependency. 
Analysis of three trials in the 80/20 loss condition correctly identified ICB patients with 
a sensitivity of 96%. 
To explore the role of dopamine agonists and the role of STN-DBS on reflection 
impulsivity, PD patients on L-dopa therapy treated with and without a dopamine agonist 
were compared to patients who were treated with STN-DBS who were either taking L-
dopa or L-dopa in combination with a dopamine agonist. Previous studies in PD patients 
with STN-DBS were inconclusive with some studies showing improvement and some 
worsening of ICBs. However, in most other studies PD patients with STN-DBS were 
treated with a dopamine agonist.  
In the present research PD patients on L-dopa therapy performed as well as controls, 
whereas patients who were taking L-dopa in combination with a dopamine agonist 
gathered significantly less evidence and made more irrational choices. There was no 
difference between STN-DBS patients treated with a dopamine agonist and the PD 
group treated with dopamine agonists. Similarly, there was no difference between the 
two PD groups who were not taking dopamine agonists, demonstrating that STN-DBS 
per se did not influence performance on the beads task.   
Taken together these results imply that the single most important risk factor for 
reflection impulsivity in PD is dopamine agonist therapy. It is, however, important to 
note that all patients who had a history of ICBs were excluded from this study. This was 
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necessary as it was anticipated that a past history of ICBs would cause permanent 
reflection impulsivity and therefore would confound results on the beads task. Thus, a 
damaging interaction between L-dopa and deep brain stimulation in individuals with 
pre-operative ICBs cannot be excluded.  
The beads task may be useful as a screening test for the risk of developing ICB in 
clinical practice. Drug naïve PD patients, who do not gather evidence and make 
irrational choices, should not be treated initially with a dopamine agonist. A prospective 
study testing never medicated PD patients on the beads task and retesting them after 12 
weeks with either L-dopa monotherapy or dopamine agonist monotherapy is currently 
underway to test this suggestion.    
Patients with ephedrone induced parkinsonism, who are known to have severe damage 
in the corpus striatum and globus pallidus, were tested to assess whether changes in 
these structures and their circuitry  cause impairments in decision making. Ephedrone 
patients were compared to substance abusers on opioid replacement therapy, as both 
share a similar premorbid personality, whereas only the ephedrone group has severe 
damage within the basal ganglia. Clinically, ephedrone patients suffer from chronic 
progressive severe extrapyramidal deficits without evidence of dopaminergic 
dysfunction on dopamine transporter SPECT scans.  
Ephedrone patients performed similarly to opioid dependent patients on the beads task, 
with both patient groups gathering significantly less evidence and making more 
irrational choices than controls. However, only opioid dependent patients were more 
risk prone and had poorer WM than healthy volunteers, which might explain why 
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relapse rates are higher in these patients compared to patients with ephedrone induced 
parkinsonism. It is therefore possible that neuronal changes in the connections between 
the anterior cingulate, the nucleus accumbens and the pallidum are responsible for 
reflection impulsivity. 
In the final chapter, the literature was reviewed to determine whether chronic stress can 
induce striatal damage. Several preclinical studies in rodents have demonstrated 
nigrostriatal degeneration after exposure to chronic stress. Chronic stress could 
theoretically trigger dopaminergic damage in susceptible patients. To explore the link 
between stress and impulsivity in PD, salivary cortisol levels of PD patients with and 
without ICBs were obtained. Results showed significantly raised cortisol levels in the 
non-impulsive PD group. However, an acute rise in cortisol levels during gambling was 
only seen in PD patients with ICBs, which may suggest that cortisol plays a role in risk 
taking in PD patients with ICBs.   
Future work 
The recognition of ICBs in PD patients on dopaminergic therapy has led to renewed 
interest in ventral striatal dysfunction in PD. Behavioural studies combining fMRI or 
PET imaging to measure potential differences in cortico-striatal networks and 
neuropsychological profiles in patients with different predominant impulsive 
compulsive behaviours (for example pathological gambling compared with compulsive 
sexual behaviour) is likely to be instructive. Whilst patients with compulsive sexual 
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disorder are clinically more aggressive and egoistic, patients with compulsive shopping 
seem to be less self-centred.  
The role of stress in PD has been poorly studied. Assessing cortisol in scalp hair rather 
than salivary, blood or urine cortisol levels has been shown to be a more valid method 
for measuring the HPA-axis and long-term cortisol secretion (Meyer and Novak 2012). 
Hair cortisol measurements also permit retrospective correlation with physical stressors 
such as motor fluctuations and emotional stressors such as anxiety, which are known to 
be more prevalent amongst PD patients with ICBs.  
It is also unclear whether reward induced endogenous ventral striatal dopamine release 
can temporarily improve motor handicaps in PD. I am planning to conduct a study 
comparing PD patients with and without pathological gambling on various decision 
making tasks and perform simultaneous tremor recordings and use an accelerometer to 
assess bradykinesia. PD patients with pathological gambling, who are known to exhibit 
a higher reward induced ventral striatal dopamine release during gambling, might be 
expected to have subtle improvement in their PD motor symptoms. This would also be 
in line with the clinical impression that PD patients report a temporary subjective 
improvement of their motor deficits after performing rewarding actions such as dancing 
to preferred music or eating chocolate.   
In the long term clinico-genetic studies combining neuropsychological tests with 
genome wide association studies on a large number of PD patients with ICBs may help 
to define a genetic predisposition, which ultimately might help treating physicians to 
identify patients at particular risk of developing behavioural addictions. 
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